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Abstract 
Skeletal muscle accounts for ~75% of whole body insulin-stimulated glucose 
uptake and contains the largest intracellular pool of free amino acids and 
consequently exerts a major influence on whole body carbohydrate and protein 
metabolism. Muscle also represents an important site for fat oxidation especially 
after fasting, but sustained over-supply of fatty acids under well nourished 
conditions can deleteriously affect signalling processes regulating carbohydrate 
and protein metabolism. In particular, there is mounting evidence that elevated 
concentration of plasma non-esterified saturated fatty acids (SFAs) leads to 
insulin resistance, whereas increased content of monounsaturated (MUFAs) or 
polyunsaturated (PUFAs) fatty acids confers a protective effect and/or improves 
insulin sensitivity. However the molecular mechanisms by which unsaturated 
fatty acids exert this beneficial effect are still unknown. To address this issue, in 
the first part of the study presented in this thesis I have examined the effect of 
the MUFA oleic acid and the PUFA linoleic acid upon proximal insulin signalling 
events in L6 rat skeletal muscle cells. I demonstrate that chronic incubation of 
L6 myotubes with oleic and linoleic acid significantly enhanced insulin 
stimulated activation of the mitogen-activated protein (MAP) kinase (ERK1/2) 
and PI3K/Akt signalling pathways and counters the detrimental effect of the 
SFA palmitate. Importantly, I show that the observed improvements in insulin 
action are not due to augmented IRS1/PI3K activation, but rather involve 
suppressing the action of protein phosphatase 2A (PP2A) towards Akt and 
ERK1/2. 
Although the effect of SFAs and UFAs upon insulin signalling has been amply 
documented, very little is known about how fatty acids may affect amino acid 
XXI 
 
transport. Interestingly, previous work from our lab has demonstrated that 
ceramide, a derivative of the saturated fatty acid palmitate, can suppress the 
basal and insulin-stimulated activity of the SNAT2 amino acid transporter by 
preventing its translocation to the plasma membrane, an effect that it also 
exerts on the insulin-regulated glucose transporter, GLUT4. The second part of 
this thesis thus reports studies that focus on the effects of palmitate, linoleic and 
oleic acid on SNAT2 expression/activity in L6 rat skeletal muscle cells and HeLa 
cells. SNAT2 is one of the most abundant and highly regulated short chain 
neutral amino acid transporter known to be expressed in mammalian cells. The 
transporter is extensively regulated in response to nutrient/osmotic cues. 
Extracellular amino acid deprivation or hyperosmotic shock, for example, induce 
SNAT2 abundance in the plasma membrane by a process known as “adaptive 
regulation”, which involves increased expression of SNAT2 and its translocation 
from an intracellular pool to the plasma membrane where it is maintained in a 
stable and active state. The results presented herein show that linoleic acid and 
palmitate significantly impair the SNAT2 adaptive response in a dose and time-
dependent manner by substantially reducing SNAT2 membrane protein and 
consequent activity. The failure to upregulate cellular SNAT2 content in 
response to amino acid limitation is not due to suppression in SNAT2 gene 
transcription but to a loss in the abundance of the mature/glycosylated form of 
SNAT2 at the membrane. Linoleic acid induces this effect by enhancing 
proteasomal degradation of SNAT2. Previous work has in fact shown that 
SNAT2 stabilization and turnover at the plasma membrane involves the 
ubiquitin–proteasomal pathway and that its ubiquitination is mediated by the E3 
ligase Nedd4.2. My work reveals that use of a proteasomal inhibitor, MG132, 
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negates the loss in SNAT2 triggered by linoleic acid. Intriguingly, however, 
shRNA silencing of Nedd4.2 does not protect against fatty-induced proteasomal 
loss of SNAT2 suggesting that SNAT2 ubiquitination is likely to involve an E3 
ligase other than Nedd4.2. In contrast, the effect of palmitate upon SNAT2 
protein abundance in the plasma membrane is due to transporter 
internalisation, promoted by its derivative ceramide, and potential palmitate-
induced lysosomal degradation of the “surface” mature form of SNAT2. 
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Chapter 1 
Introduction 
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1.1 Overview 
All organisms are faced with the constant challenge of surviving in stressful 
situations. Nutrient availability is temporally and spatially variable therefore and 
consequently organisms have developed mechanisms to store nutrients if in 
excess, in order to make them available when they become limited. Nutrients 
are stored in the body as carbohydrates, lipids and proteins and their release 
and utilisation are tightly regulated.  
Glucose represents the main source of energy of the body. During the 
postprandial period, blood glucose rises and induces the release of insulin, 
which regulates uptake of glucose into key tissues such as muscle and fat 
(Flatt, 1995). Since oxidation accounts for ~10 g glucose/h, it follows that most 
of the glucose taken up in such tissues is either stored in the form of glycogen 
or directed towards lipid synthesis and storage (Flatt, 1995). Under low-glucose 
levels, fatty acids can be used as source of energy by most body tissues. Fat 
cells that make up the adipose tissue are specialised in the storage of fatty 
acids as triacyglycerols (TAGs) (Flatt, 1995). During the fasting state, glycogen 
is the first energy store to be depleted, followed by TAGs and only after a 
prolonged period of starvation is body protein degraded for release of amino 
acids. Amino acids can be used as an alternative energy source once 
circulating levels of both glucose and fatty acids become low. Unlike glycogen 
or triacylglycerol, proteins do not primarily function as energy stores but perform 
distinct structural or functional roles within cells. The fraction of total dietary 
energy provided by proteins is relatively small and the body spontaneously 
maintains its content by regulating amino acid oxidation and uptake. Modulating 
cellular uptake, synthesis and metabolism of amino acids as well as synthesis 
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and degradation of proteins within cells collectively influence the cellular amino 
acid pool size (Flatt, 1995). 
Skeletal muscle constitutes ~50% of lean body mass and consequently skeletal 
muscle metabolism strongly influences the metabolic budget of the whole body. 
Under insulin stimulation, this tissue is responsible for ~75% of whole body 
glucose disposal, accounting for 3-4 fold greater glycogen storage than that in 
the liver (Flatt, 1995). In addition, skeletal muscle is the major bodily store of 
free amino acids and the main site of gluconeogenic amino acid synthesis 
(Frayn, 1996). During periods of muscular contraction, skeletal muscle is the 
principal site of nutrient consumption and therefore the transport of metabolic 
substrates, such as glucose and certain amino acids, is rapidly upregulated 
(Zorzano et al., 2000). Importantly, during prolonged levels of exercise most 
energy needs come from use of fat as an energy fuel rather than from 
carbohydrates. Therefore, skeletal muscle is a tissue with a complex metabolic 
network, in which exercise and hormones regulate the uptake and metabolism 
of glucose, fatty acids and amino acids.  
1.2 Overview on insulin, glucose and fatty acids 
1.2.1 Insulin 
Insulin is a peptide hormone produced by pancreatic β-cells and responsible for 
the regulation of diverse processes including glucose and fat metabolism. It 
consists of a 21 amino acid α chain and a 30 amino acid β chain, linked by 
disulfide bonds. The mammalian insulin gene is exclusively expressed in β cells 
of the endocrine pancreas and encodes for a single 110 amino acid polypeptide 
chain precursor, preproinsulin (Chan et al., 1976), then cleaved to produce 
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proinsulin. Proinsulin is packed into secretory vesicles where it matures into 
active insulin (Halban, 1991). Glucose enters into pancreatic β-cells via the 
GLUT2 glucose transporter, is metabolised and ATP generated from its 
metabolism promotes closure of KATP channels that result in plasma membrane 
depolarisation and subsequent activation of voltage-gated Ca2+ channels. The 
increase in intra-cellular Ca2+ levels stimulates the fusion of insulin-containing 
granules with the β-cell plasma membrane and consequent release of insulin 
(Newgard and McGarry, 1995). Upon its release, insulin plays a critical role in 
regulating metabolism of glucose, protein and fat. One of its primary functions is 
to stimulate glucose uptake in key target tissues, such as skeletal muscle and 
adipose tissue. Whilst adipose tissue plays a minor role with respect to insulin-
induced glucose disposal, skeletal muscle represents the predominant “sink” for 
whole body glucose disposal (Saltiel and Kahn, 2001). Whilst insulin does not 
increase hepatic glucose uptake the hormone stimulates the storage of glucose 
as glycogen in liver, while preventing its production and release by inhibition of 
gluconeogenesis and glycogenolysis (Pilkis and Granner, 1992). In adipose 
tissue, insulin suppresses the release of non-esterfied fatty acids and promotes 
their esterification and storage as TAG (Frayn, 2002). 
 1.2.2 Glucose 
Glucose is a key metabolite and a major fuel source in mammals. It is a cyclic 
aldose monosaccharide and can be found in two different stereoisoforms, D-
glucose and L-glucose, of which only the first one can be utilised by mammals 
as a source of energy and a metabolic intermediate (Berg, 2002). In addition to 
dietary glucose the hexose can also be synthesised in liver and kidneys from 
non-carbohydrate intermediates, such as pyruvate, lactate and glycerol through 
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a process known as gluconeogenesis (Stumvoll et al., 1998). Moreover, glucose 
can be obtained by breaking down glycogen stores in liver and skeletal muscle 
by glycogenolysis. Glucose uptake differs among tissues depending on glucose 
availability and the metabolic need of each tissue. The two main ways by which 
glucose can enter into cells is via facilitative transport and secondary active 
transport. Facilitative transport is driven by the downward chemical gradient of 
glucose across the plasma membrane and is mediated by members of the 
GLUT family of transporters. Among these, GLUT4 is the main insulin-sensitive 
member of this family and is uniquely expressed in adipose tissue, skeletal and 
cardiac muscle (Wood and Trayhurn, 2003). While most cells take up glucose 
by facilitative transport, epithelial cells of the small intestine and kidney proximal 
convoluted tubule absorb glucose against its electrochemical gradient by a 
secondary active transport mechanism, mediated by the family of Na+/glucose 
cotransporters (gene symbol SLC5A, protein symbol SGLT) (Wood and 
Trayhurn, 2003; Wright, 2001). 
Once taken up into cells, glucose can enter three main metabolic processes: 1) 
oxidation, 2) storage and 3) lactate production. How glucose is directed to these 
different processes depends mainly on tissue necessity (Berg, 2002). Since 
neuronal tissues lack the ability to oxidise fatty acids or amino acids without 
undergoing adverse structural and functional changes, most of the glucose 
taken up by the brain is used as fuel and therefore oxidised (Maher et al., 
1994). Skeletal muscle instead mainly channels glucose into lactate production 
during fasting, while promoting its storage as glycogen after insulin release 
(Zierler, 1999). 
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1.2.3 Fatty acids 
Fatty acids are hydrocarbon chains that terminate with carboxylic acid groups. 
Carbon atoms of the fatty acids are numbered starting at the carboxyl terminus. 
Carbon atoms 2 and 3 are also called α and β respectively, while methyl carbon 
atom at the distal end of the chain is known as ω-carbon atom (Fig 1.1 A). The 
aliphatic chain contains an even number of carbon atoms, usually between 4 
and 14, with 16- and 18- carbon-long fatty acids being the most common. The 
aliphatic chain can be saturated or contain one or more double bonds, which 
define the difference between saturated, monounsaturated and polyunsaturated 
fatty acids (Fig 1.1 B). The configuration of the double bonds in most 
unsaturated fatty acids is cis, and if more double bonds are present at least one 
methylene group separates them. Chain length and degree of saturation affect 
the biophysical features of fatty acids such as their melting point or their 
absorption (Berg, 2002). As such, shorter chain length and more unsaturation 
enhance the fluidity of the fatty acid and its derivatives (Berg, 2002). Most fatty 
acids can be synthesised in the liver but two of them, linoleic acid (C18:2) and 
α-linolenic acid (C18:3), are considered “essential” as they cannot be 
synthesised and must be supplemented in the diet (Plourde and Cunnane, 
2007). Fatty acids are generally stored as TAG, a lipid comprised of a glycerol 
backbone to which three fatty acids are esterified. TAGs circulate in the plasma 
as part of lipoproteins and are also stored in cells as neutral lipid droplets. The 
tissues that typically store TAG and hydrolyse it, either for internal oxidation or 
export, are adipose tissue, skeletal muscle and liver (Coleman and Mashek, 
2011). The main source of dietary fatty acids is in the form of TAG. In the 
intestinal lumen, TAG is broken down by pancreatic lipase to monoacylglycerol 
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and free fatty acids, which aggregate with bile acid and other lipids to form 
structures known as micelles (Carlier et al., 1991). Micelles are transported from 
the intestinal lumen into mucosal cells, where free fatty acids and 
monoacylglycerol are re-packed as TAG and combined with cholesterol, 
lipoproteins and other lipids into particles called chylomicrons. Chylomicrons are 
the largest lipoprotein particles and enter into the blood circulation to deliver 
TAG-fatty acids to the peripheral tissues. TAG and fatty acids are absorbed by 
tissues via lipoprotein lipase (LPL), an enzyme expressed on the luminal side of 
the capillary endothelial cells of adipose tissue, skeletal and cardiac muscle 
cells. LPL binds and hydrolyses chylomicrons releasing fatty acids and 
monoacylglycerol for take up by these tissues. The remnant part of the 
lipoprotein particle is taken up by the liver, which expresses hepatic lipase (HL), 
an enzyme that acts on smaller particles than LPL (Frayn et al., 2006). When 
the body has excess carbohydrate availability, the liver has the ability to 
synthesise new fatty acids from glucose and store them as TAG (Hellerstein et 
al., 1996). During fasting, the cytosolic TAG pool undergoes lipolysis to 
generate fatty acids, which are re-assembled in very low density lipoproteins 
(VLDL) and released into blood circulation to reach other tissues (Frayn et al., 
2006). Adipose tissue is the body’s largest energy reservoir and represents the 
main target of circulating chylomicrons and VLDL. In particular, during the 
postprandial state insulin stimulates the uptake of excess circulating TAG into 
the adipose tissue. Moreover, it induces uptake of glucose, whose metabolism 
provides a source of glycerol-3 phosphate necessary for esterification of free 
fatty acids and generation of TAG. During energy deprivation, enzymes such as 
hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) regulate   
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Figure 1.1 General fatty acid structure and structures of the most 
common fatty acids.  
(A) Numberig system of fatty acid structure. (B) Palmitate is a 16-carbon, 
saturated fatty acid, oleic acid is an 18-carbon fatty acid with a single cis double 
bond and linoleic acid is an 18-carbon fatty acid with a two cis double bonds. 
Modified from (Chatgilialoglu, 2010). 
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the lipolysis of stored TAG and consequent release to the blood circulation as 
glycerol and non esterified free fatty acid (NEFA), which become available for 
uptake by other tissues such as liver or skeletal muscle (Lafontan and Langin, 
2009). Skeletal muscle can take up fatty acids either from circulating TAG via 
action of LPL, or from the plasma NEFA pool. NEFAs are insoluble and those 
transported in plasma are bound to albumin. The dissociation of the fatty acids 
from albumin represents the first step in their uptake, which is then mediated by 
fatty acid transporter. Once in the muscle cell, fatty acids are activated by 
esterification to CoA by fatty acyl CoA synthetase and can be channelled into 
storage as intramyocellular TAG or used as substrate for oxidation by 
mitochondria (Frayn et al., 2006).  
1.3. Insulin signalling 
1.3.1 The insulin receptor and insulin receptor substrates 
Once released by pancreatic β cells into the circulation, insulin exerts its effect 
on insulin target tissues by binding to the insulin receptor (IR). IR is a 
membrane glycoprotein consisting of two α and two β subunits organised into 
an α2β2 heterotetrameric complex and several functional domains. The α-
subunit is extracellular and contains the insulin binding site. The binding of 
insulin to the α-subunit results in a conformational change that activates the 
intrinsic tyrosine kinase activity of the β-subunit leading to its 
autophosphorylation on select tyrosine residues (Shoelson et al., 1988). The 
phosphorylated tyrosine residues act as docking sites for several signalling 
molecules, which, in turn, bind to downstream insulin-signalling proteins 
(Kanzaki, 2006). 11 different IR substrates have been identified. Among these 
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are Grb2-associated binder-1 (Gab1), Src-homology-2-containing protein (SHP-
2) and the family of the insulin receptor substrates (IRS) proteins (Taniguchi et 
al., 2006). IRS proteins represent the first step in the activation of the insulin 
signalling pathway. The family of IRS proteins comprise six members. (Cai et 
al., 2003). IRS proteins contain both pleckstrin-homology domains (PH 
domains) and phosphotyrosine-binding domains (PTB domains) that bind the IR 
(Taniguchi et al., 2006). IRS2 is structurally different from the others since it is 
the only one that can bind IR via a kinase-regulatory loop binding domain 
(Sawka-Verhelle et al., 1996). During the transient interaction with the 
autophosphorylated IR, IRS proteins are phosphorylated on potentially 20 
different tyrosine residues, which can then be bound by proteins containing Src-
homology domains (SH2 domains). Among the proteins that bind tyrosine-
phosphorylated IRS proteins is p85, the regulatory subunit of phosphoinositide-
3-kinase (PI3K), a critical node in the insulin signalling network, and the adaptor 
molecule growth factor receptor-bound protein 2 (Grb2), which mediates the 
activation of the Ras-MAPK pathway (Virkamaki et al., 1999). In contrast, the 
SH2-domain-containing tyrosine phosphatase-2 (SHP-2) can bind to IRS1 on 
two phosphotyrosine residues at its C terminus, and dephosphorylates 
phosphotyrosines residues that mediate the interaction with PI3K and Grb2. In 
addition, kinases such as extracellular regulated kinase 1/2 (ERK1/2) and 
ribosomal protein P70S6 kinase (P70S6K) have been shown to phosphorylate 
IRS proteins on inhibitory serine residues. Since these kinases are activated by 
insulin, it follows that serine phosphorylation might act as a negative-feedback 
mechanism for the insulin pathway (Fritsche et al., 2011). Moreover, inhibitory 
serine phosphorylation has been identified as one mechanism mediating insulin 
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resistance. Activation of c-Jun-N-terminal kinase (JNK) by stress and excess 
free fatty acids results in increased serine phosphorylation of IRS-1 and a 
consequent reduction in activation of insulin signalling (Aguirre et al., 2000). In 
addition, tumor necrosis factor α (TNFα), inhibitor of kappa B kinase (IKK) and 
protein kinase C θ (PKCθ), which are elevated in states of low inflammation (as 
seen during obesity and diabetes) have been shown to promote insulin 
resistance through enhanced serine phosphorylation of IRS1 (Draznin, 2006).  
1.3.2 Phosphatidylinositide-3-kinase (PI3K) 
Phosphoinositide-3-kinase (PI3K) are enzymes that transfer phosphate to 
position 3 of the phosphoinositide ring, regulating different processes, including 
the activation of insulin signalling. Three subclasses of PI3K have been 
identified but only the class I enzymes generate phosphatidylinositol 4,5-
bisphosphate (PI(4,5)P2) and phosphatidylinositol 3,4,5-trisphosphate 
(PI(3,4,5)P3) products in vivo (Vanhaesebroeck and Waterfield, 1999). Class IA 
PI3K exists as an heterodimer comprised of a catalytic subunit of ~110kDa 
(p110) and a regulatory subunit of ~85kDa (p85) containing an SH2 domain, 
which is responsible for interaction with p110 (Shepherd et al., 1998). The 
catalytic subunit is in fact unstable and quickly degraded, therefore it is almost 
always found in a complex with the regulatory subunit. The interaction between 
p85 and p110 not only stabilises the catalytic subunit, but also inhibits its 
enzymatic function. Only when p85 binds to IRS proteins through its SH2-
domain, is the inhibition released and p110 is targeted to the plasma membrane 
where its substrate (PI(4,5)P2) is localised (Klippel et al., 1994). Once 
PI(3,4,5)P3 is generated at the plasma membrane following insulin stimulation it 
recruits several PH-domain containing proteins, including the serine/threonine 
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kinase 3’-phosphoinositide-dependent kinase 1 (PDK1) and protein kinase B 
(PKB/Akt) (Toker and Newton, 2000a, b). As the activation of the IR terminates, 
PI(3,4,5)P3 is dephosphorylated by the 3’ phosphoinositide phosphatase PTEN 
(phosphatase and tensin homolog) resulting in release of recruited PH-domain 
containing proteins into the cytoplasm (Maehama and Dixon, 1998).  
1.3.3 Protein kinase B (PKB/Akt) 
Akt is a serine/threonine kinase that has three isoforms in mammals, Akt 1-3, 
each encoded by different genes. These isoforms share a common C-terminal 
catalytic domain and an N-terminal PH domain, which interacts with PI(3,4)P2 
and PI(3,4,5)P3 (Coffer et al., 1998). AKT1-3 differ in their biological function 
and distribution. Akt1 is widely expressed and silencing its expression results in 
impaired growth but no detectable metabolic abnormalities (Chen et al., 2001). 
In contrast, Akt2 is chiefly expressed in insulin-target tissues, such as fat and 
liver (Chan et al., 1999). The finding that Akt2-deficient mice develop insulin 
resistance suggests a role in modulating insulin-mediated glucose homeostasis 
and is fully consistent with its expression in these key insulin target tissues (Cho 
et al., 2001). In contrast, Akt3 plays a role in neuronal development and is 
predominantly expressed in the nervous system and testis (Tschopp et al., 
2005). Upon PI3K activation, Akt is recruited to the plasma membrane by 
binding PI(3,4,5)P3 via its PH domain. This interaction induces a conformational 
change in Akt which leads to its activation following phosphorylation of two 
regulatory sites. The first one is a threonine residue, T308, phosphorylated by 
3-phosphoinositide-dependent protein kinase-1 (PDK1). Full activation of Akt 
requires phosphorylation of a regulatory second site, S473, which is catalysed 
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by mammalian target of rapamycin (mTOR) complex 2 (mTORC2) (Alessi et al., 
1996; Sarbassov et al., 2005).  
Akt is negatively regulated by numerous proteins. Protein phosphatase-2 
(PP2A) and PH-domain leucine-rich repeat protein phosphatase (PHLLP) 
directly target and dephosphorylate Akt (Brazil et al., 2004; Gao et al., 2005). 
Tribbles-3 (TRB3) inhibits Akt phosphorylation by binding it (Du et al., 2003) and 
RNAi-mediated down regulation of its expression results in improved insulin 
sensitivity in vivo (Koo et al., 2004). Additional mechanisms of Akt inhibition, 
which mediate insulin resistance development, will be discussed later. 
1.3.4 Akt-regulated processes 
Akt represents a critical node of the insulin signalling pathway, since it acts on 
downstream targets to regulate several cellular processes including glucose 
uptake, glycogen synthesis, protein synthesis and cell survival (Fig 1.2) 
(Manning and Cantley, 2007). 
1.3.4.1 Glucose uptake 
Insulin stimulates the uptake of glucose into skeletal muscle and adipose tissue 
through the insulin-responsive GLUT4 transporter, which is expressed 
exclusively in these tissues. Contrary to other members of the GLUT transporter 
family, GLUT4 is mainly stored in intracellular vesicles, which translocate from 
the cytoplasm to the plasma membrane upon insulin stimulation. Once the 
stimulus is terminated, GLUT4 is internalised by endocytosis and routed to 
specialised storage vesicles (Bryant et al., 2002; Watson et al., 2004). The 
molecular mechanism that mediates GLUT4 translocation and consequent 
facilitated glucose uptake are mediated by Akt. Previous work from the Hundal  
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Figure 1.2 Overview of proximal insulin signalling pathway.  
Insulin binding to IR triggers phosphorylation of IR and IRS1. IRS1 recruits 
PI3K, which, once activated, catalyses the phosphorylation of PI(4,5)P2 (PIP2) 
to generate PI(3,4,5)P3 (PIP3). PI(3,4,5)P3 recruits Akt to the membrane. Akt is 
then activated by phosphorylation on T308 by PDK1 and S473 by mTORC2, 
and stimulates several downstream pathways. IR activation also results in the 
binding of Grb2/SOS complex leading to activation of the 
Ras/Raf/MEK/ERK1/2 pathway. 
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lab has shown that overexpression of wild-type Akt1 or of a constitutively active 
membrane-targeted Akt1 results in a significant enhancement in glucose 
uptake, even in the absence of insulin (Hajduch et al., 1998). In line with this 
result, over expression of a dominant inhibitory mutant of Akt drastically reduces 
insulin-induced GLUT4 translocation (Cong et al., 1997). Although the precise 
mechanism by which Akt regulates glucose uptake remains unclear, it appears 
to involve its downstream target AS160 (Akt substrate of 160 kDa). AS160 
contains six Akt phosphorylation sites and a Rab GTPase activating protein 
(GAP) domain (Miinea et al., 2005). The phosphorylation of AS160 by Akt in 
response to insulin reduces its Rab GAP activity, which allows a Rab-family 
GTPase associated to GLUT4 vesicles to become guanosine triphosphate 
(GTP) loaded and stimulate vesicle translocation (Sakamoto and Holman, 2008; 
Sano et al., 2007).   
1.3.4.2 Glycogen synthesis 
One of the main processes regulated by insulin is the storage of glucose as 
glycogen. Glycogen is synthesised from uridine diphosphate (UDP)-glucose 
monomers by glycogen synthase (GS) (Lawrence and Roach, 1997). Two main 
mechanisms by which insulin regulates GS activity have been indentified- one 
involving allosteric regulation by glucose-6-phosphate (G6P) (Bouskila et al., 
2010) and the other covalent phosphorylation (Friedman and Larner, 1963). The 
latter can be accomplished by glycogen synthase kinase 3 α/β (GSK3α/β), a 
serine/threonine kinase responsible for the phosphorylation of several serine 
residues on GS and its consequent inhibition. Once activated by insulin, Akt 
phosphorylates GSK3α on S21 and GSK3β on S9 promoting inactivation of the 
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kinase and therefore alleviating its inhibition of GS (McManus et al., 2005; 
Sutherland et al., 1993). 
1.3.4.3 Cell growth and protein synthesis 
Upon insulin stimulation, Akt promotes protein synthesis through the activation 
of the mTOR complex 1 (mTORC1)/ P70S6K pathway. mTORC1 signalling 
plays a critical role in the regulation of mRNA translation and ribosome 
biogenesis, and can be activated not only by insulin but also by growth factors 
and nutrient provision (Wullschleger et al., 2006). Akt-mediated activation 
involves phosphorylation and consequent inactivation of the tuberous sclerosis 
complex 2 (TSC2), a negative regulator of mTORC1. TSC2 is found in a 
complex with TSC1 and acts as a GAP protein for Rheb. This is a Ras-related 
small G protein, which activates mTORC1 when it is in an active GTP-loaded 
state. Therefore, inhibition of TSC2 promoted by Akt phosphorylation of S939 
and T1462 residues allows Rheb-GTP to activate the mTORC1 pathway (Inoki 
et al., 2002; Manning et al., 2002). mTORC1 signalling and the molecular 
mechanisms mediating mRNA translation will be discussed in detail in section 
1.11.1. 
1.3.4.4 Cell survival 
Numerous studies have reported the ability of Akt to promote the survival of 
cells, principally by inhibiting proteins with pro-apoptotic function. The enhanced 
cell survival is in fact due to negative regulation of expression or function of Bcl-
2 homology domain (BH3)-only proteins, which induce apoptosis by binding and 
inhibiting prosurvival B-cell lymphoma 2 (Bcl-2) family proteins. For example, 
Datta et al. have shown that Akt can directly phosphorylate the BH3-only protein 
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Bcl-2-associated death promoter (BAD) on S316. This event creates a docking 
site, which can be bound by 14-3-3 proteins leading to the release of BAD 
target proteins B-cell lymphoma-extra large (BCL-XL) (Datta et al., 1997; Datta 
et al., 2000). Akt can also exert its prosurvival effect by negative regulation of 
transcription factors like p53 and Forkhead box-O proteins (FoxOs). The latter 
ones regulate the expression of pro-apoptotic members of the Bcl2-family, such 
as BIM, cyclin-dependent kinase inhibitors (CDKIs) and death receptor ligands 
such as FAS ligand and tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) (Brunet et al., 1999; Kikuchi et al., 2007). In the nucleus, Akt directly 
phosphorylates FoxO proteins on T24 and S256 thereby creating a binding site 
for 14-3-3 proteins, which sequester FoxOs displacing them from target genes 
(Zhang et al., 2011). Cell survival is also promoted by induction of the nuclear 
factor kappa B (NF-kB) pathway as a result of direct phosphorylation and 
consequent activation of IκB kinase α (IKKα). Once activated, IKKα 
phosphorylates and targets for proteasomal degradation inhibitor of kappa B α 
(IKBα), a negative regulator of NF-kB. The dissociation and loss of IKBα then 
allows NF-kB to translocate to the nucleus and promote the transcription of 
prosurvival genes (Dan et al., 2008).  
1.4 Mitogen activated protein kinase (MAPK) signalling pathway 
In addition to the PI3K/Akt axis, insulin stimulation leads to the activation of the 
MAPK-ERK1/2 pathway (Ray and Sturgill, 1987). ERK1/2 belongs to one of the 
serine/threonine MAPK families; other members of this family include JNK and 
p38 MAPK. All MAPK pathways contain a three-tiered kinase cascade 
consisting of an upstream MAPKKK, which phoshporylates a MAPKK, which 
activates the MAPK enzyme by dual phosphorylation on threonine and tyrosine 
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residues within the motif T-Xaa-Y (Johnson and Lapadat, 2002). While JNK and 
p38 are strongly activated by cytokines and stress stimuli, ERK1/2 activation is 
mainly induced by growth factors. The MAPK ERK1/2 pathway is activated by 
insulin following the recruitment of the Grb2-SOS (Son of sevenless protein) 
complex, which leads to the activation of Ras, Raf and MEK1/2 (mitogen-
activated extracellular-regulated kinase 1/2) (Diaz et al., 1997; Johnson and 
Lapadat, 2002; Marais et al., 1995; Skolnik et al., 1993). Once phosphorylated 
MEK1/2 can activate their sole substrates ERK1/2 by phosphorylation on T202 
and Y204 in the activation loop (Kolch, 2000; Lewis et al., 1998). ERK1/2 have 
a wide range of substrates, including growth factor-responsive targets in the 
cytosol but also several transcription factors regulating gene expression in the 
nucleus. The major target of ERK1/2 is 90 kDa ribosomal protein S6 Kinase 
(p90RSK). Once activated, p90RSK migrates to the nucleus where it activates 
several transcription factors including, for example, the product of the proto-
oncogene c-Fos at S362, SRF (Serum Response Factor) at S103, and CREB 
(Cyclic AMP Response Element-Binding protein) at S133 (Dalby et al., 1998), 
involved in the regulation of cell proliferation, differentiation and survival 
(Persengiev and Green, 2003). ERK1/2 can also migrate to the nucleus and 
directly phosphorylate transcription factors, such as Elk1 (Kortenjann et al., 
1994). In insulin signalling the ERK1/2 MAPK pathway is associated principally 
with promotion of cell proliferation and differentiation and does not have a 
critical role in the regulation of metabolic effects induced by the hormone 
(Denton and Tavare, 1995). Since MAPK activation requires dual 
phosphorylation, it follows that their activity is negatively regulated by 
phosphatases. Indeed, the serine/threonine phosphatase PP2A has been 
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identified as a negative regulator of the MEK1/2/ERK1/2 pathway (Alessi et al., 
1995). Another important mediator of this regulation is a family of 10 dual-
specificity MAPK phosphatases (DUSPs), which are able to dephosphorylate 
both threonine and tyrosine residues on MAPK (Owens and Keyse, 2007)  
1.5 Fatty acid metabolism 
1.5.1 Fatty acid synthesis 
Fatty acid synthesis is a multi-step process occurring in the cytosol and 
regulated by the fatty acid synthase (FAS), a complex multifunctional enzyme of 
~250 kDa (Jayakumar et al., 1995). The FAS enzyme coordinates the synthesis 
of palmitate, the most prevalent saturated fatty acid, from acetyl CoA, malonyl 
CoA and NADPH by the repetition of the following reaction sequence: 
condensation, reduction, dehydration and reduction (Fig 1.3). All the 
intermediates of these reactions are linked to an acyl carrier protein (ACP) 
(Chirala and Wakil, 2004). Palmitate is the only fatty acid produced by FAS, but 
longer fatty acids can be produced by a membrane-bound enzyme known as 
elongation of very-long-chain fatty acids (Elovls) (Jakobsson et al., 2006). The 
elongation process consists of the addition of two-carbon units, provided by 
malonyl CoA, to the carboxyl end of the fatty acyl CoA substrate. This occurs in 
four separate enzymatic reactions, which follow those involved in fatty acid 
synthesis. The elongase enzymes catalyse the initial and rate-controlling 
condensation reaction (Guillou et al., 2010). A combination of elongation and 
desaturation brings about the production of unsaturated fatty acids. The 
desaturation reaction is catalysed by acyl-CoA desaturase, an enzyme that 
inserts a double bond at a specific position in the fatty acid carbon chain. Three  
20 
 
 
Figure 1.3 Fatty acids synthesis.  
Fatty acids are synthesised by the repetition of the following reaction sequence: 
condensation, reduction, dehydration and reduction.   
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desaturases are present in mammals, Δ5, Δ6 and Δ9 desaturase, which can 
insert a double bond at carbon 5, 6 and 9 respectively. The desaturases can be 
divided into two families: fatty acid desaturases (FADs) and stearoyl-CoA 
desaturases (SCDs). Δ6 and Δ5 desaturases are FADs and are involved in the 
synthesis of highly unsaturated fatty acids, which are mainly esterified into 
phospholipids, while Δ9 is a SCD and is required for the generation of mono-
unsaturated fatty acids, like oleic acid (Nakamura and Nara, 2004; Paton and 
Ntambi, 2009). Mammals do not have the enzyme to introduce a double bond 
after C9 of a fatty acid chain and consequently fatty acids such as linoleic acid 
(C18:2, n-9,12) and linolenic acid (C18:3, n-9,12,15), known as essential FAs, 
have to be acquired by diet (Plourde and Cunnane, 2007). The process of fatty 
acid synthesis is activated when carbohydrate availability is high and inhibited 
during starvation, when fatty acids are released by adipose tissue by the action 
of lipases. One of the key proteins involved in the tight regulation of this process 
is acetyl CoA carboxylase (ACC) (Fig 1.4). ACC catalyses the formation of 
malonyl-CoA from acetyl-CoA, the first step in fatty acid synthesis, and can be 
regulated in two ways: allosterically by citrate and through reciprocal 
phosphorylation. When glucose levels are high, glucose-derived acetyl-CoA can 
be utilised for synthesis of fatty acids. In order to be transferred from 
mitochondria to the cytosol, where fatty acid synthesis occurs, it has to be 
converted into citrate (Berg 2002). Citrate levels are high when adequate acetyl-
CoA enters into the Krebs cycle, and allosterically activates ACC in order to 
convert excess acetyl-CoA into malonyl-CoA (Ruderman et al., 1999). 
Increasing concentrations of malonyl-CoA inhibit carnitine palmitoyl-transferase-
1 (CPT-1), which  mediates  the entry  of  fatty  acids into the  mitochondria to   
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promote their oxidation (Chien et al., 2000; Ruderman et al., 1999). ACC 
activation promoted by citrate can be antagonised by palmitoyl-CoA, which is 
abundant when fatty acid levels are high and additional fatty acid synthesis is 
not required (Ogiwara et al., 1978). As mentioned above, acetyl CoA can also 
be regulated by phosphorylation. Under low glucose conditions a decreased 
adenosine triphosphate (ATP)/adenosine diphosphate (ADP) ratio will prevail 
and this will, in turn, result in the activation of adenosine monophosphate 
(AMP)-activated protein kinase (AMPK). The latter serves as the upstream 
kinase of ACC. AMPK phosphorylates and inactivates ACC on S79 thereby 
preventing the synthesis of malonyl-CoA and promoting fatty acid oxidation 
instead (Hardie and Pan, 2002).  
1.5.2 Fatty acid uptake 
Entry of fatty acids into the cells was thought to occur primarily by passive 
diffusion across the membrane, with the rate of uptake determined by the fatty 
acid concentration in the blood circulation and the rate of intracellular fatty acid 
metabolism. The aqueous solubility of fatty acids is recognised as being 
extremely low therefore fatty acids need to be bound to protein for vascular 
transport (Vorum et al., 1992). Albumin and fatty acid binding protein (FABPc) 
act as buffers, within the extracellular and intracellular compartment 
respectively. Therefore under physiological conditions the concentration of fatty 
acids is 100-400 μM, but only 7.5 ± 2.5 nM is not bound to proteins (Richieri and 
Kleinfeld, 1995). The uptake of fatty acids into cells can occur by passive 
diffusion or be mediated by membrane proteins (Kampf and Kleinfeld, 2004). 
The most common membrane associated fatty acids transporters are shown in 
Table 1.1 (Glatz et al., 2010).   
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Protein 
Molecular 
weight (kDa) 
Sites of expression 
 
FABPpm (Plasma 
membrane fatty acid 
binding protein) 
40-43 
Liver, heart, muscle, adipose tissue, intestine, 
placenta 
FATP1 (Fatty acid 
transport protein 1) 
63 
Adipose tissue, heart, muscle brain, kidney, 
skin, lung 
FAT (Fatty acid 
translocase)/CD36 
88 
Heart, intestine, skeletal muscle, adipose tissue, 
spleen, platelets, monocyte/macrophage, 
endothelium, epidermis, kidney, brain, liver 
Caveolin 1 21-24 
Ubiquitously expressed, except in muscle and 
heart where caveolin 3 is predominantly 
expressed 
 
Table 1.1 Tissue expression and molecular weight of most common 
plasma membrane proteins that mediate fatty acid uptake.  
Modified from (Glatz et al., 2010) 
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1.5.3 Fatty acid oxidation  
Kennedy and Lehninger demonstrated in 1949 that fatty acids were oxidised in 
mitochondria (Kennedy and Lehninger, 1949). Before entering into this 
organelle fatty acids need to be activated to fatty acyl-CoA. This process 
involves esterification of fatty acids with acyl-CoA and is mediated by acyl-CoA 
synthetase on the outer mitochondrial membrane. Once activated, fatty acyl-
CoAs have to reach the mitochondrial matrix, where the oxidation process 
occurs. Long-chain fatty acyl-CoAs (LCFA-CoA) can not easily traverse the 
inner mitochondrial membrane, therefore they need to be conjugated to 
carnitine, a reaction catalysed by carnitine palmitoyl transferase (CPT) 1. CPT-1 
is located on the cytosolic face of the external mitochondrial membrane and 
represents the rate-limiting enzyme for fatty acid oxidation. Carnitine 
acylcarnitine translocase (CACT) mediates the transfer across the inner 
mitochondrial membrane of LCFA-carnitine, which is cleaved by CPT-2. 
Carnitine is released into the matrix and can be recycled back to the cytosol 
through CACT, while long-chain fatty acids are conjugated back to CoA form 
(Longo et al., 2006) (Fig 1.5). Fatty acyl-CoA can then be degraded to acetyl-
CoA via the β-oxidation process, a cycle of four reactions in which fatty acyl-
CoAs are shortened by removal of two carboxy terminal carbon atoms that are 
released as acetyl-CoA (Fig 1.6). This cycle is repeated until all the acyl-CoA is 
converted into acetyl-CoA. The acetyl-CoA can then enter into the tricarboxylic 
acid cycle to produce ATP via the respiratory chain and ATP-synthase. (Beinert 
et al., 1956; Houten and Wanders, 2010). β-oxidation of monounsaturated and 
polyunsaturated   fatty acids  share  the  same  reactions  as  for  saturated fatty  
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Figure 1.5 Transport of long chain fatty acids into the mitochondria. 
Long chain fatty acids (LC-FA) are converted in the cytosol to LCFA-CoA, a 
reaction catalysed by the enzyme long-chain fatty acyl CoA synthetase, localised 
on the external mitochondrial membrane (EMM). To be transported across the 
EMM, LC-CoA are converted to LC-carntine by carnitine palmitoyltransferase I 
(CPT-1) in a reaction that regenerates free CoA. Carnitine acylcarnitine 
translocase (CACT) regulates the transfer of LC-carnitine across the inner 
mitochondrial membrane (IMM). Once in the mitochondrial matrix, CPT-2 
catalyses the conversion of LC-carnitine to LC-CoA, which can now be oxidised. 
This process generates free carnitine that can be redirected to the cytosol 
throught CACT. Fatty acid oxidation can be blocked by using the CPT-1 inhibitor 
Etomoxir. 
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Figure 1.6 Fatty acid oxidation.  
Fatty-acyl CoA are oxidised in a four step process in which the fatty acyl cabon 
chain is sequentially shortened by two carbons that are released as acetyl CoA. 
The process is repeated until the fatty acyl CoA is completely oxidised.   
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acids, but require two additional enzymes, isomerase and epimerase 
respectively. These enzymes shift the configuration of certain reaction 
intermediates to produce regular substrates for the subsequent reaction (Berg, 
2002; Hiltunen and Qin, 2000).  
Fatty acid oxidation is a tightly regulated process. In fact, organs can select 
which substrate to use to maintain energy homeostasis and therefore switch off 
glucose or fatty acid oxidation according to fuel availability. There are several 
mechanisms for the regulation of cellular fuel use. As mentioned in section 
1.5.1, when carbohydrates are in excess, citrate accumulation derived from 
glucose oxidation leads to activation of ACC and consequent production of 
malonyl CoA. Malonyl CoA inhibits CPT-1, the rate-limiting enzyme of fatty acid 
oxidation, and serves as a substrate for fatty acid synthesis. Moreover when 
blood glucose is high, the increased delivery and utilisation of glucose promotes 
inhibition of lipolysis thus suppressing the availability of fatty acids as a 
competing fuel substrate (Hue and Taegtmeyer, 2009; Ruderman et al., 1999). 
In contrast, in the fasting state, when circulating glucose is low fatty acids 
become the main energy source. Under such circumstances, glucagon 
stimulates HSL, inducing lipolysis and release of free fatty acids from adipose 
tissue. This event is significant as fatty acids can bind and activate peroxisome 
proliferator-activated receptor (PPARs), such as PPARα, which stimulate fatty 
acid utilisation by activating pathways regulating their transport, esterification 
and oxidation (Mandard et al., 2004). Moreover, during starvation or glucose 
deprivation, the ratio of AMP/ATP rises resulting in the activation of AMPK and 
consequent inhibition of its downstream target ACC. ACC inhibition leads to 
CPT-1 activation, inducing energy production by fatty acid oxidation. In addition, 
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fatty acid oxidation impairs glucose metabolism by short-term inhibition of 
different glycolytic steps. For example, high level of β-oxidation increases 
mitochondrial ratio of acetyl CoA/CoA, which activates the pyruvate 
dehydrogenase kinase (PDHK). Pyruvate dehydrogenase catalyses the 
oxidative decarboxylation of pyruvate to acetyl-CoA thus linking glycolysis to 
oxidative metabolism and can be inhibited by PDHK-mediated phosphorylation. 
The latter results in cytosolic citrate accumulation, which has been 
demonstrated to inhibit other glycolytic enzymes such as phosphofructokinase. 
This reciprocal competition between the oxidation of glucose or fatty acids is 
known as the “Randle cycle” (Garland et al., 1963; Randle et al., 1963).  
1.5.4 TAG synthesis 
In the well-fed state, glucose serves as the primary source of energy, so fatty 
acids are channeled into TAG synthesis. TAG represent highly concentrated 
stores of energy as they are much more reduced than carbohydrates and do not 
bind water. The complete oxidation of fatty acids produces 9 kCal/g against the 
4 kCal/g of carbohydrates, explaining why the body has selected TAG over 
glycogen as the major energy store. Although they can be synthesised in almost 
every cell, adipocytes are higly specialised for synthesis and storage of TAG 
(occupying ~90% of cell volume) and for their mobilization during the fasting 
state (Berg, 2002). There are three different pathways involved in the synthesis 
of TAG: the glycerol-phosphatase (GP) pathway in mitochondria or 
endoplasmatic reticulum (ER), the dihydroxyacetone phosphate pathway in 
peroxisomes and the monoacyglycerol (MAG) pathway in the ER (Coleman and 
Mashek, 2011; Kindel et al., 2010). In most mammalian cells the major 
pathways involve GP and MAG (Coleman and Mashek, 2011) and their 
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reactions are shown in Fig 1.7. During fasting stored TAG is catabolised by 
lipolysis, a process that releases fatty acids from the glycerol backbone to be 
metabolised or released into the blood circulation for use in other tissues. This 
process occurs in every cell, but mainly in adipocytes given their specialised 
role in the storage of TAG. Although initially HSL was thought to be the only 
enzyme involved in TAG hydrolysis, it is now clear that the major TAG 
hydrolase in adipose tissue is the adipose TAG Lipase (ATGL) (Zimmermann et 
al., 2009; Zimmermann et al., 2004). Both ATGL and HSL can catalyse the 
hydrolysis of TAG to produce diacylglycerol (DAG) (Zimmermann et al., 2004). 
DAG is then preferentially hydrolysed by HSL (Fredrikson et al., 1981; 
Haemmerle et al., 2002), while ATGL presents a really weak affinity for this 
substrate (Zimmermann et al., 2004). To date, HSL is recognised as the main 
lipase responsible for breaking down of both DAG and MAG and preferably  
hydrolyses sn-1(3) ester bonds (Yeaman, 2004). Therefore, an additional 2-
ester monoacylglycerol lipase is required in adipocytes to act with HSL to 
ensure a complete breakdown of TAG (Fredrikson et al., 1986). Lipolysis plays 
an important role not only in the release and redistribution of fat as fuel, but also 
in the production of lipid molecules that are involved in several signalling 
pathways. Products of TAG catabolism, such as DAG, ceramide and fatty acids, 
are in fact involved in the modulation of cellular pathways like insulin signalling 
or regulation of gene transcription (Zechner et al., 2012).  
1.6 Saturated fatty acids (SFAs) and their effect on insulin signalling 
There is considerable evidence that sustained increase in the blood levels of 
SFAs result in the development of insulin resistance. Insulin resistance is 
described  as  the  reduction  in  insulin  ability to  stimulate glucose  uptake and   
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Figure 1.7 Glycerol phosphate and monoacylglycerol pathways.  
Long-chain fatty acyl CoA (LCFA-CoA) are sequentially esterified to a glycerol 
backbone to generate diacylglycerol and triacylglycerol. 
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other metabolic processes in insulin-target tissues (Martins et al., 2012). Since  
insulin-induced glucose uptake occurs mainly in skeletal muscle, it follows that 
free SFAs may cause insulin resistance by primarily exerting their effect in this 
tissue. Indeed, chronic exposure of myotubes to SFAs, such as palmitate, 
results in a significant impairment of insulin signalling (Boden, 2006; 
Dimopoulos et al., 2006; Feng et al., 2012; Yuzefovych et al., 2010). Although 
the exact molecular mechanisms by which they exert this negative effect is 
unclear, it is recognised that accumulation of lipid derivatives (Macrae et al., 
2013; Stratford et al., 2004; Watson et al., 2009), oxidative stress (Hirabara et 
al., 2010; Lambertucci et al., 2008), mitochondrial dysfunction (Dela and Helge, 
2013; Hirabara et al., 2010; Yuzefovych et al., 2010) and inflammation (Boden, 
2006; Green et al., 2011; Salvado et al., 2013) induced by SFAs may be 
contributing factors (Fig 1.9).  
1.6.1 DAG and PKC 
DAG is one of the candidate molecules implicated in the development of insulin 
resistance by SFAs. In high-fat fed rats a two-fold increase in DAG levels has 
been found to be associated with the development of tissue insulin resistance 
(Schmitz-Peiffer et al., 1997). DAG can be synthesised de novo via GP or MAG 
pathways (Coleman and Mashek, 2011; Timmers et al., 2008), or by hydrolysis 
of TAG by HSL. Furthermore, it is noteworthy that DAG is not only an 
intermediate of TAG metabolism, but also plays a role in regulating intracellular 
signalling (Schmitz-Peiffer, 2000). Indeed, DAG is a potent activator of 
conventional and novel protein kinase C (PKC) isoforms, which have been 
implicated in the pathogenesis of insulin resistance (Heydrick et al., 1991; 
Schmitz-Peiffer et al., 1997). PKC is a family of serine/threonine kinases that 
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can be activated by transient increase in intracellular DAG in a Ca2+ dependent 
manner or in response to tumor-promoting phorbol esters. Based on structure, 
substrate specificity and cofactor requirement PKC kinases are classified into 
three groups: conventional (α, βI, βII and γ), novel (δ, ɛ, θ and η) and atypical (ζ 
and ι/λ) (Newton, 1995; Timmers et al., 2008). Numerous studies have linked 
the activation of PKC with insulin resistance, especially if that is mediated by 
increased lipid availability (Heydrick et al., 1991; Itani et al., 2002; Schmitz-
Peiffer et al., 1997). In particular, elevated levels of DAG lead to the activation 
of the classical PKCs α and βI, and of the novel PKCs ɛ, δ and θ, which 
negatively regulate insulin signalling mainly via inhibitory phosphorylation of 
IRS1 on its serine residues (Samuel et al., 2010). Indeed, once activated PKCθ 
can inhibit IRS1 by increasing its phosphorylation on S301, 302, 307 and 1101 
(Li et al., 2004; Samuel et al., 2010; Werner et al., 2004). PKCɛ has been 
shown to impair insulin signalling by phosphorylation on S636/639 (Mack et al., 
2008) and by direct association with the IR, which results in its decreased 
activity (Ikeda et al., 2001). In addition, in skeletal muscle PKCδ promotes 
phosphorylation of IRS1 on S357, which is associated with an attendant 
reduction in insulin action (Waraich et al., 2008).  
1.6.2 Ceramide 
Ceramide is an important lipid intermediate, which links inflammatory cytokines, 
such as TNFα, and SFAs to the regulation of insulin signalling. It is a 
sphingolipid that can be generated by de novo synthesis or sphingomyelin 
hydrolysis. De novo synthesis of ceramide can be induced by stress stimuli (e.g. 
UV radiation) and cytokines (e.g. TNFα) and starts from the condensation of 
palmitoyl-CoA and serine; a rate-limiting reaction catalysed by serine 
34 
 
palmitoyltransferase (SPT) (Fig 1.8). Since this enzyme has great affinity for 
long chain SFAs, it follows that increased levels of ceramide are linked to lipid 
oversupply and insulin resistance (Summers, 2006). Indeed, chronic exposure 
of adipocytes and myotubes to palmitate (C16:0), stearate (C18:0), arachidate 
(C20:0) and lignocerate (C24:0) but not unsaturated fatty acids induces 
ceramide synthesis (Chavez and Summers, 2003). Studies performed in 
rodents with streptozotocin-induced diabetes show a 78% increase in 
intramuscular ceramide levels (Gorska et al., 2004), while in muscle of obese 
human subjects ceramide content was doubled compared to the insulin-
responsive subjects (Straczkowski et al., 2004). The notion that ceramide may 
contribute to fatty acid induced-insulin resistance is supported by the finding 
that treating myotubes with an SPT inhibitor protects them from the detrimental 
effects of palmitate on insulin signalling (Powell et al., 2004; Watson et al., 
2009). Several groups have shown that ceramide impairs insulin signalling by 
suppressing activation of Akt by two distinct, but not mutualy exclusive 
mechanisms (Chavez et al., 2003; Powell et al., 2003; Stratford et al., 2001; 
Stratford et al., 2004). First, ceramide inhibits Akt activation by preventing its 
translocation to the plasma membrane. Previous work from the Hundal group 
has shown that ceramide can activate atypical PKCζ, and that this results in 
increased association of Akt with PKCζ and phosphorylation of the former by 
the latter on T34 within the Akt PH domain. This event results in decreased 
affinity of Akt for the phosphoinositide PI(3,4,5)P3. Using a T34A mutated AKT 
or expressing a dominant-interfering kinase dead-PKCζ mutant ameliorated the   
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Figure 1.8 De novo ceramide synthesis pathway.  
Ceramide is synthesised in a 4 step process that is initiated with the 
condensation of palmitoyl-CoA and serine. This rate-limiting reaction of 
ceramide synthesis is catalysed by serine palmitoyltransferase, an enzyme that 
can be inhibited by myriocin. Ceramide can impair insulin signalling by the 
activation of phosphatase PP2A and kinase PKCζ.   
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negative effects of ceramide on Akt-PI(3,4,5)P3 interaction and its insulin-
mediated activation (Powell et al., 2003). It has also been noticed that ceramide 
induces recruitment of Akt and PKCζ to caveolin-enriched microdomains, where 
their interaction with each other is stabilised and inhibition of Akt is further 
enhanced (Hajduch et al., 2008). Second, ceramide has been shown to activate 
PP2A, a phosphatase responsible for the dephosphorylation and consequent 
inhibition of Akt (Dobrowsky et al., 1993). Treatment with okadaic acid (Chavez 
et al., 2003; Salinas et al., 2000) or overexpression of the SV40 (simian virus 
40) small T antigen (Yang et al., 1991) both inhibit PP2A and, as such, these 
negate the inhibitory effect of ceramide on Akt activation. Ceramide also 
appears to induce insulin resistance by promoting ER stress (Boslem et al., 
2011), mitochondrial stress (Bikman and Summers, 2011) and inducing pro-
inflammatory signalling (Grigsby and Dobrowsky, 2001; Holland et al., 2011).  
1.6.3 TAG 
Evidence in literature shows that increased fatty acid availability, as seen during 
obesity, causes a loss in skeletal muscle insulin sensitivity and that this is 
associated with increased intramyocellular triacylglycerol (TAG) deposition 
(Forouhi et al., 1999). However, there is mounting evidence to suggest that 
accumulation of fatty acids as neutral lipid may in fact serve as a protective 
mechanism that helps counter the effect of lipotoxic intermediates that would 
otherwise build up in muscle. This proposition is supported by rodent studies 
showing that high-fat feeding in mice over-expressing diacylglycerol 
acyltransferase 1 (DGAT1), which facilitates TAG synthesis, protects mice from 
developing insulin resistance (Timmers et al., 2011). 
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1.6.4 Pro-inflammatory signalling 
There is mounting evidence that activation of the NFkB pathway and increased 
level of pro-inflammatory cytokines are involved in the development of obesity-
induced insulin resistance. Indeed, SFAs can activate inflammatory pathways in 
different cell types by both direct interaction with Toll-like receptors (TLRs) and 
indirect modulation of cytokine release, such as that of TNFα, interleukin (IL)-6, 
IL-8 (Haversen et al., 2009) and IL-1β (Green et al., 2011; Joshi-Barve et al., 
2007). SFA-induced TLR activation in turn promotes activation of JNK and IKK, 
which induces NFkB activation and inhibition of insulin signalling via 
phophorylation of IRS1 on inhibitory serine residues (Aguirre et al., 2000; 
Huang et al., 2012; Solinas and Karin, 2010). This is further supported by the 
finding that mice with TLR-4 loss of function mutation are protected from fat-
induced inflammation (Tsukumo et al., 2007) and obese mice treated with a 
JNK-inhibitory peptide exhibit improved insulin sensitivity and glucose tolerance 
(Kaneto et al., 2004). Holland et al. have shown that fatty acid-driven synthesis 
of ceramide is initiated by TLR-4 receptor and IKK activation since over-
expression of a dominant negative-IKK mutant in skeletal muscle cells 
antagonised palmitate-induced ceramide synthesis and insulin resistance 
(Holland et al., 2011). In insulin target tissues, TLR activation by SFAs induces  
secretion of pro-inflammatory cytokines, such as TNFα and IL-6, which can act 
on peripheral tissues leading to impair insulin signalling (Cai et al., 2005; Jove 
et al., 2006). TNF-α expression is elevated in both obese rodents and humans 
(Hotamisligil et al., 1993; Kern et al., 2001) and its inhibition using a TNF-α-
neutralising antibody leads to improved insulin sensitivity in obese rats 
(Hotamisligil et al., 1993). TNF-α can transiently activate the JNK and IKK 
38 
 
inflammatory pathways leading to negative modulation of insulin signalling by 
serine phosphorylation and inhibition of IRS1 (Liu et al., 1996). Moreover, TNF-
α infusion in healthy human subjects has been shown to induce insulin 
resistance in skeletal muscle by impairing Akt-mediated phosphorylation of 
AS160, thus leading to decreased whole-body glucose uptake (Plomgaard et 
al., 2005). Like TNF-α, IL-6 levels are also increased in obese subjects (Kern et 
al., 2001). IL-6 can be secreted by different cell types, including adipocytes, 
macrophages and skeletal muscle where it induces insulin resistance via 
impaired IRS-1/PI3K association and increased acyl-CoA levels (Kim et al., 
2004).  
1.6.5 Mitochondrial dysfunction and oxidative stress 
There is increasing evidence that mitochondrial dysfunction and oxidative 
capacity have a primary role in the pathophysiology of insulin resistance. 
Indeed, a significant reduction in mitochondrial function and fatty acid oxidation 
has been observed in skeletal muscle of insulin resistant obese and type 2 
diabetic patients (Hulver et al., 2003; Kim et al., 2000). Several studies suggest 
an important role for SFAs in the induction of mitochondrial dysfunction 
associated with insulin resistance. High-fat diets in both humans and rodents 
result in reduced ATP synthesis and oxidative phosphorylation (Brehm et al., 
2006; Sparks et al., 2005) while chronic exposure of cultured skeletal muscle 
cells to palmitate induces increased reactive oxigen species (ROS) production 
and impairs fatty acid oxidation (Pimenta et al., 2008; Yuzefovych et al., 2010). 
One main mechanism by which fatty acids can exert this negative effect on 
mitochondria is by altering expression of genes involved in mitochondrial 
function and biogenesis. Studies performed both in mice and humans have 
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shown that a high-fat diet induces a significant decrease in expression of 
peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-
1alpha); a master regulator of genes crucial for oxidation/biogenesis and 
cellular energy metabolism (Sparks et al., 2005). In addition it is noteworthy that 
in skeletal muscle of obese subjects the activity of CPT-1 and citrate sythase, 
two key mitochondrial enzymes, is reduced (Kim et al., 2000). The impaired 
mitochondrial oxidative capacity can then lead to accumulation of toxic lipid 
derivatives, such as DAG and ceramide, which, as mentioned earlier, impair 
insulin signalling (Bruce et al., 2009). There is evidence that ceramide itself 
contributes to mitochondrial stress. Indeed, ceramide has been found to alter 
membrane permeability, inhibit electron transport chain intermediates and 
induce oxidative stress (Bikman and Summers, 2011). The finding that inhibition 
of de novo ceramide synthesis in high-fat diet fed mice enhances citrate 
synthase activity and oxygen consumption is consistent with this latter view 
(Ussher et al., 2010). SFA-induced inflammation can also impair mitochondrial 
function. Indeed, cells exposed to cytokines such as TNF-α, IL-1β and IL-6 
show decreased mitochondrial membrane potential, decreased cellular ATP 
production and increased intracellular ROS levels (Ji et al., 2011; Yasuhara et 
al., 2005).  
Fatty acid-induced insulin resistance is also associated with production of ROS 
and oxidative stress. ROS are produced mainly at complex I and III in 
mitochondria and under normal circumstances can regulate several biological 
processes including, for example, immune responses, cell adhesion and growth 
factor/hormone action (Martins et al., 2012). However, high levels of ROS are 
negatively    associated   with   atherosclerosis,    neurodegenerative   diseases,   
40 
 
   
Figure 1.9 Mechanisms contributing to SFA-induced insulin resistance. 
Increased levels of saturated fatty acids result partially in raised triacylglycerol 
storage but mainly in increased concentration of lipid derivatives, such as DAG 
and ceramide. DAG impairs insulin signalling by activation of novel PKCs, which 
inhibit IR and IRS1 directly by phosphorylation of serine residues and indirectly 
by activation of JNK and IKK. These proinflammatory kinases are activated as a 
consequence of SFA-induced TLR4 activation, which induces secretion of 
proinflammatory cytokines, such as TNFα and IL-6, promoting a low-grade 
inflammatory state. Ceramide promotes the activation of PKCζ and PP2A, both 
of which inhibit Akt through different mechanisms. Ceramide also contributes to 
mitochondrial stress and dysfunction by altering membrane permeability and 
inhibiting the electron transport chain. Mitochondrial stress is also promoted by 
impaired fatty acid oxidation that leads to increased production of ROS. SFAs 
have also been shown to decrease the expression of PGC1α, mitochondrial 
complexes I, II, III and IV and to impair the activity of CPT-1. 
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obesity-induced insulin resistance and type 2 diabetes (Bonnard et al., 2008; 
Martins et al., 2012). Studies in diet-induced obese mice demonstrate enhanced 
expression of inducible nitric oxide synthase (iNOS) and production of reactive 
nitrogen species (RNS) in skeletal muscle (Pilon et al., 2010). The notion that 
ROS and RNS are associated with decreased insulin sensitivity is supported by 
the finding that mice lacking iNOS are protected by diet/obesity-induced insulin 
resistance in skeletal muscle (Dallaire et al., 2008; Perreault and Marette, 
2001). Indeed, it has been shown that treating L6 myotubes with H2O2 lowers 
insulin-stimulated glucose uptake (Maddux et al., 2001), while exposure of rat 
soleus muscle to nitric oxide donors reduces insulin-mediated activation of IR, 
IRS and Akt (Carvalho-Filho et al., 2005). In skeletal muscle ROS are mainly 
produced in mitochondria, consequently it follows that mitochondria DNA, 
protein and lipids can be affected by irreversible modification induced by these 
metabolites, thus resulting in impaired mitochondrial function (Indo et al., 2007).  
1.7 Unsaturated fatty acids (UFAs) and their effect on insulin signalling 
In addition to the dietary fat intake numerous studies have shown that the 
quality of fat is also a crucial factor in the development of insulin resistance and 
metabolic syndrome (Coll et al., 2008; Dimopoulos et al., 2006; Yuzefovych et 
al., 2010). Kinsell et al. were probably the ﬁrst to suggest that SFAs and UFAs 
could exert different effects on insulin activity in diabetic patients (Kinsell et al., 
1959). Indeed, as already discussed above, high levels of SFAs are implicated 
strongly in the development of insulin resistance, whereas monounsaturated 
(MUFAs) and polyunsaturated (PUFAs) fatty acids do not display overt 
pathogenic effect and, if anything, confer protection against the several 
detrimental effect of SFAs (Coll et al., 2008; Fedor and Kelley, 2009; 
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Kalupahana et al., 2011; Kwon et al., 2014; Salvado et al., 2013; Yuzefovych et 
al., 2010). 
1.7.1 Monounsaturated fatty acids (MUFAs) 
The important role of MUFAs in preventing insulin resistance has been 
determined by the KANWU study. In this study, 162 healthy men and women 
were followed for three months on a controlled isoenergetic diet either rich in 
SFAs or MUFAs. Insulin sensitivity was reduced by 10% on the high-SFA diet 
while it was enhanced on the MUFA diet, with no effect on insulin secretion 
(Vessby et al., 2001). However, the benificial effect of MUFAs was not seen in 
individuals with a high fat intake (>37% of energy), suggesting that both amount 
and quality of the fat were important in the modulation of insulin action (Vessby 
et al., 2001). There are several mechanisms that explain the beneficial effect of 
MUFAs. First, MUFAs preferentially accumulate as TAG due to affinity of DGAT 
for UFAs, while SFAs are mainly incorporated into DAG and ceramide, which 
induce insulin resistance (Bergouignan et al., 2009). In addition, co-provision of 
oleic acid, the most common and studied MUFA, to palmitate-treated human 
skeletal muscle cells has been shown to promote TAG accumulation, thus 
preventing DAG production and associated PKC activation (Pickersgill et al., 
2007). Moreover, MUFAs are more rapidly oxidised than long-chain SFAs 
(DeLany et al., 2000) and can prevent insulin resistance by channeling 
palmitate towards mitochondrial β-oxidation thereby reducing accumulation of 
lipotoxic lipid intermediates (Coll et al., 2008). The ability to stimulate β-
oxidation arises, in part, because MUFAs act as ligands and activators of 
PPARα, a transcription factor responsible for expression of genes encoding 
proteins involved in fatty acid oxidation, such as PGC1α and CPT-1 (Kliewer et 
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al., 1997). Whilst palmitate suppresses expression of both PGC1α and CPT-1 in 
muscle cells, oleic acid antagonises the effect of palmitate on both genes. As a 
consequence mitochondrial respiration is mantained and this helps counter 
insulin resistance (Coll et al., 2008; Yuzefovych et al., 2010). It is noteworthy 
that oleic acid supplementation also has the ability to protect skeletal muscle 
cells against palmitate-induced oxidative stress, apoptosis, JNK-mediated pro-
inflammatory signalling and impaired insulin sensitivity (Yuzefovych et al., 
2010). In addition to oleic acid, palmitoleate also enhances insulin sensitivity by 
promoting basal glucose uptake in muscle cells via increased translocation of 
GLUT1 and GLUT4 (Dimopoulos et al., 2006) and prevents palmitate-induced 
pro-inflammatory signalling and mitochondrial dysfunction (Macrae et al., 2013). 
1.7.2 Polyunsaturated fatty acids (PUFAs) 
As well as MUFAs, PUFAs have been linked to modulation of insulin sensitivity, 
although there are differences in term of benefits between n-3 and n-6 PUFAs. 
Linoleic acid represents the most abundant n-6 PUFA and a diet enriched in this 
and other n-6 PUFAs has been shown to improve insulin sensitivity after only 5 
weeks (Summers et al., 2002). Moreover, rats fed a diet enriched with n-6 
PUFAs show improved glucose tolerance and enhanced partitioning into TAG 
compared to DAG in skeletal muscle (Lee et al., 2006). Similarly, in vitro studies 
indicate that incubation of palmitate-treated L6 myotubes with linoleic acid 
alleviates insulin resistance by greater partitioning of palmitate into TAG (Lee et 
al., 2006).  
Of the n-3 PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), which are found mainly in fish, have a primary role in the modulation of 
insulin sensitivity (Fedor and Kelley, 2009; Kalupahana et al., 2011; Li et al., 
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2008). Replacement of only 6% of n-6 PUFAs and SFAs in a high-fat diet (60%) 
with fish oil rich in n-3 PUFAs effectively prevented insulin resistance in skeletal 
muscle and liver of rat (Storlien et al., 1987). Furthermore, substitution of fish oil 
with SFAs over a three week period in healthy young subjects induced (i) a 40% 
decrease in insulinaemic response with no change in the glycaemic response 
and (ii) a 35% increase in fat oxidation after oral glucose load; responses that 
are indicative of improved insulin sensitivity (Delarue et al., 1996).  
The beneficial effect of both n-3 and n-6 PUFAs is mainly due to their 
modulation of lipid metabolism. By direct interaction with PPARs, PUFAs can 
enhance the expression of genes encoding proteins involved in fatty acid  
transport and oxidation (Clarke, 2000), and mitochondrial biogenesis (Clarke, 
2000), such as fatty acid binding proteins (Kletzien et al., 1992), fatty acid 
transporter (Martin et al., 1997), CPT-1 and PGC1α (Feillet-Coudray et al., 
2013; Flachs et al., 2005). On the other hand, PUFAs suppress hepatic 
lipogenesis by decreasing the expression of ACC, with consequent reduction of 
malonyl-CoA levels and fatty acid synthase via a reduction in the liver 
expression of sterol regulatory element binding protein-1 (SREBP-1); a key 
transcription factor that regulates lipid homeostasis (Toussant et al., 1981; 
Wilson et al., 1990; Xu et al., 1999). In addition, studies performed in both 
cultured human skeletal muscle cells and obese mice have reported the ability 
of PUFAs to increase GLUT4 expression thus enhancing uptake and 
metabolism of glucose with associated benefits upon insulin sensitivity (Mikami 
et al., 2012; Vaughan et al., 2012). 
Recent work has started to dissect how the ratio of n-3 and n-6 provided in a 
diet influences health and metabolic processes. Indeed, it is believed that 
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humans have evolved on a diet with a ratio of n-6 to n-3 of ~1, but that the 
present day Western diet provides a ratio ~15:1 and that this is associated with 
cardiovascular, inflammatory and autoimmune diseases (Simopoulos, 2002). 
Despite the beneficial insulin sensitising effects mentioned above, many n-6 
PUFAs, especially arachidonic acid, are substrates for cyclooxygenase and 
lipooxygenase that catalyse the synthesis of eicosanoids, which propagate 
inflammatory signalling. This high levels of n-6 PUFAs or a high-n-6/n-3 ratio in 
the diet contributes to the development of inflammatory and immune diseases, 
whereas increased intake of n-3 PUFAs confers protective effects (Sijben and 
Calder, 2007). 
1.8 PP2A 
PP2A is a ubiquitously expressed serine/threonine phosphatase, which 
represents 0.3-1% of the total cellular protein in mammalian cells (Ruediger et 
al., 1991). PP2A is a multi functional phosphatase with more than thirty 
substrates, of which Akt, PKC, p70S6K, cAMP dependent kinases, CaM-
kinases and ERK/MAP kinases are notable targets (Millward et al., 1999). It 
follows that it is involved in the regulation of several cellular processes, such as 
cell metabolism, cell cycle, DNA replication, cell proliferation, transcription, 
translation, signal transduction, cell mobility, apoptosis and cancer (Alberts et 
al., 1993; Glenn and Eckhart, 1993; Schonthal, 2001; Tung et al., 1985).  
1.8.1 PP2A structure 
Different holoenzyme complexes of PP2A have been identified and 
characterised in a variety of tissues. The PP2A complex is present in vivo as a 
dimeric (PP2AD) or trimeric (PP2AT) form. PP2AD consists of a catalytic subunit 
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(PP2Ac) of ~36kDa bound to a scaffolding subunit (PR65/A) of ~65 kDa. This 
dimeric complex can then interact with a regulatory B subunit, which stabilises 
the holoenzyme. Four different families of regulatory subunits have been 
identified so far and each of them seems to influence the substrate specificity 
and the cellular localization of PP2A (Table 1.2) (Mayer-Jaekel and Hemmings, 
1994; Zolnierowicz, 2000). The catalytic subunit is present in mammalian cells 
in two isoforms, α and β, which are ubiquitously expressed and share 97% 
identity (Khew-Goodall et al., 1991). However, mice lacking the PP2Acα die 
during the embryonic state demonstrating that despite the high similarity, the 
two isoforms do not have redundant functions (Gotz et al., 1998). The second 
constituent of PP2AD is the PR65/A subunit, which, like the catalytic subunit, 
exists as two different isoforms (α and β) in mammalian cells. These isoforms 
share 86% identity and are ubiquitously expressed (Hemmings et al., 1990). 
The structure of PR65/A is characterised by 15 tandem leucine rich repeats of 
39-amino-acid sequence, known as HEAT (huntingtin/elongation/A 
subunit/TOR) motifs. HEAT- motifs are stacked parallel to each other, creating a 
surface for protein-protein interaction between PR65/A and the catalytic and 
regulatory subunits (Groves et al., 1999; Hemmings et al., 1990).  
1.8.2 PP2A regulation 
Considering the role that PP2A plays within reciprocal control of cell signalling 
events regulated by phosphorylation, it is not surprising that it is itself subject to 
a tight regulation. PP2A can regulate its own abundance via an auto-inhibition 
mechanism during translation. PP2A can dephosphorylate specific proteins that 
form part  of the  translational apparatus, resulting in the  inhibition of its  mRNA  
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B subunit 
family 
Isoforms Tissue expression 
Subcellular 
localization 
B/PR55 
α Widely distributed Cytosolic fraction 
β Brain Cytosolic fraction 
γ Brain 
Cytoskeletal 
fraction 
δ Widely distributed Cytoplasm 
B’/PR61 
α Heart and skeletal muscle  
β Brain Cytoplasm 
γ Heart and skeletal muscle Nucleus 
δ Brain 
Nucleus and 
cytoplasm 
ε  Cytoplasm 
B’’/ PR72 
PR72 Heart and skeletal muscle  
PR130 Widely-distributed  
PR59 
Widely-distributed but 
absent in skeletal muscle 
 
PR48  Nucleus 
B’’’/PR93/PR110 
PR93  Nucleus 
PR110  
Postsynaptic 
densities of 
neuronal 
dendrites 
 
Table 1.2. Tissue distribution and subcellular localisation of PP2A 
regulatory subunits. 
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translation thereby maintaining control of cellular PP2A abundance (Baharians 
and Schonthal, 1998).  
Another level of control of PP2A activity involves post-translational modification 
of the catalytic subunit on the highly conserved C-terminal domain 
(304TPDYFL309) (Fig 1.10). PP2Ac can be reversibly phosphorylated on a 
tyrosine residue (Y307) leading to inactivation of the phosphatase. In vitro, the 
transient phosphorylation of Y307 is mediated by both receptor tyrosine 
kinases, such as epidermal growth factor and insulin receptors, or non receptor 
tyrosine kinases such as pp60v-srk, pp56lck, Lyn, Fyn and Src (Chen et al., 1992; 
Chen et al., 1994). The PP2A inhibitor okadaic acid can enhance 
phosphorylation of PP2Ac suggesting that PP2A can also act as a 
phosphotyrosine phosphatase and mediate autodephosphorylation as a means 
of self reactivation (Chen et al., 1992). In vivo transient phosphorylation of Y307 
is promoted in response to IL-1 and TNFα (Guy et al., 1995), epidermal growth 
factor, serum (Chen et al., 1994) and insulin (Begum and Ragolia, 1996; 
Srinivasan and Begum, 1994). It is possible that such reversible inhibition of 
PP2A works as an accelerating factor during the transmission of signals 
initiated from receptors to their downstream cellular effectors. PP2Ac can also 
be phosphorylated in vitro on an unidentified threonine residue by an 
autophosphorylation-activated protein kinase, resulting in the inactivation of 
both phosphoserine/threonine and phosphotyrosine phosphatase activity 
(Damuni et al., 1994; Guo and Damuni, 1993). 
In addition to phosphorylation, the C-terminal end of PP2Ac can also be 
methylated. Reversible methylation occurs on the carboxyl group of L309 (Lee 
et al., 1996; Xie and Clarke, 1994). Two enzymes are involved in the regulation 
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of this process: the leucine carboxyl methyl transferase-I (LCMT-I) (De Baere et 
al., 1999) and the PP2A methylesterase-1 (PME-1) (Ogris et al., 1999). L309 
methylation can affect PP2A holoenzyme assembly. This notion is supported by 
the finding that inactivation of LCMT-1 inhibits the formation of PP2AT (Wu et 
al., 2000) and that methylated L309 is required for the association of the 
B/PR55α subunit to the catalytic subunit (Bryant et al., 1999). Okadaic acid can 
inhibit PP2A not only by increasing its phosphorylation but also by reducing its 
methylation by binding to the catalytic subunit and therefore preventing the 
interaction of LCMT-1 to the C-terminal part of PP2Ac (Li and Damuni, 1994).  
1.8.3 PP2A role in cellular signalling 
PP2A plays a major role in the regulation of several cellular processes including 
cell cycle, apoptosis and mRNA translation (Zolnierowicz, 2000). The 
phosphatase can regulate the activities of numerous kinases, such as Akt. Such 
regulation is significant as aberrant modulation of Akt-directed insulin signalling 
by PP2A could promote insulin resistance as seen in response to sustained 
increases in SFA availability. Palmitate, a SFA, can drive synthesis of ceramide, 
which is a potent activator of PP2A and, as such, contributes to enhanced 
dephosphorylation/inactivation of Akt and thus insulin signalling (Galbo et al., 
2011). In addition to Akt, PP2A can also modulate the ERK/MAPK kinase 
pathway. Both ERK1/2 and MEK1 have been identified as PP2A substrates 
(Gomez and Cohen, 1991) and treatment with either okadaic acid or SV40 
small-t antigen, which inhibit the phosphatase, results in the activation of these 
kinases (Gause et al., 1993; Sonoda et al., 1997; Sontag et al., 1993). PP2A is 
also involved in the modulation of mRNA translation. P70S6K, which plays a 
key role in control of translation, has  been found  to form a stable complex with  
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Figure 1.10 Structure and regulation of PP2A.  
PP2A complex consists of a catalytic subunit (C), a scaffolding subunit (A) and 
a regulatory subunit (B). The activity of PP2A depends on post translational 
modification of its catalytic subunit. Demethylation of the L309 residue by 
PP2A methylesterase-1 (PME-1) and phosphorylation of Y307 residue by 
insulin/grow factor induced-Src result in the inactivation of the phosphatase.  
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PP2A in vivo (Westphal et al., 1999) and evidence exists showing that P70S6K 
can be dephosphorylated by the purified phosphatase in vitro (Ballou et al., 
1988). The protein Tap42/α4 (type 2A-associated protein of 42 kDa) can directly 
interact with and inhibit the catalytic subunit of PP2A. This interaction is 
disrupted by rapamycin, an inhibitor of mTOR, suggesting that PP2A may 
participate in the rapamycin-sensitive pathway that links extracellular stimuli 
with mRNA translation (Murata et al., 1997). PP2A is also involved in the 
termination of translation since it can interact with the eukaryotic release factor 
1 (eRF1), which may help bring the phosphatase in proximity of putative 
ribosomal targets belonging to the translation apparatus (Andjelkovic et al., 
1996b; Lechward et al., 1999). There is also evidence that this phosphatase is 
connected to apoptosis, since the scaffolding subunit A/PR65 has been 
identified as a substrate for caspase 3. Caspase 3 is responsible for the 
cleavage of key enzymes involved in DNA repair (Cryns et al., 1996). By 
cleaving the A/PR65 subunit, caspase 3 enhances the phosphatase activity of 
the free catalytic subunit, which can then act on its substrates like MAPK 
(Santoro et al., 1998). In addition, PP2A can dephosphorylate Bcl-2 on its S70 
residue. Bcl-2 requires this phosphorylation in order to exert its anti-apoptotic 
effect (Deng et al., 1998). Several studies have implicated PP2A in the 
regulation of the cell cycle, especially in the G2/M transition. This transition is 
mediated by cyclin dependent kinase 1 (Cdk1/Cdc2), which forms a complex 
with cyclin B. Cdc2 activity requires it to be phosphorylated on T161 and PP2A 
has been identified in vitro as the phosphatase responsible for 
dephosphorylation of this residue. T14 and 15 are two inhibitory residues of 
Cdc2 and their phosphorylation is regulated by the kinase WEE1 and the dual-
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specificity phosphatase cell division cycle 25 (CDC25). PP2A can indirectly 
inhibit Cdc2 by activating WEE1 kinases and inactivating the CDC25 
phosphatase (Clarke et al., 1993; Mueller et al., 1995; Yamashita et al., 1990). 
There is also evidence of PP2A involvement in inflammation (DiDonato et al., 
1997; Sun et al., 1995) and carcinogenesis (MacKintosh and MacKintosh, 1994; 
Wang et al., 1998). 
1.9 An alternative source of energy: amino acids  
As mentioned earlier, cells can handle different types of fuel depending on 
nutrient availability and tissue need. Whilst glucose and fatty acids represent 
the primary fuel sources, amino acids also represent a potential energy source 
and their pool size requires to be strictly regulated by cells via modulation of 
their transport and metabolism. 
1.10 Amino acids classification 
Amino acids represent the building blocks of proteins. However, of the three 
hundred amino acids present in nature, only twenty actually constitute 
components of proteins. Most microoorganisms can synthesise all twenty amino 
acids, but mammals cannot synthesise nine of them. These are known as 
essential amino acids and have to be consumed in the diet, whereas the 
remaining amino acids are designated as non essential and can be synthesised 
in a small number of steps (Berg, 2002). Due to variations in the side chain (R-
groups) each amino acid has different functions and chemical properties (Berg, 
2002). Table 1.3 shows a classification based on polarity and charge of the R-
group.  
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Amino acid Abbreviation 
Single letter 
code 
Side-Group 
polarity 
Side-group 
charge 
Arginine Arg R polar positive 
Asparagine Asn N polar positive 
Aspartate Asp D polar negative 
Cysteine Cys C polar neutral 
Glutamate Glu E polar negative 
Glutamine Gln Q polar neutral 
Histidine His H polar positive 
Lysine Lys K polar positive 
Serine Ser S polar neutral 
Threonine Thr T polar neutral 
Tyrosine Tyr Y polar neutral 
Alanine Ala A non-polar neutral 
Glycine Gly G non-polar neutral 
Isoleucine Ile I non-polar neutral 
Leucine Leu L non-polar neutral 
Methionine Met M non-polar neutral 
Phenylalanine Phe F non-polar neutral 
Proline Pro P non-polar neutral 
Tryptophan Trp W non-polar neutral 
Valine Val V non-polar neutral 
 
Table 1.3 Nomenclature and chemical features of the 20 major Amino 
Acids.   
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1.11 Amino acid sensing 
Cells are able to ‘sense’ and respond to changes in extracellular nutrients by 
functional adaptations, such as up or down regulation of genes involved in 
metabolism or nutrient transport in order to maintain normal cellular 
homeostasis. Such adaptation involves nutrient sensors such as receptors, 
transporters and enzymes, which initiate or affect signalling cascades 
responsive to changes in the nutrient environment (Taylor, 2014). Two main 
intracellular amino acid sensing-signalling pathways have been identified in 
mammalian cells: the mTORC1 and the general control non-derepressible 2 
(GCN2) pathways. While mTORC1 pathway is activated in response to amino 
acids sufficiency to regulate protein synthesis and cell proliferation, GCN2 is 
stimulated by amino acid insufficiency to induce expression of genes that allow 
cells to adapt to amino acid deprivation (Fig 1.11) (Taylor, 2014). 
1.11.1 mTOR 
TOR (target of rapamycin, mTOR in mammals) is a conserved atypical 
serine/threonine kinase of ~290 kDa which plays a crucial role in the regulation 
of cell growth and proliferation. As suggested by the name, TOR is sensitive to 
rapamycin, a Streptomyces hygroscopicus derived fungicide which has been 
discovered to have anti-proliferative properties (Heitman et al., 1991; Tsang et 
al., 2007; Vezina et al., 1975). mTOR is present as two functionally distinct 
complexes: mTORC1 and mTORC2. mTORC1 is rapamycin sensitive whereas 
mTORC2 is insensitive to the drug and can be activated by growth factors 
leading to phosphorylation of Akt on S473 and regulation of cytoskeletal 
organisation (Jacinto et al., 2004). mTORC1 can be activated by both growth 
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factors and amino acids and plays a major role in the regulation of protein 
synthesis and cell growth. mTOR is the catalytic subunit of the mTORC1 
complex, which also consists of a scaffolding protein Raptor (regulatory-
associated protein of mTOR) that is responsible for substrate recognition; the 
positive regulator mLST8 (mammalian lethal with sec 13 protein 8), and the 
inhibitory modulators PRAS40 (proline-rich Akt substrate 40 kDa) and Deptor 
(Dep-domain mTOR interacting protein) (Kim et al., 2013). The two best-
characterised substrates of mTORC1 are P70S6K and eIF4E-binding protein 1 
(4EBP1), which are involved in the regulation of protein synthesis (Kim et al., 
2002). Under nutrient-rich conditions, amino acids induce a conformational 
change in the mTORC1 complex promoting mTOR interaction with P70S6K and 
4EBP1 via Raptor and their phosphorylation (Kim et al., 2002). Phosphorylation 
of 4EBP1 results in its inhibition and release of the eukaryotic translation 
initiation factor, eIF4E, which is involved in directing ribosomes to the cap 
structure of mRNA to promote cap-dependent translation (Proud, 2002). Raptor 
recognises P70S6K via its TOS (TOR-signalling) motif and allows its interaction 
with mTOR (Schalm et al., 2005). P70S6K regulates translation through its 
downstream targets ribosomal protein S6 and eukaryotic translation initiation 
factor (eIF4A). Ribosomal protein S6 is a component of the 40S ribosome 
subunit involved in translation initiation at the 5’ 7-methylguanylate cap of 
mRNA. Phosphorylation by P70S6K enhances S6 cap-binding activity 
improving protein synthesis (Ruvinsky and Meyuhas, 2006). As indicated 
earlier, amino acids can stimulate mTOR activation, an event potentially 
involving a number of different mechanisms. First, amino acids have been 
shown  to  enhance  the activity  of  the  vacuolar  protein  sorting 34  (Vps34), a   
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phosphatidylinositol 3-kinase that appears to participate in nutrient-induced 
mTOR activation (Gulati et al., 2008). Indeed, silencing of human Vps34 has 
been shown to inhibit amino acid-induced activation of P70S6K, whilst its 
overexpression leads to activation of its mTOR downstream target (Nobukuni et 
al., 2005). mTORC1 activation also involves small GTPases. The Ras-related 
GTPase (Rag) family consists of four members, A, B, C and D, which exist as 
heterodimers of RagA/B and RagC/D (Shaw, 2008). The combination of 
RagA/B-GTP and RagC/D-GDP represents the active form while the inverse 
nucleotide association represents the inactive one (Duran and Hall, 2012). Rag 
GTPase heterodimers interact with a protein termed the Ragulator that is 
localised on the lysosome membrane (Bar-Peled et al., 2012). Amino acids 
stimulate a direct interaction between the active form of the Rag GTPases and 
Raptor, leading to localisation of the mTORC1 complex to the lysosome 
surface. This event allows mTORC1 to interact with Ras homologue enriched in 
brain (Rheb), a small GTPase that binds to the N-terminus of the mTOR 
catalytic domain resulting in mTORC1 activation (Long et al., 2005). Rheb-GTP 
loading is itself regulated by the TSC1/2, a Rheb GAP that induces the 
conversion of Rheb-GTP to Rheb-GDP leading to its inhibition (Inoki et al., 
2003). 
1.11.2 GCN2  
While amino acid provision activates the mTORC1 pathway, amino acid 
deprivation induces an amino acid response (AAR) signal transduction pathway 
(Kilberg et al., 2009). This pathway is mediated by GCN2 that acts as a nutrient 
sensor by binding to uncharged tRNAS, whose levels are increased by amino 
acid limitation (Dong et al., 2000). Once activated by this interaction, GCN2 
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phosphorylates the translation initiator factor eIF2α on S51, leading to its 
inhibition and consequent reduction of protein synthesis (Dong et al., 2000). 
Paradoxically, eIF2α phosphorylation results in increased translation of a group 
of stress-responsive mRNAs, such as activating transcription factors (ATF) 4 
and 5 (Vattem and Wek, 2004; Zhou et al., 2008) and growth arrest and 
damage-inducible 34 (GADD34) (Lee et al., 2009). ATF4 is a transcription factor 
with ubiquitous distribution but very low expression. This is due to two upstream 
open reading frames present in the 5’UTR of ATF4 mRNA, which inhibits its 
translation in normal conditions but induces it under stress conditions, such as 
amino acid deprivation (Harding et al., 2000). ATF4 promotes the transcription 
of genes encoding for proteins involved in the regulation of stress response, 
such as the amino acid transporters CAT-1 (Cationic amino acid transporter 1) 
and SNAT2 (System A/sodium-coupled neutral amino acid transporter), the 
regulator of cell growth TRB3 (Tribbles homolog 3) and the transcription factor 
CHOP (C/EBP homology protein) (Kilberg et al., 2009). ATF4 induces the 
transcription of these genes by binding to CCAAT-enhancer binding protein-
activating transcription factor (C/EBP-ATF) response elements (CARE), which 
can act as amino acid response elements (AARE) but also mediate the 
transcription of these genes under ER stress (Barbosa-Tessmann et al., 2000). 
1.12 Amino acid transport 
Cellular supply of amino acids to meet the demands for protein synthesis can 
be met both by biosynthesis and transport of amino acids into the cells. The 
transport of amino acids across the membrane is a tightly regulated process, 
which responds to several stimuli, such as substrate availability, stress and 
hormones and is mainly catalysed by transporters characterised as being, 
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primary, secondary or tertiary active transporters (Fig 1.12) (Hundal and Taylor, 
2009). Primary active transporters utilise ATP hydrolysis to help mediate the 
transport of solutes against their electrochemical gradient. The Na+/K+ pump 
belongs to this category and is capable of ATP hydrolysis to promote the efflux 
of 3Na+ ions in exchange for 2K+ ions. This process contributes to maintenance 
of a membrane potential and a transmembrane ion gradient that can be utilised 
to drive secondary active transporters (e.g. SNAT2). Most of these transporters 
bind amino acid substrates and Na+, and use the electrochemical gradient of 
the latter to translocate both substrates across the membrane. The 
concentration gradient produced by secondary active transport can then be 
utilised by tertiary active transporters (e.g. System L/L-type amino acid 
transporter 1 (LAT1)) as a driving force for counter-exchange of extracellular 
solutes for those resident in the intracellular compartment (Hundal and Taylor, 
2009). Christensen et al. first classified amino acid transporters as “systems” by 
identifying those systems that accepted structurally related amino acids 
(Christensen, 1984). By this process, different systems have been identified for 
the transport of neutral, cationic and anionic amino acids (Table 1.4).  
1.13 Role of amino acid transporters in amino acid sensing: the 
transceptor concept 
It is widely known that amino acids influence several cell functions including, for 
example, regulation of cell signalling gene expression and metabolism (Hyde et 
al., 2003). As mentioned earlier, changes in amino acid availability can lead to 
activation of the GCN2/ATF4 pathway, resulting in expression of genes 
encoding amino acid transporters and amino acid biosynthetic enzymes and 
stimulation  of  the  mTORC1/P70S6K  axis,  which  enhances  cell  growth  and 
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proliferation. Since the activity of amino acid transporters can help modulate the 
intracellular amino acid pool via their gate-keeping functions, they are 
increasingly thought to play a role also in amino acid sensing and cell signalling 
(Hundal and Taylor, 2009). It is plausible that transporters could initiate a signal 
transduction cascade in direct response to changes in substrate loading or by 
regulating the availability of a specific amino acid, which interacts with an 
intracellular nutrient sensor(s) and receptor(s) (Hyde et al., 2003). Amino acid 
transporters that possess both transporter and receptor functions have been 
termed “transceptors” and have been observed mainly in lower eukaryotes with 
recent candidates also being identified among the family of mammalian amino 
acid transporters (e.g. SNAT2) (Hundal and Taylor, 2009; Hyde et al., 2007). 
The first evidence that nutrient transporters can also act as sensors derives 
Table 1.4 Mammalian Amino Acid transporters.  
(Hyde et al., 2003) 
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from studies performed on the prokaryotic phosphoenol pyruvate- carbohydrate 
phosphotrasferase system (PTS) (Postma et al., 1993). Several transceptors 
have now been identified in eukaryotic systems, all belonging to the amino acid-
polyamine-organocation (APC) superfamily of transporters, suggesting that this 
function has been highly conserved through evolution (Hundal and Taylor, 
2009). For example, in Saccharomyces cerevisiae the transporter Ssy1p also 
possesses a sensing function. Binding of the amino acids to Ssyp1 induces a 
conformational change in the transporter activating a signal transduction 
cascade that results in the activation of transcription factors that promote 
expression of amino acid permeases (Hundal and Taylor, 2009). In Drosophila 
three distinct transporters with relevant effects on cell growth have been 
identified: Minidiscs (MDN), Slimfast (Slif) and Pathetic (Path). Mutations in 
MDN result in larvae with growth defects, suggesting the involvement of the 
transporter in the nutrient/signalling pathway that modulates proliferation (Martin 
et al., 2000). Mutations in Slif also lead to larvae with growth retardation and 
morphological problems, mimicking the phenotype obtained by loss of TOR 
signalling (Zhang et al., 2000). Path over expression induces over growth of the 
differentiating eye, suggesting its involvement in mediating TOR signalling 
(Goberdhan et al., 2005). Since path has very low transport capacity, it is 
thought that transporter occupancy provides a stimulus to preserve TOR 
signalling in response to changes in amino acid availability (Goberdhan et al., 
2005). In the mammalian central nervous system the glial glutamate/aspartate 
transporters GLutamate ASpartate Transporter (GLAST)/ Excitatory Amino Acid 
Transporter 1 (EAAT1) can sense extracellular glutamate abundance and 
regulate its clearance. In the presence of high levels of glutamate the binding of 
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the amino acid to EAAT1 stimulates the recruitment of this transporter to the 
plasma membrane in astrocyte cultures (Duan et al., 1999). The effects of 
glutamate upon EAAT1 also influences the surface expression of the ASC-
amino acid transporter 2 (ASCT2), a carrier that transports protonated 
glutamate, suggesting that EAAT1 functions both as a sensor and an effector in 
the process of clearing excess extracellular glutamate (Gegelashvili et al., 
2007). Another mammalian transporter that is thought to act as a transceptor is 
the Na+ dependent neutral amino acid transporter SNAT2. 
1.14 Na+ dependent neutral amino acid system: System A/SNAT2 
Oxender and Christensen first identified two distinct systems for the transport of 
neutral amino acids in Ehrlich cells, defined System A and L (Oxender and 
Christensen, 1963). System A is a secondary active transporter as movement of 
amino acids is coupled to the downhill movement of Na+. System A  mediates 
the transport of neutral amino acids containing short, polar or linear side chains 
but can also promote the uptake of N-methylated substrates, such as 2-
methylaminoisobutyric acid (MeAIB) (Christensen et al., 1965). Its activity is 
reduced at low extracellular pH (Oxender and Christensen, 1963) and by the  
presence of intracellular substrates, a phenomenon  known as trans-inhibition 
(Christensen, 1975). Moreover, System A can be regulated by hormones such 
as insulin and by changes in amino acid availability and cell stress (McGivan 
and Pastor-Anglada, 1994).  
1.14.1 SNAT2 
Among the subtypes of System A family of carriers, SNAT2 (sodium-coupled 
neutral amino acid transporter 2), encoded by SLC38A2 gene, is the most 
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widely expressed (Hatanaka et al., 2000; Sugawara et al., 2000; Yao et al., 
2000). SNAT2 is thought to be composed of eleven transmembrane domains 
with its N-terminus residing in the cytosol and its short C-terminal tail located 
within the extracellular compartment (Mackenzie and Erickson, 2004). SNAT2 is 
thought to be glycosylated, since consensus glycosylation sites are present in 
the predicted extracellular loops of the transporter (Fig 1.13). Work from the 
Hundal lab, using two antibodies raised against the intracellular N-terminal 
region and the extracellular loop between transmembrane domains 7 and 8 of 
SNAT2, revealed that a 60 kDa protein is recognised by both antibodies. 
Although the predicted molecular size of rat SNAT2 is ~55 kDa, the two 
glycosylation sites identified on the transporter could alter its mass post-
translationally. Interestingly, the antibody against the intracellular N-terminal 
region detected an additional band of ~40 kDa, which is thought to represent 
the immature non-glycosylated form of SNAT2 (Hyde et al., 2001). The 
transporter has also been identified in microsomal and intracellular membranes 
in rat skeletal muscle cells indicating the presence of an intracellular pool of 
immature transporters that could be released in response to different stimuli, 
which are known to enhance System A activity (Hyde et al., 2001). In fact 
SNAT2 is subject to complex regulatory control mediated by a variety of stimuli 
including, for example, hyperosmotic shock (Alfieri et al., 2001), amino acid 
deprivation (Gazzola et al., 2001; Iresjo et al., 2005; Ling et al., 2001; Palii et 
al., 2004; Yao et al., 2000) and insulin stimulation (Kletzien et al., 1976; 
McDowell et al., 1998). The effects of such stimuli have been studied in skeletal 
muscle cells. Kashiwagi et al. showed that in L6 rat skeletal muscle cells 
hyperosmotic   shock,   induced   by  adding   sucrose   to  the   media  for   4 h,  
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upregulated SNAT2 activity by inducing de novo synthesis of the transporter 
(Kashiwagi et al., 2009). This upregulation appears to be mediated by the 
tonicity enhancer binding protein (TonEBP)/NFAT5 giving that decreased 
function of this transcription factor resulted in diminished amount of SNAT2 
mRNA in transgenic T cells following hypertonic shock (Trama et al., 2002). 
Insulin stimulation rapidly increases plasma membrane SNAT2 abundance, as it 
does for the GLUT4 glucose transporter, through its recruitment from an 
intracellular compartment by a PI3K-dependent mechanism (Hyde et al., 2002; 
Kashiwagi et al., 2009). Both rapid and long-term upregulation of SNAT2 were 
observed by amino acid deprivation, a response known as “adaptive regulation”.  
1.14.2 SNAT2 adaptive response 
The adaptive modulation of SNAT2 is one of the most-studied responses to 
amino acid withdrawal in mammalian cells. It is a process occurring in two 
phases: a rapid phase consists of release of the transporter from an intracellular 
pool and recruitment to the plasma membrane, and a long-term upregulation 
which involves changes in gene expression via activation of the GCN2/ATF4 
axis (Kashiwagi et al., 2009; Thiaville et al., 2008). The adaptive response 
phenomenon was described over 40 years ago by Gazzola et al. who showed 
System A-mediated transport is increased in response to amino acid deprivation 
in chick embryo heart cells (Gazzola et al., 1972). This increase in transporter 
activity is prevented by cycloheximide and actinomycin D, which inhibit protein 
synthesis and gene transcription respectively, suggesting that the adaptive 
response requires an induction of gene expression. (Gazzola et al., 1972). 
Subsequently, Palii et al. identified an amino acid response element (AARE) in 
the first intron of the human SNAT2 sequence, which regulates SNAT2 gene 
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expression in response to amino acid availability (Palii et al., 2004). This AARE 
is identical to that found in the promoter region of CHOP, a transcription factor 
that also exhibits adaptive regulation under amino acid withdrawal (Palii et al., 
2004). It follows that the increase in SNAT2 expression would partly occur by 
activation of the GCN2 pathway in response to increased uncharged tRNA 
levels and consequent transcription of ATF4-dependent AARE containing genes 
(Thiaville et al., 2008). GCN2 activation also results in the phosphorylation and 
inhibition of translation initiation factor eIF2α and dephosphorylation of eIF4E, 
which recognises the 7-methylguanylate cap of mRNA (Wek et al., 2006). 
Although the translation of the majority of cellular mRNAs is decreased by these 
events, a pool of mRNAs that encode proteins essential for the cellular stress 
response are endowed with internal ribosome entry sites (IRES) and therefore 
translated in a cap-independent manner (Komar and Hatzoglou, 2005). An 
IRES sequence has been identified at the 5’-UTR of SNAT2 mRNA suggesting 
that this transporter is efficiently translated under amino acid deprivation 
(Fernandez et al., 2001). In addition to these mechanisms, the interaction 
between SNAT2 and its substrates is thought to take part in the adaptive 
response. Gazzola et al. have shown in fact that the adaptive increase in 
SNAT2 can be inhibited by resupply of a single substrate amino acid or the non-
metabolizable substrate MeAIB (Gazzola et al., 1981). Given that 
resupplementation of one amino acid is not sufficient to decrease uncharged 
tRNA level, it follows that SNAT2 binding to a substrate induces a repressive 
signal that is able to block the adaptive response, although the molecular 
mechanisms behind this event remain unknown. One possibility is that, 
substrate binding induces a conformational change in SNAT2 that allows it to 
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initiate a signal cascade regulating its own expression. Work from the Hundal 
lab has identified two different pathways involved in the repression effect by 
single amino acids upon the adaptive response. One pathway involves JNK, 
which becomes activated in response to amino acid withdrawal and whose 
inhibition suppresses SNAT2 adaptation. The second pathway is independent 
of JNK but sensitive to PI3K inhibition (Hyde et al., 2007). In addition to a 
requirement for SNAT2 gene transcription, studies from the Hundal lab have 
revealed that increased SNAT2 protein stability also contributes to the adaptive 
response. Hyde et al. demonstrated that expression of a C-terminally-V5-tagged 
SNAT2 construct expressed under the control of a CMV promoter, which was 
not responsive to changes in amino acid availability, leads to increased 
expression and stabilisation of SNAT2-V5 protein (Hyde et al., 2007). In 
contrast to SNAT2, expression of a related SNAT family member, SNAT5-V5, 
did not result in increased stabilisation upon cellular amino-acid withdrawal. 
This fundamental divergence may arise because of differences in the N-terminal 
domain of SNAT2 and SNAT5 since a SNAT2-5 chimera, in which just the 
cytosolic N-terminal tail of SNAT2 was substituted for that of SNAT5, led to 
enhanced stabilisation of the chimeric protein in cells subjected to amino-acid 
withdrawal (Hyde et al., 2007). The N-terminal tail of SNAT2 harbours putative 
lysine ubiquitination residues and there is evidence that SNAT2 stabilization 
and turnover at the plasma membrane involves the ubiquitin–proteasomal 
pathway. Although most membrane proteins are degraded by lysosomes, some 
of them, such as the epithelial sodium channel, have been shown to be targeted 
by ubiquitin and degraded through the proteasome system (Malik et al., 2001; 
Malik et al., 2005). Hatanaka et al. have shown that SNAT2 is polyubiquitinated 
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and degraded by the proteasome through the action of the E3 ligase Nedd4.2 
(neural precursor cell expressed, developmentally down-regulated 4-2) in 3T3-
L1 adipocytes (Hatanaka et al., 2006). Data from the Hundal lab demonstrated 
that in L6 skeletal muscle cells treatment with the proteasome inhibitor MG132 
results in increased accumulation of SNAT2. This latter observation implies that 
in skeletal muscle cells SNAT2 turnover at the cell membrane could be 
regulated by proteasomal degradation.   
1.14.3 SNAT2 as a transceptor 
In addition to its role as a transporter, SNAT2 is also thought to exhibit a 
receptor function that is capable of sensing extracellular amino acid availability 
and may potentially couple to the mTOR signalling pathway (Hundal and Taylor, 
2009; Hyde et al., 2007). As mentioned earlier, the initial observation of Gazzola 
that a single substrate amino acid can repress the SNAT2 adaptive response 
suggested that the transporter may be able to sense extracellular amino acid 
availability in the extracellular space (Gazzola et al., 1981). Moreover, there is 
evidence that SNAT2 is capable of modulating signalling pathways. Treatment, 
for example, of muscle cells with a saturating concentration of the non-
metabolisable substrate MeAIB enhances insulin-stimulated PI3K activity and 
consequent Akt phosphorylation, while silencing SNAT2 by RNA interference 
impairs insulin signalling through PI3K (Evans et al., 2008). Evidence of SNAT2 
control of mTOR signalling has also been demonstrated in MCF-7, breast 
cancer cell line in which chronic exposure to MeAIB induced S6K 
phosphorylation (Pinilla et al., 2011). Since System A is functionally coupled to 
the activity of the tertiary active transporter, LAT1, it has also been implicated in 
the regulation of the intracellular amino-acid pool size and pathways that 
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influence growth and proliferation of cells. For example, the glutamine gradient 
generated by SNAT2 is used by LAT1 to mediate the influx of leucine, a major 
regulatory stimulus for the mTOR pathway and consequent regulation of 
processes such as growth and proliferation (Kimball et al., 1999). Bevington et 
al. have in fact shown that incubation of L6 skeletal muscle cells with MeAIB 
leads to decreased intracellular levels of not only SNAT2 amino acid substrates 
but also branched chain amino acids, whose transport is mediated by System L 
(Bevington et al., 2002).   
1.15 Fatty acid modulation of amino acid transporter 
The effect of SFAs and UFAs on insulin and stress signalling has been amply 
documented; however little is known about how fatty acids may affect amino 
acid transport. Interestingly, previous work from the Hundal lab has 
demonstrated that ceramide, a fatty acid derived sphingolipid, can suppress 
basal and insulin-stimulated SNAT2 activity by preventing its translocation to 
the membrane, an effect that it also exerts on GLUT4 (Hyde et al., 2005). There 
is mounting evidence that PUFAs affect the activity of several amino acid 
transporters. For example, docosahexaenoic acid (DHA) has been shown to 
differentially modulate the various subtypes of the glutamate transporter, Glial 
Glutamate Transporter 1 (GLT1), GLAST and EAAC1. DHA appears to 
stimulate D-[3H] aspartate uptake via GLT1 and EAAC1 through a mechanism 
involving CaM kinase II and PKC; whereas the PUFA exerts an inhibitory effect 
on GLAST-mediated uptake in a calcium-independent manner (Berry et al., 
2005). As well as DHA, arachidonic acid (ARA) can also differentially regulate 
members of the glutamate transporter family. ARA inhibits glutamate uptake by 
EAAT1 whilst increasing transport via EAAT2 (Zerangue et al., 1995).  
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1.16 Aims and objectives 
Increasing evidence in the literature suggests that diets enriched with MUFAs 
and PUFAs can help antagonise the harmful metabolic and physiological effects 
associated with consuming excessive saturated fat and thereby significantly 
reduce the risk of developing obesity, insulin resistance and Type 2 diabetes 
(Bergouignan et al., 2009). However, the mechanisms by which MUFAs and 
PUFAs provide this protective effect against SFAs is still not fully understood. 
Therefore, the main aim of the studies presented in Chapter 3 was to 
investigate what impact different UFAs have upon insulin signalling in skeletal 
muscle, a primary insulin target tissue.  
The specific objectives of these studies were: 
 Understand how the hormonal activation of Akt and ERK1/2 is 
enhanced in response to linoleic and oleic acid;  
 Assess whether linoleic and oleic acid can prevent the insulin-
desensitising effects elicited by SFAs, such as palmitate, and define 
the role played by the phosphatase PP2A. 
Given that, previous work from the Hundal lab has shown that ceramide, a 
palmitate-derived lipid, can suppress the activity of the SNAT2 amino-acid 
transporter (Hyde et al., 2005), a further aspect of the studies described herein 
was to explore the impact that SFAs and UFAs have upon SNAT2/System A 
transport. Investigating this topic was a major goal of the studies described in 
Chapter 4 whose specific aims were to: 
 Assess the effect of linoleic acid, oleic acid and palmitate on 
expression and activity of SNAT2; 
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 Understand the molecular mechanisms by which linoleic acid 
modulates SystemA/SNAT2 activity with specific focus on the fatty 
acid-induced SNAT2 degradation via the ubiquitin proteasomal 
pathway. 
 Assess the involvement of ceramide as a mediator of palmitate’s 
effect upon SystemA/SNAT2 activity. 
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Chapter 2 
Materials and 
Methods 
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2.1 Materials 
2.1.1 General 
α-MEM (α-minimal essential medium), DMEM (Dulbecco's modified Eagle's 
medium), FBS (fetal bovine serum), EBSS (Earle's Balanced Salt Solution), 
Opti-Mem, Trypsin/ Ethylenediaminetetraacetic acid (EDTA), 
penicillin/streptomycin solution, amphotericin B and Lipofectamine-2000 were 
from Gibco/Invitrogen Life Technologies (Paisley, UK). All other reagent-grade 
chemicals, including bovine serum albumin (BSA) and fatty acids, were 
obtained from Sigma–Aldrich (Poole, UK) unless otherwise stated. Wortmannin, 
PI-103, okadaic acid and polyvinylidene difluoride (PVDF) membranes were 
from Calbiochem-Merck Millipore (Darmstadt, Germany). Fraction V fatty acid-
free BSA and complete protein phosphatase inhibitor tablets were purchased 
from Boehringer-Roche Diagnostics (Basel, Switzerland). Insulin was from 
Tocris Bioscience (Bristol, UK). Go Taq DNA polymerase, deoxyribonucleotide 
phosphates (dNTPs) and Moloney Murine Leukemia Virus (M-MLV) reverse 
transcriptase were purchased from Promega (Southampton, UK). All restriction 
enzymes used and alkaline calf intestinal phosphatase were from New England 
Biolabs (Ipswich, US). All primers were synthesised by the Oligonucleotide 
Synthesis Service (University of Dundee). All antibodies used in this study and 
their source are listed in Appendix 1. X-ray films were purchased from Konica 
Minolta (Tokyo, Japan).  
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2.2 Tissue Culture 
For tissue culture, media and buffers were pre-warmed to 37°C in a water bath 
prior to use. Frozen cell stocks were resuscitated by heating in a 37°C water 
bath and then transferred into a 15 cm dish or T75 flask containing 15 ml of 
appropriate media for cell line propagation. To create cell stocks, cells seeded 
and plated from a low passage number were washed with sterile phosphate 
buffered-saline (PBS) (Appendix 2), trypsinised, pooled and centrifuged at 1000 
g for 5 min. The supernatant containing the media was aspirated off and the 
pellet containing the cells was resuspended in storage media, which consisted 
of α-MEM for L6 myoblasts and DMEM for HeLa and MEFi cells. The storage 
media in each case was supplementend with 10% (v/v) FBS, 7% (v/v) dimethyl 
sulfoxide (DMSO), 1% (v/v) antibiotic/antimycotic solution (100 units/ml 
penicillin, 100 mg/ml streptomycin and 250 ng/ml amphotericin B). Cells were 
aliquoted into cryotubes and placed in a cryotube cooler container at -80°C for 
24 h prior to being moved for long term storage in liquid nitrogen.  
2.2.1 L6 cells 
The L6 rat skeletal muscle cell line was generated originally by Yaffe from 
primary cultures of thigh muscle of a day old neonatal rat, maintained for the 
first two passages in the presence of methyl cholanthrene (Yaffe, 1968). L6 
muscle cells for this study were kindly provided by Dr Amira Klip (Hospital for 
sick children, Toronto, Canada). L6 muscle cells were thawed from a storage 
stock as described above, and were cultured in α-MEM containing 2% (v/v) FBS 
and 1% (v/v) antibiotic/antimycotic solution (100 units/ml penicillin, 100 mg/ml 
streptomycin and 250 ng/ml amphotericin B) at 37°C with 5% CO2. Cells were 
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splitt every 2-3 days to avoid premature differentiation. Prior to myoblast 
alignment, cells were washed with sterile PBS and incubated with 
Trypsin/EDTA for a few minutes at 37°C to detach myoblasts from the plate. α-
MEM media was then added, and cells washed-off the plate and used to 
maintain passages or seeded onto culture plates for use in experiments. Cells 
of passage 2-4 were used for all experiments and seeded at a density of 4000 
cells/cm2 in appropriate dishes. Cells were maintained in culture for 7-8 days 
with media being replaced every 2 days, to facilitate spontaneous myoblast 
fusion into myotubes. Upon differentiation, cells were treated as indicated in 
Figure Legends.  
2.2.2 HeLa cells 
Hela cells were cultured in DMEM, supplemented with 10% (v/v) FBS, and 1% 
(v/v) antibiotic/antimycotic solution (100 units/ml penicillin, 100 mg/ml 
streptomycin and 250 ng/ml amphotericin B) at 37°C in an atmosphere 
containing 5% CO2. After a confluent monolayer had formed, Hela cells were 
passaged as described previously for L6 muscle cells. 
2.2.3 MEFi cells 
An immortalised mouse embryonic fibroblast cell line was provided as a gift by 
Dr. Miguel Constancia from University of Cambridge. E14 embryos were 
dissected to remove liver and gonads, which cannot be used to generate 
MEFis, and the carcasses washed using PBS. After incubation in 1 mL 0.25% 
(v/v) Trypsin at 37ºC, 5% CO2 for 30 min the digested tissues were suspended 
in 4 volumes of DMEM medium (DMEM, 10% (v/v) FBS, 1% (v/v) penicillin-
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streptomycin, 1% (v/v) L-glutamine, 1% (v/v) MEM non essential amino acids) 
per tube and plated densely onto culture plates. After a 4 h incubation at 37ºC, 
5% CO2, the DMEM medium was replaced and cells maintained in culture. After 
24 h in culture, cells were washed in PBS and then maintained for a further 24 h 
in fresh medium. The following day, cells were trypsinised and re-plated at 1:3 
dilution (passage P0). MeFi cells were cultured in DMEM, supplemented with 
10% (v/v) FBS, and 1% (v/v) antibiotic/antimycotic solution (100 units/ml 
penicillin, 100 mg/ml streptomycin and 250 ng/ml amphotericin B), at 37°C with 
5% CO2. MEFis were split and propagated as described earlier for other cell 
lines.  
2.3 Cell stimulation 
2.3.1 Fatty acid treatment 
L6 myotubes were exposed to fatty acids that had been pre-conjugated for at 
least 1 h to 2% fatty acid-free BSA (w/v) at the concentrations and for the times 
indicated in Figure legends. L6 myotubes were routinely serum- deprived for the 
period of fatty acid exposure prior to any treatment with insulin. Serum 
deprivation was performed using α-MEM lacking the normal serum supplement. 
In some experiments, cells were incubated with inhibitors at concentrations and 
times indicated in Figure legends; controls were incubated with the vehicle 
solution lacking the inhibitor.  
2.3.2 Amino acid availability experiments 
For investigating the effect of fatty acids on amino acids transport, cells were 
incubated with EBSS supplemented with individual amino acids (2 mM). For 
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amino acid deprivation experiments, cells were incubated with EBSS lacking 
amino acids for times indicated in figure legends. Fatty acid treatment was 
performed as described previously. 
2.4 Cell lysis 
Following appropriate treatment of cells with fatty acids, insulin or inhibitors, 
cells were washed once with cold PBS and then lysed using appropriate volume 
of lysis buffer (Appendix 2). Cells were harvested from culture dishes and 
whole-cell lysates were centrifuged for 10 min at 3800 g, 4°C. The supernatant 
was collected and frozen in liquid nitrogen prior to being stored at -20°C. 
2.5 Isolation of total cell membranes 
For isolation of total membranes, cells were grown in 15 cm dishes and treated 
as indicated in Figure legends. Cells were washed twice with ice cold PBS and 
scraped off culture plates using a plastic scraper. The cell suspension was 
centrifuged at 700 g for 10 min and the resultant pellet resuspended in 3 ml of 
ice cold buffer I (Appendix 2). Cells were homogenized using a 5 ml Dounce 
glass homogenizer (40 strokes) and then centrifuged at 760 g for 10 min. The 
resulting supernatant was centrifuged at 177,000 g for 1 h at 4°C (Beckman 
TLA 100.3 rotor). The pellet obtained from this latter spin, containing the total 
membranes, was resuspendend in 100 μl of Buffer I supplemented with 
protease inhibitor and stored at -20°C. 
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2.6 Protein analysis 
Protein concentration was measured using the Bradford method  (Bradford, 
1976). The assay is based on the observation that the maximum absorption of 
the dye Coomassie Brilliant Blue G-250, contained in the assay reagent (Biorad, 
Herts, UK), shifts from 465 nm to 595 nm when bound to proteins. 2 μl of 
standard or protein samples was added in triplicate to a 96-well plate. 200 μl of 
Biorad protein assay (diluted 1:5) was added to each well and the absorbance 
measured at 595 nm on a spectrophotometer. Bovine serum albumin (1 μg-10 
μg) was used to generate a standard curve to calculate the protein 
concentration of experimental samples. 
2.7 Immunobiology 
2.7.1 Immunoprecipitation 
1 mg of L6 cell lysate protein was incubated with anti-IRS1, anti-PP2Ac-
demethylated or anti-V5 antibody over night at 4°C on an orbital platform 
shaker. Protein G–Sepharose beads were washed three times in PBS and 
incubated with the lysate-antibody mixture for 2 h at 4°C. Lysate-antibody/beads 
complex were then centrifuged at 1000 g for 3 min and the supernatant was 
removed from the beads and discarded. The immunoprecipitates were washed 
twice with 1 ml of lysis buffer containing 0.5 M NaCl and twice with PBS, and 
then boiled for 5 min in Laemmli buffer (Appendix 2) to dissociate the lysate-
antibody/beads complex. The immunopellets were then resolved by Sodium 
Dodecyl Sulphate (SDS)-PolyAcrylamide Gel Electrophoresis (PAGE) and 
immunoblotted with appropriate antibodies to protein of interest. 
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2.7.2 SDS-PAGE and Immunoblotting 
Proteins from cell lysates or total membranes were separated by SDS-PAGE as 
described by Laemmli (Laemmli, 1970). Whole cell lysate (30 μg) or total 
membranes (10 μg) were diluted in 6X Laemmli buffer and boiled for 5 min. 
Samples and Protein-Precision Plus molecular weight markers (New BioLabs) 
were resolved by running at a constant voltage (110 V) through a gel of 
appropriate percentage of polyacrylamide. Resolved proteins were transferred 
onto PVDF membrane, pre-soaked with methanol. Electrophoresis transfer was 
performed in cold running buffer (Appendix 1) at constant voltage of 100 V for 
90 min. Proteins were visualized by Ponceau S stain and membranes blocked 
with 5% (w/v) milk in 0.05% (v/v) Tween 20/Tris Buffered Saline (TBST) 
(Appendix 2) for 1 h. Membranes were then washed once in TBST before 
incubation overnight with primary antibodies (as indicated in Figure legends). 
Primary antibody was removed and PVDF membranes were washed three 
times for 15 min in TBST. Membranes were then incubated with an appropriate 
peroxidase-conjugated IgG for 1 h at room temperature and then washed three 
times for 15 min in TBST. Immunoreactive bands were detected by enhanced 
chemiluminescence (Appendix 2) on Kodak X-OMAT film. Quantification of 
immunoblots was performed using Image J software (http://rsbweb.nih.gov/ij/). 
2.8 Measurement of phosphatidylinositol 3,4,5 trisphosphate (PI(3,4,5)P3)  
The effects of fatty acids and insulin on cellular PI(3,4,5)P3 content was 
assessed using a sensitive time-resolved FRET (fluorescence resonance 
energy transfer)-based assay. This assay monitors the displacement of GST-
tagged GRP1 (general receptor of phosphoinositides 1)-PH domain from a 
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sensor complex consisting of Eu Lance® chelate-labeled GST antibody, the 
GST-tagged GRP1-PH domain, biotinylated-PI(3,4,5)P3 and the FRET 
acceptor, streptavidin allophycocyanin, by nonbiotinylated lipid (Gray et al. 
2008). After the appropriate incubation of cells with insulin or the PI3K inhibitor 
PI-103, cells were rapidly washed and cellular material precipitated by the 
immediate addition of 0.5 ml of ice-cold 0.5 M trichloroacetic acid (TCA). After 
standing on ice for 5 min, cells were harvested from the plates and the acid 
precipitate pelleted by centrifugation. The pellet was washed two times with 1 
ml of 5% TCA, 1 mM EDTA. Neutral lipids were extracted from the pellet and 
PI(3,4,5)P3 content determined as described previously using an LJL Analyst 
plate reader (Gray et al, 2008). PI(3,4,5)P3 abundance was calculated by 
reference to a standard curve constructed by addition of known amounts of the 
3-phosphoinositide to the sensor complex. 
2.9 Amino acid uptake 
Cells, seeded in 12 well plates, were washed twice with Hepes buffered saline 
(HBS) (Appendix 2) prior to incubation with uptake buffer (HBS, 10 μM MeAIB 
and 0.0074MBq [14C]-MeAIB tracer, or 10 μM leucine and [14C]-Leucine tracer). 
After the assay period (10 min for MeAIB and 2 min for Leucine uptake) the 
uptake was terminated by rapidly aspirating the media and washing cells twice 
with cold 0.9% (w/v) NaCl. Cells were lysed in 50 mM NaOH and 1 ml of the 
lysate was transferred into 6 ml scintillation vials with addition of 4 ml of 
scintillation fluid (Ecoscint, national Dagnostics). Cell radioactivity was 
measured using a 1450 microbeta liquid scintillation counter. Protein 
concentration was determined from the rest of the lysates using the Bradford 
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method as described before. Uptake of radiolabelled substrate was calculated 
using the equation as follow: 
Flux =  (RADspec)-(RADquench) 
                   RADsa* P * T 
(units= pmol/min/mg/protein) 
RADspec = measured radioactivity associated with 1 ml of cell lysate 
(disintegrations per min (DPM)/ml) 
RADquench = measured radioactivity associated with 1 ml of cell lysate in the 
presence of saturating dose of substrate (DPM/ml) 
RADsa = measured radioactivity associated with 1 pmol of transport substrate 
(specific acitivty, DPM/ml) 
P = protein concentration of cell lysate (mg/ml) 
T = time span of assay (min) 
2.10 shRNA mediated silencing of AMPK, Caveolin and Nedd4.2.  
Expression of Ampk α1, Caveolin1/3 and Nedd4.2 was silenced in L6 myoblasts 
using a lentiviral knockdown strategy. Knockdown of the above proteins was 
performed by Dr Clare Stretton. 
2.10.1 Hairpin design 
Short hairpin interfering RNA (shRNA) sequences targeting the genes of 
interest were found on Sigma-Aldrich website. To generate oligos for cloning, 
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the selected shRNAs were inserted into a replication-incompetent lentiviral 
vector pLKO.1. Each shRNA sequence was inserted into the two oligo 
sequences below (Appendix 3). 
Forward oligo: 
5’  CCGG – 21bp sense – CTCGAG – 21bp antisense – TTTTTG  3’ 
Reverse oligo: 
5’   AATTCAAAAA – 21bp sense – CTCGAG – 21bp antisense   3’. 
2.10.2 Cloning oligos in PLKO.1 
To allow the annealing of forward and reverse oligos, 2 μg of each were added 
to 2 mM Tris-HCl (pH 8.5) in a total volume of 50 μl, heated to 94°C for 12 min 
followed by cooling by 1°C each minute until 21°C. 6 μl of 10x ligation buffer, 3 
μl of water and 1 μl of T4 polynucleotide kinase were added and the mixture 
incubated at 37°C for 30 min, followed by incubation at 70°C for 20 min to 
inactivate the enzyme. 10 μg of pLKO.1 vector was digested with 2 μl EcoRI 
and 2 μl AgeI for 2 h at 37°C and then incubated for 1 h at 37°C with calf 
intestinal phosphatase. For the ligation reactions 100 ng of plasmid was added 
to 2 μl of the annealed oligo mixture, 2U of T4 DNA ligase and an appropriate 
amount of ligase buffer and water for a total volume of 10 μl followed by 
incubation at room temperature for 2-3 h. 5 μl of ligation reaction was 
transformed into 50 μl of XL-1 cells using a standard heat shock method and 
half of the transformation was plated out onto ampicillin plates and incubated 
overnight. Colonies were picked and screened using primers to pLKO.1 (see 
Appendix 4 for sequences) and run on a 1.5% agarose gel, using pLKO.1 
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containing a scrambled shRNA sequence insert as a positive control. To 
confirm the insertion of hairpin sequences into the pLKO.1 vector, 1 μg of each 
plasmid (including the empty vector and one containing the scrambled 
sequence) was digested with AgeI, a site which is lost after insertion of hairpin 
oligos and the products were run out on a 0.8% agarose gel. The plasmids 
lacking the AgeI site were identified and sequenced using the reverse primer to 
confirm the presence of the shRNA.  
2.10.3 Preparation of Lentivirus 
HEK 293T cells were seeded onto 6 cm dishes (one for each hairpin, plus one 
each for the empty vector and the scramble vector) one day prior to transfection 
at a density of 1.5 x 106 cells per dish. For each hairpin a DNA mixture for the 
transfection, consisting of 1.5 μg of pLKO.1, 1 μg of pHR CMV8.2ΔR packaging 
and 1 μg pCMV VSVg envelope vector was added to 0.5 ml serum-free 
medium. 12.5 μl 1 mg/ml Polyethylenimine was added to the solution, mixed 
and incubated at room temperature for 30 min. Cell media was replaced with 
fresh 2.5 ml complete medium and the transfection mix was added to cell 
culture plate for incubation overnight. From this point on cells were considered 
virally infectious. Medium was replaced the day after with 3 ml of complete 
medium and incubated for a further 48 h. The media containing the released 
virus was collected, centrifuged for 5 min at 200 g to pellet any residual cells, 
then divided into 1 ml aliquots and stored at -80°C. 
2.10.4 Lentiviral infection of L6 and HeLa cells 
L6 muscle cells or HeLa cells were seeded into 6 cm dishes one for each 
hairpin plus a control with approximately 20,000 cells and incubated for 4-6 h. 1 
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ml of virus was mixed with 2 ml of complete medium and polybrene was added 
to a final concentration of 8 μg/ml. The media on cells was replaced with this 
mix and cells were considered to be virally infectious from this point on. After 24 
h of incubation the media on cells was replaced with 3 ml medium containing 3 
μg/ml puromycin (for cells in which AMPK α1 and Nedd4.2 were silenced) or 15 
μg/ml hygromycin (for the Caveolin1/3 knock down cell line). The pLKO.1 vector 
encodes gene which confers either puromycin or hygromycin resistance. 
Consequently cells that have incorporated pLKO.1 into the host genome will be 
resistant to antibiotic treatment. Media was replaced with fresh antibiotic-
containing media every two days until all cells in the control plate were dead. 
After five media changes, cells were no longer considered as infectious. Once a 
sufficient number of cells had grown, the established cell lines were screened 
by western blot for decreased levels of target protein expression to determine 
which shRNAs were successful. Cell lines expressing the empty vector and 
scrambled sequence were used as positive control. 
2.11 Molecular biology 
2.11.1 RNA extraction  
Total RNA was extracted from L6 myotubes using TRIzol® reagent according to 
the manufacturer's instructions (Sigma–Aldrich). Cells were grown in 6 cm 
dishes and following treatments were washed in ice cold PBS and then scraped 
and collected in TRI reagent. 0.2 ml of chloroform per ml of TRI reagent used 
was added. Samples were shaken and, after 5 min incubation at room 
temperature, were centrifuged at 18,000 g for 15 min at 4°C. The upper 
aqueous phase containing RNA was transferred into a new 1.5 ml tube and 0.5 
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ml of 99.9% isopropanol per ml of TRI reagent added. Samples were shaken 
and after 10 min incubation at room temperature, centrifuged at 18,000 g for 10 
min at 4°C. The supernatant was removed and the pellet containing RNA was 
washed in 1 ml 70% (v/v) ethanol per ml of TRI reagent and centrifuged at 
12,800 g for 5 min at 4°C. The ethanol was removed and the pellet air-dried and 
resuspended in 15 μl of DEPC water. After 10 min incubation on ice, RNA 
samples were quantified using an Ultraspec 2100 pro UV/Visible 
Spectrophotometer (Amersham Biosciences) and then stored at -80°C. 
2.11.2 Generation of cDNA 
Complementary DNA was generated from 1 μg of RNA. RNA was added to 0.5 
μg of oligo T and DEPC water up to a volume of 17.7 μl and incubated at 70°C 
for 5 min to denature the secondary structure. Samples were then cooled to 
allow oligo T annealing to the poly A tail of messenger RNA. The reaction mix 
composed of 5 μl M-MLV reverse transcriptase 5X reaction buffer, 1.3 μl 10 mM 
dNTP, 1 μl M-MLV reverse transcriptase was added and the samples incubated 
at 42°C for 1 h to allow reverse transcription. After this period the mixture was 
incubated for 10 min at 70°C to inactivate the enzyme. Samples were stored at -
20°C. 
2.11.3 Real-time quantitative-polymerase Chain Reaction 
Quantitative real-time PCR was carried out using a StepOnePlus Real-Time 
PCR System (Applied Biosystems), SYBR Green JumpStart Taq ReadyMix 
(Sigma–Aldrich) and primers targeting the gene of interest. 3 μl of cDNA diluted 
1:15 in Milli-Q water were added to 5 μl of SYBR Green, 1 μl of forward (2 μM) 
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and 1 μl of reverse (2 μM) primers. The sequences for these primers are shown 
in Appendix 4. PCR amplification was performed with an initial denaturation at 
95 C for 10 min followed by 40 cycles of denaturation at 95 C for 15 s, 
annealing at 55°C for 15 s and extension at 68°C for 1 min. The ratio of target 
gene mRNA expression to housekeeping gene mRNA expression were 
calculated as described previously (Pfaffl et al, 2001). 
2.11.4 Plasmid constructs 
pCDNA6-SNAT2-V5 was generated by Dr Russel Hyde, by introducing SNAT2  
into a tagging vector so that a simian virus 5 hexahistidin epitope (V5-His6) 
could be introduced at the carboxyl-terminus of the protein. Rat SNAT2 was 
PCR amplified using the primers shown in Appendix 4 and introduced into 
pcDNA6 V5-His6 version A (Invitrogen) using XhoI and XbaI.  
pCDNA6-7A-SNAT2 mutant was generated by Dr Thorsten Hoffmann. The 
SNAT2 DNA sequence in which the 7 lysines in the N-terminus have been 
mutated to alanine was generated by Life Technologies. SNAT2-7A sequence 
was then introduced into pcDNA6 V5-His6 version A (Invitrogen) using XhoI and 
XbaI. 
pCMV5-Ubiquitin-FLAG was obtained from Division of Signal Transduction 
Therapy at the University of Dundee. 
2.11.5 Transformations 
All DNA plasmids were transformed into XL1-Blue competent cells E.coli. 1 μl of 
plasmid was added to 50 μl of E.coli cells and incubated on ice for 20 min. The 
mixed solution was then heat-shocked at 42°C for 1 min and put back on ice. 
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250 μl of Luria-Bertani (LB) media lacking of antibiotic was added to the solution 
followed by incubation at 37°C on a shaking incubator for 1 h. Half of the 
solution was then plated onto appropriate antibiotic containing LB agar plates 
and incubated overnight at 37°C. 
2.11.6 Plasmid purification 
Single colonies were picked from the LB-agar plates and grown in 5 ml of LB 
media containing the appropriate antibiotic. The cells were grown at 37°C in a 
shaking incubator for 8-15 h. Cells were then either pelleted for plasmid 
preparation (miniprep) or transferred to the media (200 ml for maxi prep) 
containing antibiotic and incubated overnight in 37°C in a shaking incubator. 
Mini-prep and Maxi-prep were performed according to the manufacturer’s 
protocols (Qiagen). 
2.11.7 Transient transfection 
HeLa cells were transfected with pCDNA6-V5 or pCMV5-FLAG constructs by 
using either Lipofectamine or polyethilenimine (PEI) as indicated in Figure 
legends. 
In the first case, cells were seeded in 6 cm dishes until 70% confluent for 
transfection. For each dish a solution containing 250 μl of Opti-Mem plus 10 μl 
of Lipofectamine-2000 and one containing 250 μl of Opti-Mem plus 5 μg of DNA 
were prepared and incubated at room temperature in a tissue culture hood for 5 
min. The solution containing Lipofectamine was then added to the DNA and 
mixed by tapping the tube. After a 20 min incubation at room temperature the 
mixed solution was added drop wise into culture media of a 6 cm dish of HeLa 
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cells. Cells were incubated for 24 h at 37°C before being treated as described in 
section 2.3.  
For transfection with the PEI method HeLa cells were seeded in 10 cm dishes 
until 70% confluent. 15 μl of PEI were added to a solution of serum-free DMEM 
containing 10 μg DNA vector and immediately vortexed for 5-10 s. The solution 
was incubated at room temperature in a tissue culture hood for 15-30 min 
before being added drop wise into culture media of a 10 cm dish of HeLa cells. 
Cells were incubated for 24 h at 37°C and then splitted into experimental culture 
plates. 48 h post-transfection cells were treated as described in section 2.3. 
2.12 Statistical analyses 
For multiple comparisons, statistical analysis was performed using one-way 
ANOVA. For individual comparisons statistical analysis was performed using a 
Student's t test. Data analysis was performed using GraphPad Prism software 
and considered statistically significant at P<0.05. 
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Chapter 3 
Unsaturated fatty acid provision 
enhances insulin sensitivity and 
ameliorates palmitate-induced 
insulin resistance in skeletal 
muscle cells  
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3.1 Introduction 
Sustained increases in the circulating concentration of free fatty acids (FFA), as 
often occurs in plasma of obese or type 2 diabetic individuals, have been linked 
to impaired insulin-dependent control of blood glucose (Boden, 2011; Kahn et 
al., 2006). In particular, saturated fatty acids (SFA) have been implicated 
strongly in the pathogenesis of insulin resistance in skeletal muscle, a tissue, 
which, by virtue of its sizable contribution to lean body mass, represents a major 
site for the disposal and metabolism of circulating glucose in the postprandial 
state (DeFronzo et al., 1985). Numerous studies have shown that chronic over-
provision of SFAs (e.g. palmitate) promote a significant reduction in the insulin 
signalling capacity of skeletal muscle which may help account for disturbances 
in whole body glucose metabolism in individuals who are obese or diabetic 
(DeFronzo et al., 1985). Several studies have demonstrated that supply of 
SFAs in excess of what skeletal muscle can safely utilise lead to the tissue 
accumulation of lipotoxic fatty acid derivatives, such as DAG, ceramide and 
gangliosides like GM3, which impact negatively upon insulin action.  Increases 
in DAG induce activation of DAG-sensitive PKCs that promote serine 
phosphorylation of IRS proteins thereby reducing their insulin signalling 
potential. Intramyocellular accumulation of ceramide on the other hand disrupts 
Akt-directed insulin signalling by mechanisms that involve activation of atypical 
PKCs and PP2A, which retain Akt in a repressed and dephosphorylated state 
(Cazzolli et al., 2001; Galbo et al., 2011; Powell et al., 2003; Powell et al., 2004; 
Stratford et al., 2004). The ganglioside GM3 impairs insulin signalling by a 
mechanism involving the dissociation of insulin receptors from caveolin-1, thus 
uncoupling them from their downstream signalling effectors (Inokuchi, 2009). In 
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addition to the lipotoxic effects of DAG and ceramide, palmitate (PA) also 
invokes an increase in NFkB-dependent proinflammatory signalling and an ER 
stress response (Green et al., 2011; Hage Hassan et al., 2012). Precisely how 
these latter responses are triggered by PA availability and whether they play a 
role in the development of insulin resistance is currently unclear given that their 
pharmacological repression fails to negate the PA-induced loss in insulin 
sensitivity (Green et al., 2011; Hage Hassan et al., 2012). In addition to 
promoting a rise in intramyocellular ceramide and DAG, SFAs also affect 
cellular energy balance. Indeed, there is mounting evidence suggesting that 
many of the metabolic defects in muscle associated with sustained PA 
oversupply may arise through an inability to match respiratory drive with fuel 
supply and that the heavy metabolic burden ultimately results in mitochondrial 
dysfunction, cell stress and insulin resistance (Koves et al., 2008; Lipina et al., 
2013).   
Strikingly, monounsaturated fatty acids (MUFAs) or certain polyunsaturated 
fatty acids (PUFAs) do not initiate some of the adverse metabolic responses 
associated with oversupply of SFAs. Indeed, evidence in the literature indicates 
that dietary substitution of SFAs or co-supplementation with unsaturated fatty 
acids antagonise the insulin desensitising effects of SFAs, enhance energy 
expenditure and improve muscle lipid composition and serum acylcarnitine 
profiles in humans (Fedor and Kelley, 2009; Gillingham et al., 2011; Kien et al., 
2013b; Kien et al., 2011; Parillo et al., 1992). Such observations are in line with 
cell-based studies demonstrating that MUFAs, such as palmitoleate and oleic 
acid, prevent the suppressive effect of PA on mitochondrial biogenesis and 
function via a peroxisome proliferator-activated receptor alpha dependent 
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mechanism (Yuzefovych et al., 2010), and antagonise cellular inflammation and 
ER stress by an AMPK-mediated mechanism (Salvado et al., 2013; Xue et al., 
2012). Moreover, the observation that specific enrichment of serum with 
palmitoleate induces a strong insulin potentiating effect in mouse liver and 
skeletal muscle implies that this MUFA may possesses unique metabolic 
attributes not held by its saturated counter-part, PA (Cao et al., 2008).  
However, despite the observed gain in insulin sensitivity brought about by 
palmitoleate in these peripheral tissues, our understanding of the underlying 
mechanism remains poor (Cao et al., 2008). 
 
In this chapter I investigated the effects of two of the most common unsaturated 
fatty acids (UFAs), oleic acid (OA) (a cis-C18:1, n-9 MUFA) and linoleic acid 
(LOA) (a cis-C18:2, n-6 PUFA), upon insulin signalling events in cultured rat 
and human skeletal myotubes. I have found that both OA and LOA induce an 
increase in insulin sensitivity based on enhanced Akt- and ERK1/2-directed 
insulin signalling. These effects cannot be attributed to an elevation in upstream 
IRS1/PI3K signalling, suggesting that modulation of a phosphatase may be 
involved in the regulation of both Akt and ERK1/2. In this respect, the insulin 
sensitivity promoted by the unsaturated fatty acids was associated with 
increased tyrosine phosphorylation (Y307) and demethylation of the 
phosphatase PP2A – events thought to retain the phosphatase in a repressed 
state (Janssens and Goris, 2001; Seshacharyulu et al., 2013). In contrast, PA 
attenuated the tyrosine phosphorylation and demethylation of PP2A induced by 
insulin in line with the known stimulatory effects that this SFA has upon PP2A 
activity. These PA-induced changes in PP2A were potently repressed by both 
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OA and LOA.  My data indicate that increases in insulin sensitivity brought 
about by exposure of muscle cells to OA and LOA may, in part, be mediated by 
covalent modification and cellular repression of PP2A. 
I also investigated whether the beneficial effect of OA and LOA provision may 
involve changes in fatty acid β-oxidation, given that insulin resistance caused by 
PA has been linked to its reduced oxidation and greater partitioning into  
lipotoxic PA-derivatives (Macrae et al., 2013). However, even in presence of a 
CPT-1 inhibitor, OA and LOA still exert their beneficial effect. In the end, I found 
that the sensitising effect does not involve key protein of insulin signalling and 
energy metabolism, such as caveolin1/3 and AMPK, as resulted by using 
skeletal muscle cell line knock down for these proteins. 
 
The aims of the studies reported in this chapter were as follows: 
 To investigate the effects of OA and LOA upon insulin signalling in 
skeletal muscle cells. 
 To investigate how OA and LOA may confer protection against PA-
induced insulin resistance. 
 To assess whether the insulin-sensitising effect associated with provision 
of OA and LOA may also be supported by modulation of AMPK and 
caveolins 1 and 3, which have been implicated in the control of cellular 
energy balance and metabolism. 
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3.2 Results 
3.2.1 Effects of different unsaturated fatty acids on insulin signalling 
The effect of different unsaturated fatty acids upon insulin signalling was 
investigated using a sub-maximal (20 nM) insulin concentration, determined 
using AktS473 phosphorylation as a readout for proximal insulin signalling. At this 
concentration, insulin induced a modest increase in Akt phosphorylation, which 
was barely detectable in untreated cells (Fig 3.1A). L6 myotubes were 
incubated with serum free medium in the absence or presence of 700 µM  
elaidic acid (EA, trans-C18:1, n-9), oleic acid (OA, cis-C18:1, n-9), α-linolenic 
acid (α-LNA, cis-C18:3, n-3), γ-linolenic acid (γ-LNA, cis-C18:3, n-6) and linoleic 
acid (LOA, cis-C18:2, n-6) for 16 h, prior to insulin stimulation for the 
penultimate 10 min. The fatty acid concentration used in these studies was 
similar to the total free fatty acid concentration found in serum of obese 
individuals and widely regarded as pathophysiological. Cell lysates were then 
analysed by immunoblotting to determine the level of phosphorylation of AktS473 
(Fig 3.1B) and that of ERK1/2T202/Y204 (Fig 3.1C), which are also activated in 
response to insulin stimulation in L6 cells. The results show that the insulin-
induced phosphorylation/activation of Akt and ERK1/2 was significantly 
increased by exposure to oleic acid, -linolenic acid and linoleic acid. In 
contrast, -linolenic acid exerted an inhibitory effect on both kinases whilst 
elaidic acid significantly enhanced ERK1/2 phosphorylation, but did not have 
any apparent effect upon Akt activation. Since oleic acid (OA) (a MUFA) and 
linoleic acid (LOA) (a PUFA) induced the greatest insulin-sensitising effect with 
respect to Akt activation, I focussed on these two specific fatty acids. 
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Figure 3.1 Effect of different 18C unsaturated fatty acids on Akt and ERK 
phosphorylation in L6 myotubes.  
(A) L6 myotubes were serum-starved for 2 h prior to stimulation with insulin (10 
min) at concentrations indicated. (B, C) L6 myotubes were incubated with 
serum free medium containing 2% (w/v) BSA (vehicle) ± 700 μM elaidic (EA), 
oleic (OA), α-linolenic (α-LNA), γ-linolenic (γ-LNA) or linoleic (LOA) acid for 16 
h, prior to stimulation with or without insulin (20 nM) for 10 min. Cell lysates 
were analysed by immunoblotting for phospho Akt (S473) and Akt (A, B), or for 
phospho ERK1/2 (T202/Y204) and ERK1/2 (C). Values in the bar graphs 
represent the mean ± SEM from three separate experiments. Asterisks 
represent a significant change from the insulin-treated value alone (P<0.05). 
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3.2.2 Effects of OA and LOA on Akt and ERK1/2 activation 
In order to analyse any potential effect of OA and LOA acid upon insulin 
signalling a time and dose-response study was performed for both the 
unsaturated fatty acids. Akt phosphorylation was enhanced significantly when 
myotubes were preincubated with OA or LOA for 16 h in a dose-dependent 
manner. Concentrations as low as 200 μM (i.e. within the physiological range) 
were able to cause an enhancement in Akt phosphorylation, which was ~2-fold 
greater than that elicited by insulin treatment alone when myotubes were pre-
exposed to maximally effective doses (700 μM) of OA or LOA (Fig 3.2A and B). 
The increase in Akt phosphorylation was detectable after 9 h but was not 
maximal until 16 h of fatty acid treatment (Fig 3.2C and D). Fig 3.2C and 3.2D 
show that the increase in signalling was not restricted to Akt and that ERK1/2 
phosphorylation was also enhanced. In the absence of insulin, neither fatty acid 
had any effect on Akt or ERK1/2 phosphorylation (Fig 3.2C and D). It is also 
important to stress that treatment of myotubes with the vehicle (i.e. BSA) alone 
did not enhance insulin-dependent phosphorylation of Akt or ERK when 
compared with cells not exposed to the vehicle (Fig 3.3). 
3.2.3 OA and LOA improve insulin sensitivity in both rat and human muscle 
cells without affecting proteins lying upstream Akt  
The above studies utilised a sub-maximal insulin dose to amplify any potential 
insulin-sensitising effect of the fatty acids, but, in parallel, I also compared the 
effect of both fatty acids in cells treated with sub-maximal and maximally 
effective insulin doses. Fig 3.4A and B show that the increased sensitisation 
towards insulin elicited by both NEFAs was most apparent and significant when  
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Figure 3.2 Effects of OA and LOA on Akt and ERK phosphorylation in L6 
myotubes.  
(A,B) L6 myotubes were incubated with serum-free media containing 2% (w/v) 
BSA (vehicle) + (A) oleic acid (OA) or (B) linoleic acid (LOA) at concentrations 
indicated, for 16 h prior to stimulation with insulin (20 nM, 10 min). (C, D) L6 
myotubes were incubated as in (B) + 700 µM (C) OA or (D) LOA for times 
indicated, prior to stimulation with insulin (20 nM, 10 min). (A-D) Cell lysates 
were immunoblotted using antibodies against the proteins indicated. The 
asterisks signify a significant change between the indicated bars (A, B) or 
compared to the insulin-treated value alone (C, D) (P<0.05). 
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Figure 3.3 BSA does not affect insulin signalling activation in L6 
myotubes.  
L6 myotubes were incubated with serum-free media ± 2% (w/v) BSA for 16 h 
prior to stimulation with insulin (20 nM, 10 min). Data in the bar graphs is 
presented as mean + SEM (n=3).  
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monitored using a sub-maximal insulin dose as no additional increase in Akt 
phosphorylation was observed when OA- and LOA-treated myotubes were 
treated with a maximally effective (100 nM) insulin concentration. Since the 
sensitising effect was most apparent after a chronic fatty acid treatment (9 h), I 
wanted to assess the possibility that OA and LOA may enhance insulin 
signalling by increasing the expression and/or activation of key proteins 
implicated in insulin pathway. Fig 3.4C shows that there was no major change 
in the expression of the insulin receptor β-subunit, IRS-1, PI3K-p85 subunit or 
PTEN, all of which lie upstream of Akt and ERK1/2, in response to OA or LOA 
treatment. Furthermore, neither OA nor LOA had any effect on total Akt or 
ERK1/2 abundance thus excluding this as a possible explanation for the net 
increase in their phosphorylation. The data highlights that in addition to 
promoting AktS473 phosphorylation, both OA and LOA induce an equivalent gain 
in AktThr308 phosphorylation (Fig 3.4C and D). Equimolar phosphorylation of both 
sites is required for full activation of Akt and consistent with this I observed 
elevated phosphorylation of GSK3; a physiological downstream Akt target. 
Likewise, enhanced ERK1/2 activation promotes greater 
phosphorylation/activation of CREB, a transcription factor regulated 
downstream of the ERK pathway (Fig 3.4C).  The increase in insulin-stimulated 
Akt phosphorylation induced by OA and LOA was not restricted to L6 myotubes. 
Fig 3.5 shows that incubation of human skeletal myotubes with OA or LOA 
caused a similar enhancement in Akt and ERK1/2 phosphorylation in response 
to insulin and that of GSK3 and CREB, which respectively lie downstream of Akt 
and ERK signalling.   
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Figure 3.4 OA and LOA effect upon insulin signalling in L6 myotubes.  
(A, B) L6 myotubes were incubated with serum-free media containing 2% (w/v) 
BSA + 700 µM (A) oleic acid (OA) or (B) linoleic acid (LOA) for 16 h prior to 
stimulation with insulin at concentrations indicated (10 min). (C, D) L6 myotubes 
were incubated as in (A, B) prior to stimulation with insulin (20 nM, 10 min). Cell 
lysates from A-C were subsequently immunoblotted using antibodies against 
the proteins indicated with quantification of phospho-Akt (S473 and T308) and 
phospho-ERK1/2 shown in panel A, B and D expressed as mean + SEM of at 
least three experiments. The asterisks signify a significant change (P<0.05) 
between the indicated bars (A, B) or the insulin-treatment alone (D). 
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Figure 3.5 OA and LOA improve insulin sensitivity in human myotubes.  
Human myotubes were incubated with 200 µM oleic acid (OA) or linoleic acid 
(LOA) for 24 h prior to stimulation with insulin (20 nM, 10 min). Cell lysates were 
subsequently immunoblotted using antibodies against the proteins indicated. 
The immunoblots shown are representative of two separate experiments. 
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3.2.4 OA and LOA sensitise muscle cells to insulin but not nutrients 
Since insulin and nutrient-sensing via the mTOR pathway are closely linked, I 
investigated whether the effect elicited by OA and LOA could enhance 
sensitivity of the mTOR pathway to nutrient (amino acid) stimulation. To check 
this possibility, L6 myotubes were incubated with serum free (Fig 3.6A) or 
serum containing (Fig 3.6B) medium in the absence or presence of 700 µM OA 
or LOA. L6 cells were then stimulated with 20 nM insulin for 10 min (Fig 3.6A) or 
with amino acids for 20 min, after 2 h of starvation (Fig 3.6B). As expected, only 
the rise in insulin modulated Akt, GSK3 and ERK1/2 activation, whereas amino 
acid stimulation did not activate the Akt-GSK3 axis or MAPK pathway; however, 
LOA treatment increased ERK phosphorylation in starved cells independently of 
amino acid replacement (Fig 3.6B). In addition, the fatty acid treatment did not 
elicit any sensitising effect upon activation of P70S6K, a downstream mTOR 
target, both after insulin and amino acid stimulation.  
3.2.5 OA and LOA insulin sensitising effect is not due to a hyperactivation of 
IRS1/PI3K axis 
To understand how OA and LOA might enhance insulin-signalling I monitored 
the effect of both fatty acids on p85-PI3-kinase association with IRS1 and 
cellular PI(3,4,5)P3 synthesis. As anticipated, based on coprecipitation analysis, 
Fig 3.7A shows that insulin induced p85-PI3K interaction with IRS1. This 
interaction was not influenced by OA or LOA.  Since Akt activation relies upon 
insulin-dependent PI(3,4,5)P3 synthesis it is possible that OA and LOA may 
have enhanced production of this lipid.  However, Fig 3.7B shows that, 
irrespective of whether muscle cells were incubated in the absence or presence    
105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Unsaturated fatty acids appear to only sensitise cells to insulin 
and not nutrients in L6 myotubes.  
(A, B) L6 myotubes were incubated with serum free (A) or serum-containing 
medium (B) containing 2% (w/v) BSA (vehicle) in the absence or presence of 
linoleic (LOA) or oleic acid (OA) (700 µM) for 16 h. Cells were stimulated in the 
absence or presence of insulin (20 nM) for 10 min (A) or amino acid for 20 min, 
after being starved in the penultimate 2 h of 16 h of treatment (B). Immunoblots 
are representative of three separate experiments.   
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of OA or LOA, insulin stimulated PI(3,4,5)P3 synthesis by ~2-fold. 
3.2.6 OA and LOA help sustain Akt and ERK1/2 activation 
Given that signalling events at the level of IRS1/PI3K were unaffected by OA or 
LOA, the possibility that increased phosphorylation/activation of Akt and 
ERK1/2 by insulin may be a consequence of their reduced dephosphorylation 
was investigated. L6 myotubes were incubated in the absence or presence of 
these fatty acids for 16 h and subject to an acute insulin challenge in the 
penultimate 10 min period of this fatty acid incubation. Myotubes were 
subsequently washed to remove extracellular insulin and reincubated in media 
with 100 nM wortmannin (to inhibit PI3K and any PI(3,4,5)P3 synthesis still 
occurring following removal of insulin) for up to 60 min post-wash. Muscle cells 
were lysed at time points indicated in Fig 3.8A and Akt and ERK1/2 
phosphorylation assessed in cell lysates. In the absence of OA or LOA 
treatment, Akt and ERK1 were rapidly dephosphorylated upon removal of 
insulin and returned to baseline by between 15-30 min.  However, both kinases 
retained a greater level of phosphorylation (~2-fold at each post-wash time 
point) in myotubes pretreated with OA or LOA (Fig 3.8B-E). Analysis of the t1/2 
with which Akt was dephosphorylated revealed that this was increased from 13 
min (untreated cells) to 18 min and 25 min in cells that had been preincubated 
with OA or LOA, respectively. Similarly, the t1/2 with which ERK1/2 become 
desphosphorylated following cell incubation with OA and LOA was increased to 
20 min and 25 min respectively, when compared with untreated cells (12 min).   
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Figure 3.7 Effects of insulin, OA and LOA on p85/IRS1 association and 
cellular PI(3,4,5)P3 generation in L6 myotubes.  
(A, B) L6 myotubes were incubated with serum-free media containing 2% (w/v) 
BSA (vehicle) ± 700 μM (A) oleic acid (OA) or (B) linoleic acid (LOA) for 16 h 
prior to stimulation with insulin (20 nM, 10 min). (A) IRS-1 was 
immunoprecipitated from whole cell lysates (WCL) using an anti-IRS-1 antibody. 
The immunopellet was probed with an anti-p85 antibody. (B) Cells were treated 
as in (A) lysed and assayed for PI(3,4,5)P3 content (Gray et al., 2003). The bar 
graph values (A and B) are presented as mean ± SEM of three separate 
experiments with NS indicating a no significant change between the indicated 
bars.  
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Figure 3.8 OA and LOA enhance and prolong insulin-dependent 
phosphorylation of Akt and ERK in L6 myotubes.  
The experimental approach used to test the effect of OA and LOA provision on 
Akt and ERK1/2 phosphorylation is depicted in (A). L6 myotubes were 
incubated with serum-free media containing 2% (w/v) BSA (vehicle) ± 700 μM 
(B, C) oleic acid (OA) or (D, E) linoleic acid (LOA) for 16 h prior to stimulation 
with insulin (20 nM, 10 min). Cells were washed to remove insulin and 
subsequently incubated with 100 nM wortmannin (WM) and lysed at times 
indicated. Immunoblots and relevant quantification of phospho-Akt and 
phospho-ERK1/2 in L6 myotubes incubated with OA (B, C) or LOA (D, E). Data 
in the bar graphs is presented as mean ± SEM (n=3) with asterisks indicating a 
significant change (P<0.05) between the respective filled (fatty acid treatment) 
and unfilled (control) bar at each time point. 
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3.2.7 Pharmacological inhibition of protein phosphatase-2A emulates OA and 
LOA insulin-sensitising effect 
The prolonged phosphorylation of Akt and ERK1/2 observed in presence of OA 
and LOA suggested that these fatty acids might affect a phosphatase targeting 
these kinases. Both Akt and ERK1/2 are physiological targets for PP2A 
(Andjelkovic et al., 1996a; Junttila et al., 2008).  Therefore I hypothesised that 
inhibiting PP2A using okadaic acid should emulate the effect observed following 
exposure to OA or LOA. Using a similar strategy to that shown in Fig 3.8A, L6 
myotubes were pretreated with okadaic acid (or vehicle control) for 15 min and 
with insulin in the penultimate 10 min period prior to washing myotubes free 
from okadaic acid or insulin and reincubation in media containing wortmannin 
for up to 60 min post-wash. Cells were lysed at time points specified in Fig 3.9A 
for analysis of AktS473 and ERK1/2T202/Y204 phosphorylation and reveals that 
pharmacological inhibition of PP2A induces heightened and sustained 
phosphorylation of both kinases (Fig 3.9B and C) in a manner comparable to 
that seen following fatty acid treatment (Fig 3.8B-E). To test whether OA and 
LOA further enhance the sensitising effect promoted by okadaic acid, L6 
myotubes were treated with OA and LOA (700 μM) for 16 h and with increasing 
concentrations of okadaic acid during the penultimate 15 min of this period of 
incubation, prior to insulin stimulation (20 nM, 10 min). Fig 3.9D shows that 
PP2A inhibition by okadaic acid promotes an increase in Akt phosphorylation in 
a dose dependent manner. Chronic OA and LOA treatment resulted in a 
comparable Akt activation and no additional gain in phosphorylation was 
observed when myotubes were incubated with both fatty acids and okadaic 
acid, suggesting that they might act through the same mechanism.   
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Figure 3.9 Okadaic acid emulates the insulin-sensitising effect of OA and 
LOA upon Akt and ERK phosphorylation in L6 myotubes.  
(A, B, C) L6 myotubes were incubated with serum-free media containing 
okadaic acid (100 nM) or vehicle (dH2O) for 15 min and with insulin (20 nM) 
during the penultimate 10 min of this incubation. Cells were washed and then 
maintained in serum-free media containing wortmannin (WM, 100 nM) and 
lysed at times indicated. Cell lysates were subsequently immunoblotted using 
antibodies against the proteins indicated. Data in the bar graphs is presented as 
mean ± SEM (n = 3) with asterisks indicating a significant change (P<0.05) 
between the respective filled (okadaic acid treatment) and unfilled (control) bar 
at each time point. (D) L6 myotubes were incubated with serum-free media 
containing 2% (w/v) BSA (vehicle) ± 700 μM oleic acid (OA) or linoleic acid 
(LOA) for 16 h. Cells were treated with okadaic acid or vehicle (dH2O) at the 
concentrations indicated for 15 min and with insulin (20 nM) during the 
penultimate 10 min of this incubation. Cell lysates were subsequently 
immunoblotted using antibodies against the proteins indicated. Blots are 
representative of two different experiments.  
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3.2.8 OA and LOA increase PP2Ac inhibitory phosphorylation and 
demethylation 
The above findings support the idea that OA and LOA may enhance insulin 
signalling via repression of PP2A.  To assess this possibility I investigated the 
effect of OA, LOA and the SFA palmitate (PA), on PP2A. Akt-directed insulin 
signalling is suppressed by PA and this effect is partly reliant upon the known 
stimulatory effect that PA exerts upon PP2A (Blouin et al., 2010). Fig 3.10A 
shows that, unlike OA or LOA, sustained exposure of L6 myotubes to PA 
reduced insulin-stimulated AktS473 phosphorylation (compare lane 2 with 4 and 
also lanes 6 and 8 with lane 4). This reduction appears to be antagonised when 
PA-treated myotubes were co-incubated with OA or LOA (compare Lane 4 with 
lanes 10 and 12). However, the overall gain in phosphorylation remains 
significantly lower when compared to myotubes exposed to OA or LOA alone 
(compare lanes 6 and 8 with 10 and 12, respectively).  
To assess whether PP2A may be regulated in a manner that accounts for 
changes in Akt phosphorylation seen in response to insulin, PA, OA and LOA 
(Fig 3.10A) I assessed Y307 phosphorylation and carboxy-methylation of the 
catalytic subunit of PP2A (PP2Ac)– two different covalent modifications known 
to impact on PP2A holenzyme assembly and PP2A activity (Janssens and 
Goris, 2001). Fig 3.10B shows that compared to untreated cells, insulin was 
able to acutely induce PP2AcY307 phosphorylation by 35%, but that this was 
negated in myotubes preincubated with PA. In contrast, cellular pre-treatment 
with OA or LOA not only induced a significant enhancement in PP2AcY307 
phosphorylation in response to insulin, but blocked the reduction caused by PA. 
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The ability of OA and LOA to enhance PP2AcY307 phosphorylation in response 
to insulin is not an acute event, but requires at least 9 h of cell treatment with 
either fatty acid to manifest (Fig 3.10C) and thus is consistent with the time 
course over which there is a detectable increase in insulin sensitivity as judged 
on the basis of Akt and ERK1/2 phosphorylation (Fig 3.2C and D). It is also 
noteworthy, that this fatty acid-induced increase in PP2AcY307 phosphorylation is 
not restricted to cultured rat muscle cells as I also observe this modulation in 
primary human muscle cells (Fig 3.11). Src has been implicated as the tyrosine 
kinase that phosphorylates PP2AcY307 and consistent with this insulin, LOA and 
OA all promoted Src activation based on phosphorylation of its Y416 site (Fig 
3.10B). It is noteworthy that SrcY416 phosphorylation can be induced 
independently by insulin and both OA and LOA, although the latter appear 
slightly more potent. There appears to be no additional gain in phosphorylation 
of this site if myotubes are co-treated with insulin and OA or LOA (Fig 3.10D). 
Analysis of immunoprecipitated PP2Ac with an antibody detecting the 
demethylated (inactive) protein revealed that insulin enhances PP2Ac 
demethylation, but that this was abrogated in PA-treated myotubes (Fig 3.12A). 
In contrast, both OA and LOA enhanced accumulation/detection of 
demethylated PP2Ac that occurs with insulin and, when coincubated with PA, 
repress the anti-demethylation effect of the SFA. PME-1 is the enzyme 
responsible for PP2Ac L309 demethylation (Lee et al., 1996). Therefore, I 
wanted to assess whether LOA and OA promote demethylation of the 
phophatase by increasing expression of PME-1. However, Fig 3.12B shows that 
neither PA nor LOA and OA affect the mRNA level of the PME-1. 
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Figure 3.10 Effects of insulin, PA, OA and LOA on Akt, Src and PP2Ac 
phosphorylation in L6 myotubes.  
L6 myotubes were incubated with serum-free media containing 2% (w/v) BSA 
(vehicle) ± 700 μM palmitate (PA), oleic acid (OA) or linoleic (LOA) for 16 h or 
for times indicated. In some experiments, cells were treated with fatty acids 
either alone or in combination as indicated or stimulated with insulin (20 nM, 10 
min) as indicated (A-D). Cell lysates were immunoblotted using antibodies 
against the proteins/ phospho-proteins indicated. Bar graphs values (A, n=3; B, 
n=4) are Mean ± SEM. The asterisks in (A) signify a significant change (P<0.05) 
compared to the insulin treated value (Lane 2) or between the indicated bars 
(B). Blots in panels C and D are representative of three different experiments.  
  
117 
 
 
  
Figure 3.11 OA and LOA enhance PP2Ac phosphorylation in human 
myotubes. 
Human myotubes were incubated with 200 µM oleic acid (OA) or linoleic acid 
(LOA) for 24 h prior to stimulation with insulin (20 nM, 10 min). Cell lysates were 
subsequently immunoblotted using antibodies against the proteins indicated. 
The immunoblots shown are representative of two separate experiments. 
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Figure 3.12 Effects of insulin, PA, OA and LOA on Akt, Src and PP2Ac 
demethylation in L6 myotubes. 
 (A, B) L6 myotubes were incubated with serum-free media containing 2% (w/v) 
BSA (vehicle) ± 700 μM palmitate (PA), oleic acid (OA) or linoleic (LOA) for 16 
h. In some experiments, cells were treated with fatty acids either alone or in 
combination as indicated or stimulated with insulin (20 nM, 10 min) as indicated. 
(A) PP2Ac was immunoprecipitated from cell lysates and the immunopellet 
probed with an antibody recognising demethylated PP2Ac. (B) The expression 
of PME 1 was tested by conventional RT-PCR analysis of RNA isolated from L6 
myotubes. Bar graphs values (A, n=7; B, n=3) are Mean ± SEM. The asterisks 
signify a significant change (P<0.05) and NS a no significant change between 
the indicated bars.   
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3.2.9 OA and LOA improve ERK1/2 activation by inhibiting not only PP2A but 
also dual specificity phosphatases 
Since OA and LOA increased both ERK1T202 and ERK2Y204, I hypothesised that 
their beneficial effect on signalling could be due not only to inhibition of PP2A 
but also that of tyrosine phosphatases. MAPKs are known to be mainly 
regulated by a class of dual specificity phosphatases (DUSPs), which 
dephosphorylate both threonine and tyrosine residue (Caunt and Keyse, 2013; 
Nunes-Xavier et al., 2011). To explore the possible involvement of DUSPs, L6 
myotubes were incubated for 16 h with or without OA and LOA prior to 
stimulation of MAPK signalling with H2O2 (1 mM) for 15 min. After this short 
period of H2O2 stimulation, cells were washed and incubated with fresh media 
for periods up to 60 min, and then lysed at regular intervals to assess p38, 
JNK1/2 and ERK1/2 phosphorylation. As shown in Fig 3.13A, cells treated with 
LOA and OA exhibit greater phosphorylation/activation of MAPKs compared to 
myotubes not treated with fatty acid (e.g. compare lane 7 with lanes 14 and 21 
for p38 MAPK). The result suggests that unsaturated fatty acids could reduce 
MAPKs dephosphorylation by inhibiting DUSPs, although additional 
experiments are required to confirm this hypothesis. The effect of LOA and OA 
on cellular tyrosine phosphorylation was also assessed. L6 myotubes were 
incubated with fatty acids for 16 h and insulin for 10 min and then washed as 
described above. As shown in Fig 3.13B, unsaturated fatty acids do not affect 
tyrosine phosphorylation state of the whole cell lysates indicating that fatty acids 
were unlikely to exert a generalised suppressive effect on tyrosine 
phosphatases and the effect appeared restricted to PP2A and possibly DUSPs.  
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Figure 3.13 OA and LOA inhibit DUSPs but not tyrosine phosphatases in 
L6 myotubes.  
(A, B) L6 myotubes were incubated with serum-free media containing 2% (w/v) 
BSA (vehicle) ± 700 μM linoleic (LOA) or oleic acid (OA) for 16 h prior to 
stimulation with (A) H2O2 (1 mM) for 15 min or (B) insulin (20 nM) for 10 min. 
H2O2 and insulin were then washed off the cells and cells incubated with serum-
free media for different post-wash periods indicated before being lysed. Cells 
lysates were subsequently immunoblotted using antibodies against proteins 
indicated. Blots are representative of three different experiments. 
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3.2.10 β-oxidation of unsaturated fatty acids is not essential to promote their 
beneficial effect 
In order to understand whether mitochondrial transport and β-oxidation are 
required for the insulin sensitising effect of unsaturated fatty acids, I assessed 
the effect of inhibiting these processes by treatment with etomoxir (ethyl-2-[6-(4-
chlorophenoxy) hexyl]-oxirane-2-carboxylate). Once taken up by cells fatty 
acids are activated by esterification with acyl-CoA to form fatty acyl-CoA. In 
order to be transported into the mitochondria to undergo β-oxidation, long-chain 
fatty acyl-CoA must be conjugated to carnitine by CPT-1, a protein associated 
with the outer mitochondrial membrane. (Longo et al., 2006). Etomoxir is a 
competitive inhibitor of CPT-1, the rate limiting enzyme for β-oxidation, and 
therefore represents an efficient strategy for blocking fatty acid oxidation (Agius 
et al., 1991; Declercq et al., 1987). L6 myotubes were incubated, in absence or 
presence of etomoxir (100 µM), for 16 h with OA and LOA alone or combined 
with PA (700 µM), prior to stimulation with insulin (20 nM) for 10 min (Fig 
3.14.A). Interestingly, cell treatment with etomoxir did not affect the ability of 
unsaturated fatty acids to enhance insulin sensitivity of skeletal muscle cells 
suggesting that their mitochondrial oxidation is not essential for their insulin-
sensitising effect. In contrast, suppressing mitochondrial fatty acid oxidation 
exacerbated the insulin-desensitising effect of PA as demonstrated by further 
loss in Akt phosphorylation (compare lanes 3 and 10, Fig 3.14A). Studies from 
the last two decades have shown that the development of insulin resistance is 
associated with reduced fat oxidative capacity (Kelley and Simoneau, 1994; 
Phielix and Mensink, 2008). Reduced PA oxidation would promote greater 
partitioning of the  fatty acids towards  synthesis of intermediates, such as DAG,   
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Figure 3.14 OA and LOA β-oxidation is not necessary to promote insulin 
sensitising effect in in L6 myotubes. 
(A) L6 myotubes were incubated with serum-free media containing 2% (w/v) 
BSA (vehicle) ± 700 μM linoleic (LOA) or oleic acid (OA) for 16 h, in presence or 
absence of etomoxir (100 µM). In some cases, cells were treated with palmitate 
(PA) (700 µM) for 16 h alone or in combination with LOA or OA. Cells were then 
stimulated with insulin (20 nM) for 10 min as shown, lysed and immunoblotted 
using antibodies against proteins indicated. Blots are representative of three 
different experiments. 
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which are responsible for lipotoxicity and consequent development of insulin 
resistance. Importantly, OA and LOA can still attenuate PA inhibitory effect on 
insulin signalling in the presence of etomoxir, suggesting that MUFAs and 
PUFAs retain their protective effect and limit lipotoxicity despite their reduced 
oxidation.  
3.2.11 The insulin sensitising effect of OA and LOA does not involve 
caveolin1/3 proteins 
Several studies have shown that dietary fatty acid can alter membrane lipid 
composition, which may be of particular significance for lipid rafts and caveolae 
(Li et al., 2007; Ma et al., 2004), as these have been suggested to play an 
important role in the compartmentalisation, modulation and integration of many 
distinct signalling cascades. Experiments performed in our laboratory have 
demonstrated, for example, that silencing the expression of caveolin 1 and 3 in 
L6 skeletal muscle cells is associated with reduced activation/phosphorylation 
of Akt in response to insulin. Given the ability of caveolins to influence insulin 
signalling, I investigated whether the beneficial effect of OA and LOA on insulin 
action may depend on caveolar integrity and function as assessed by lentiviral 
mediated gene knockdown of caveolin 1 and 3 in L6 cells. Control cells 
(infected with lentiviral particles harbouring a scrambled shRNA insert) and 
caveolin 1/3 knockdown (kd) L6 cells were treated for 16 h with LOA and OA 
prior to stimulation with insulin (20 nM) for 10 min. As shown in Fig 3.15A, 
Cav1/3 kd cells present a decreased Akt and ERK1/2 phosphorylation (compare 
lane 2 with 8), confirming that reduced caveolins expression results in induction 
of insulin resistance (Cohen et al., 2003; Oh et al., 2008). However, OA and 
LOA  can still  improve Akt and  ERK1/2  activation, suggesting  that their insulin   
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Figure 3.15 The insulin sensitising effect of OA and LOA is not dependent 
upon caveolin 1 and 3 expression in L6 myotubes.  
(A, B) Fully differentiated stable cav1/3 knockdown L6 cells along with 
corresponding scramble control cells were incubated with serum-free media 
containing 2% (w/v) BSA (vehicle) ± 700 μM oleic acid (OA) or linoleic acid 
(LOA) for 16 h, prior to insulin stimulation (20 nM) for 10 min. Cell lysates were 
then analysed by immunoblotting with antibodies against proteins indicated. 
Blots are representative of three separate experiments.  
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sensitising effect is unlikely to be dependent upon caveolin 1 and 3. 
 3.2.12 AMPK is not involved in the modulation of OA and LOA-induced insulin 
sensitivity 
A recent study has demonstrated that MUFAs improve insulin sensitivity and 
prevent PA-induced insulin resistance through an AMPK-dependent mechanism 
(Salvado et al., 2013). AMPK is a potent regulator of skeletal muscle 
metabolism, by regulating several intracellular systems including glucose 
uptake, fatty acid oxidation, biogenesis of GLUT4 and mitochondria (Hardie et 
al.; Jorgensen et al., 2004). The heterotrimeric AMPK holoenzyme consists of 
one catalytic subunit (α) and two functionally and structurally different regulatory 
subunits (β, γ). The catalytic subunit is present as 2 isoforms, a universally 
expressed α1 isoform and an α2 isoform (O'Neill, 2013). Since AMPK plays an 
important role in promoting glucose uptake and preventing insulin resistance 
(Fujii et al., 2008; Jorgensen et al., 2004), I investigated whether this protein 
kinase may mediate the beneficial effects of OA and LOA. Fig 3.16A shows that 
in skeletal muscle cells, as previously seen in other tissues (Horman et al., 
2006; Kovacic et al., 2003; Minokoshi et al., 2004), insulin stimulation inhibits 
AMPK activation- the down-regulation appears more evident based on 
phosphorylation analysis of its downstream target ACC. In sharp contrast, 
chronic treatment with fatty acids resulted in increased phosphorylation of 
AMPKT172 and ACCS59. To further investigate the role of AMPK in the fatty acid-
induced insulin sensitising effect, L6 myotubes in which AMPK α1 had stably 
been silenced were incubated for 16 h with the OA and LOA prior to stimulation 
with insulin (20 nM) for 10 min. Silencing the AMPK α1 catalytic subunit led to a 
decreased  insulin-stimulated  Akt   phosphorylation  compared  to  control  cells   
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Figure 3.16 AMPK α1 is not involved in the modulation of insulin 
sensitising effect by OA and LOA in L6 myotubes.  
(A) L6 myotubes were incubated with serum-free media containing 2% (w/v) BSA 
(vehicle) ± 700 μM linoleic (LOA) or oleic acid (OA) for 16 h, prior to insulin 
stimulation (20 nM) for 10 min. Cell lysates were then analysed by 
immunoblotting with antibodies against proteins indicated. Data in the bar graphs 
is presented as mean ± SEM (n = 3) with asterisks indicating a significant change 
(P<0.05) relative to the insulin treatment alone. (B) Lentiviral mediated gene 
knockdown (kd) of AMPK α1 in L6 cells. (C) Stable AMPK α1 knockdown in fully 
differentiated L6 cells along with corresponding control cells (infected with 
scramble shRNA construct) were incubated with serum-free media containing 2% 
(w/v) BSA (vehicle) ± 700 μM linoleic (LOA) or oleic acid (OA) for 16 h, prior to 
insulin stimulation (20 nM) for 10 min. Cell lysates were then analysed by 
immunoblotting with antibodies against proteins indicated. Blots are 
representative of three separate experiments.  
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infected with the scrambled shRNA construct (Fig 3.16C, compare lane 2 with 
8), although it is noterworthy that total Akt expression was also reduced in these 
cells. In any event the unsaturated fatty acids were still able to sensitise L6 
myotubes to insulin (Fig 3.16C), suggesting that AMPK was not an essential 
requirement for mediating their insulin sensitising effect. A previous study has 
shown that high-fat diet α2 Tg mice presented reduced IRS1 and Akt protein 
level in skeletal muscle compared to the control, which contributed to a reduced 
insulin-stimulated glucose uptake (Fujii et al., 2008); anyway the molecular 
mechanism by which this effect could occur is still unclear.  
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3.3 Discussion 
Numerous studies in the literature have shown that increased availability of 
SFAs is linked to a decreased insulin sensitivity in insulin-target tissues, with 
important knock-on consequences for processes such as gene expression and 
cell metabolism that are normally regulated by the hormone (Lipina and Hundal, 
2010). In contrast, considerable evidence supports the view that development of 
insulin sensitivity is positively correlated with supply of MUFAs and PUFAs and 
that, in many instances, their provision not only promotes beneficial metabolic 
changes but negates some of the harmful effects associated with SFA 
oversupply (Coll et al., 2008; Dimopoulos et al., 2006; Macrae et al., 2013).  
Since skeletal muscle is responsible for 75-80% of insulin-stimulated glucose 
uptake in a healthy individual, it follows that this tissue is the more affected by 
elevation in circulating free fatty acids and their effect upon insulin signalling 
(Manco et al., 2004). Indeed, studies carried out in both animals and humans 
have shown that the fatty acid composition of stored and structural lipids in 
skeletal muscle cells reflects the intake of dietary fat and is related to peripheral 
insulin sensitivity (Andersson et al., 2002). Therefore, although it is still unclear 
how unsaturated fatty acids act on insulin signalling, the sensitising effect 
performed by them could be due mainly to their effect on skeletal muscle. The 
major aim of this study was to analyse the effects of different MUFAs and 
PUFAs on L6 rat skeletal muscle cells and gain further insight of how 
unsaturated fatty acids can prevent some of the detrimental effects promoted by 
SFAs. 
The results obtained showed that incubation of muscle cells with MUFA oleic 
(18:1, n-9), and with PUFAs linoleic (18:2, n-6) and α-linolenic (18:3, n-3) 
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induces an increase in the insulin-stimulated phosphorylation of Akt and MAPK 
ERK1/2. In contrast, treatment with γ-linolenic acid (a PUFA, 18:3, n-6) impairs 
Akt activation (Fig 3.1). Since the fatty acids used are all of 18 carbon chain- 
length, it follows that the position of double bonds along the chain could have a 
bearing upon their insulin-sensitising effect thus explaining the opposite effect 
elicited by γ-linoleic acid. Among all of the unsaturated fatty acids used for 
treatment, linoleic acid (LOA) and oleic acid (OA) have been shown to promote 
the greatest positive effect upon insulin signalling. Interestingly, the improved 
insulin sensitivity elicited by these unsaturated fatty acids was most prominent 
when cells were stimulated with a sub-maximal concentration of insulin. The 
sensitisation was not apparent upon challenging cells with a 100 nM insulin 
stimulation, which may explain why other studies (using maximally effective 
insulin concentrations) did not report beneficial gains in Akt activation by insulin 
in the presence of unsaturated fatty acids (Dimopoulos et al., 2006; Yuzefovych 
et al., 2010). Indeed, previous work from the Hundal lab has shown that 
provision of MUFAs (e.g. palmitoleate and oleic acid) can induce insulin-like 
effects upon distal cellular responses, such as glucose uptake by inducing the 
plasma membrane recruitment of glucose transporters (Dimopoulos et al., 
2006); however, no additional enhancement in glucose uptake is observed 
when muscle cells are simultaneously challenged with the MUFA and a 
maximally effective concentration of insulin (Dimopoulos et al., 2006).  
Given that the sensitising effect of unsaturated fatty acids on the Akt pathway is 
a chronic response that develops over a 16 h period, I hypothesised that LOA 
and OA may act by increasing expression of upstream signalling proteins of 
insulin pathway. However, protein expression of the insulin receptor (IR), insulin 
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receptor-substrate 1 (IRS1) and PI3K p85 were not influenced by chronic 
treatment with LOA and OA (Fig 3.4). Moreover, the interaction between IRS1 
and p85-PI3K and PI(3,4,5)P3 lipid production, events necessary for Akt 
activation, were unaffected by provision of unsaturated fatty acids (Fig 3.6). The 
finding that unsaturated fatty acids do not affect the tyrosine phosphorylation 
state within whole cell lysates (Fig 3.13B) is consistent with this finding, thus 
excluding the possibility that enhancement of insulin signalling may has been a 
direct consequence of enhanced insulin receptor tyrosine phosphorylation.  
Intriguingly, I did not observe any increase in mTOR activation, which is 
stimulated not only by nutrient provision but also by insulin (Bolster et al., 2004). 
Indeed, activation of P70S6K, a direct target of mTOR, by insulin was not 
enhanced by cell incubation with OA and LOA, despite increased 
phosphorylation of Akt, which has been suggested to stimulate mTOR 
signalling. This effect might be due to Akt-mediated inhibition of GSK3. Shin et 
al. have reported that GSK3 positively regulates P70S6K via S371 
phosphorylation (Shin et al., 2011). The S371 residue is located within a turn 
motif and is required for mTOR-mediated T389 phosphorylation and 
consequent P70S6K activity (Dann et al., 2007; Fingar and Blenis, 2004). 
Therefore, by promoting GSK3 inhibition through Akt, LOA and OA might 
negate any increase in P70S6K activation. In addition, my data indicate that OA 
and LOA provision does not induce modulation of mTOR/P70S6K axis in 
response to amino acid provision, suggesting that unsaturated fatty acids do not 
influence this pathway in response to acute nutrient stimulation.  
Since the beneficial effect exerted by LOA and OA cannot be attributed to an 
increased activation of upstream components of the insulin signalling cascade, 
133 
 
it follows that the inhibition of a phosphatase that targets AKT and ERK1/2 may 
be a possible mechanism. Among the phosphatases involved in regulation of 
insulin signalling, protein phosphatase-2A, PP2A, can dephosphorylate both Akt 
and ERK1/2 (Cazzolli et al., 2001; Ruvolo, 2003; Ugi et al., 2004; Van Kanegan 
et al., 2005). PP2A is a serine/threonine phosphatase that accounts for ~1% of 
total cellular proteins and plays an important role in many cellular processes, 
including proliferation, cell death and regulation of cell cycle (Janssens and 
Goris, 2001). Moreover, evidence in the literature demonstrates that PA and its 
derivative ceramide can positively regulate the expression and activity of this 
phosphatase resulting in a suppressive effect upon insulin signalling (Cazzolli et 
al., 2001; Ruvolo, 2003). Therefore, the sensitising effect exerted by LOA and 
OA may involve suppression of PP2A. This proposition is based on the 
following lines of evidence. First, while sustained exposure of muscle cells to 
OA and LOA by themselves have no effect on Akt and ERK1/2 both fatty acids 
significantly enhance phosphorylation of these kinases and their downstream 
targets in response to an acute sub-maximal insulin challenge in a PI3K-
independent manner. Second, inhibition of PP2A mimics the enhanced and 
sustained phosphorylation pattern seen for Akt and ERK1/2 following cell 
treatment with OA or LOA. Third, both unsaturated fatty acids promote PP2A 
tyrosine phosphorylation and demethylation. The latter is relevant as 
carboxymethylation of L309 on PP2Ac is required for assembly of the PP2A 
holoenzyme and for catalytic activation, whereas phosphorylation of Y307 
inhibits PP2A catalytic activit (Begum and Ragolia, 1996; Chen et al., 1992). 
Several groups have reported hyperactivation of PP2A in response to sustained 
oversupply of glucose and SFAs (i.e. glucolipotoxicity), which may be important 
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in the pathogenesis of insulin resistance (Galbo et al., 2011; Kowluru and Matti, 
2012; Kowluru and Metz, 1997; Wu et al., 2007). Such hyperactivation may not 
only involve an increase in PP2Ac expression but that also of the many 
regulatory PP2A subunits (Eichhorn et al., 2009), a proposition based on the 
finding that Ptpa, B55α and B56β (which encode PP2A regulatory subunits) are 
all elevated in muscle and liver of insulin resistant (ZDF) rats (Galbo et al., 
2011). Whilst I cannot discount the possibility that OA and LOA may repress 
expression of the catalytic and certain regulatory PP2A subunits, my finding that 
they restrain PA-induced changes in PP2Ac phosphorylation/methylation is 
likely to be of significance in helping to counter PP2A hyperactivation by SFAs. 
(Blouin et al., 2010; Chen et al., 1992; Eichhorn et al., 2009; Kowluru and Matti, 
2012).  
The differential effect that unsaturated and saturated fatty acids have upon 
PP2A may be explained, in part, by their contrasting effects on Src, which 
affects PP2A activity via direct phosphorylation of PP2Ac at Y307. In line with 
previous studies (Feng et al., 2012), my findings indicate that PA reduces Src 
activation based on a striking reduction in SrcY416 phosphorylation that leads to 
an associated reduction in the downstream phosphorylation of PP2Ac on Y307 
(Fig 3.10B). As a consequence, PP2A would be expected to be more active 
under these circumstances leading to the counter-modulation of signalling 
molecules activated by insulin such as Akt and ERK1/2. In sharp contrast, both 
OA and LOA induced ScrY416 phosphorylation to a level comparable if not 
greater than that seen in response to insulin that promotes a concomitant 
increase in PP2Ac tyrosine phosphorylation (Fig 3.10B). It is noteworthy that the 
ability of OA and LOA to promote Src activation is not unprecedented and has 
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been previously reported in both human breast cancer cells and mouse 
gustatory cells in which activation of Src was linked to increases in ERK1/2 
activation and calcium signalling, respectively (El-Yassimi et al., 2008; Soto-
Guzman et al., 2008). Unlike PA, the modulation of Src by OA and LOA in 
skeletal muscle cells would suppress the action of PP2A leading, as I show, to 
greater and more sustained activation of some of its targets (i.e. Akt and ERK) 
by insulin. The molecular basis for this differential fatty acid effect on Src is 
currently unclear but may depend upon their ability to activate membrane bound 
fatty acid receptors, such as GPR40 and GPR120, that couple to signalling 
molecules influencing the activation status of Src. Indeed, long and medium-
chain fatty acids have been identified as ligands for these receptors, which may 
be involved in ameliorating insulin resistance (Talukdar et al., 2011). In 
particular, it has been demonstrated that GPR120 expression in adipocytes is 
required for allowing the beneficial effects of omega-3 (ω-3) PUFAs to be 
expressed in conditions characterised by chronic inflammation and insulin 
resistance (Oh et al., 2010). In contrast, the role of GPR40 in mediating insulin-
sensitising effects remains controversial. Some studies have demonstrated that 
mice deficient in GPR40 are protected from obesity-induced hyperglycemia and 
glucose intolerance (Steneberg et al., 2005), whereas others have shown that 
loss of GPR40 promotes obesity, glucose intolerance and insulin resistance 
(Kebede et al., 2008). Nonetheless, there is evidence in the literature that 
suggests GPR40 is involved in mediating the effects of unsaturated fatty acids 
upon glucose-stimulated insulin secretion from pancreatic β-cells (Schnell et al., 
2007). Moreover, activation of such a receptor has been implicated in OA-
induced activation of ERK1/2 and AP-1 DNA binding activity by a mechanism 
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involving Src activation in MCF-7 breast cancer cells (Yonezawa et al., 2004). 
Whether such a mechanism may also explain activation of Src by OA and LOA 
in skeletal muscle cells is currently unknown, although I do have evidence that 
GPR40 (but not GPR120) is expressed in our cultured L6 myotubes. If GPR40 
is indeed involved in initiating changes in insulin sensitivity in response to 
increased availability of MUFAs and PUFAs then my findings would suggest 
that either PA is not a ligand for GPR40 or that both OA and LOA have far 
greater efficacy for the receptor than the SFA in skeletal muscle cells. Testing 
these latter possibilities and defining whether GPR40 is a component of the 
mechanism by which OA and LOA enhance skeletal muscle insulin-sensitivity 
represent important investigative goals of future work. 
While my findings indicate that both OA and LOA promote an increase in 
proximal insulin signalling and are able to attenuate the effect that PA has upon 
Src and PP2A they do not confer complete protection against the insulin-
desensitising effect that PA has, for example, upon Akt activation (Fig 3.10A). 
Recent work from the Hundal lab has demonstrated that PA uptake into muscle 
cells is not affected by coprovision of MUFAs and that under these 
circumstances there is no reduction in PA-derived synthesis of ceramide 
(Macrae et al., 2013). Consequently, sustained generation of this sphingolipid 
will activate atypical PKCs that are known to physically associate with and 
negatively regulate Akt activation (Powell et al., 2003; Powell et al., 2004). 
However, despite the inability to restrain ceramide synthesis from the SFA it is 
apparent that provision of MUFAs and PUFAs do nonetheless help mitigate 
against some of the deleterious effects that PA has upon insulin-action via, for 
example, its ability to activate PP2A.   
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It is important to stress that such mitigation is not solely dependent upon 
counter-regulation of PP2A. In addition to increases in the intramyocellular 
abundance of lipids such as ceramide and DAG, sustained over-supply of PA 
promotes expression of pro-inflammatory genes (e.g. IL-6, TNFα) (Green et al., 
2011), induces ER stress (Hage Hassan et al., 2012; Salvado et al., 2013) and 
mitochondrial dysfunction, which, increasingly, is being seen as a major factor 
contributing to the development of muscle insulin resistance (Muoio and Neufer, 
2012; Turner and Heilbronn, 2008). The Hundal group has very recently 
demonstrated that sustained increases in PA promote a reduction in the 
expression of key mitochondrial respiratory proteins (SDHA and COX1V) and 
that of PGC1α which plays a major role in regulating mitochondrial biogenesis 
(Lipina et al., 2013; Macrae et al., 2013). A critical consequence of these 
changes is a reduction in respiratory drive, which will promote incomplete 
oxidation of fatty acids and accumulation of acylcarnitines, which have also 
been implicated as a cause of insulin resistance by mechanisms that currently 
remain unclear (Koves et al., 2008). Importantly, however, reducing the carbon 
load on mitochondria by withdrawing glucose or inhibiting its metabolism or 
coprovision of palmitoleate is found to strongly antagonise the SFA-induced 
reduction in PGC1α, SDHA and COX1V expression, which results in more 
efficient oxidation and/or partitioning of fatty acids into neutral triglyceride 
(Lipina et al., 2013; Macrae et al., 2013) with beneficial gains in both insulin 
sensitivity and metabolic status (Lipina et al., 2013). My data showed that LOA 
and OA can still antagonise PA detrimental effect upon insulin signalling in 
presence of a CPT1-inhibitor, suggesting that they rather enhance partionioning 
of the fatty acid into neutral lipids (Fig 3.14B-C). However, OA and LOA may 
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also modulate fatty acid mitochondrial oxidation since chronic treatment of 
muscle cells with these unsaturated fatty acids result in an enhanced 
phosphorylation of AMPK and its downstream target ACC (Fig 3.16A). ACC is a 
modulator of fatty acid mitochondrial oxidation, since it promotes production of 
malonyl CoA, a potent inhibitor of CPT-1 (Ruderman et al., 1999). As such, 
phosphorylation of ACC by AMPK will result in its inhibition and a concomitant 
reduction of malonyl CoA, facilitating, in turn, mitochondrial fatty acid uptake. 
Another potential mechanism by which provision of unsaturated fatty acids may 
bring about these favorable changes in mitochondria may involve their ability to 
bind and activate members of the peroxisome proliferator-activated receptor 
(PPAR) family of nuclear receptors, which, along with PGC1α, regulate genes 
whose products have been shown to influence fuel and energy metabolism 
(Muoio and Neufer, 2012).   
As mentioned earlier, PA over-supply promotes pro-inflammatory signalling and 
cytokine production in insulin target tissues (Ajuwon and Spurlock, 2005; Green 
et al., 2011; Joshi-Barve et al., 2007). It is now clear in fact that obesity, 
characterised by increased levels of circulating SFAs, is associated with a low 
grade inflammation, which contributes to the development of insulin resistance 
(Attie and Scherer, 2009; Lumeng and Saltiel, 2011). Whilst, PA is able to 
instigate proinflammatory signalling, cell exposure to MUFAs such as 
palmitoleate or oleate does not induce similar cytotoxic or proinflammatory 
effects. Indeed, MUFAs are able to restrain the proinflammatory effect of SFAs 
(Coll et al., 2008; Kwon et al., 2014; Macrae et al., 2013). Previous work has 
suggested that activation of AMPK by MUFAs and ω-3 PUFAs may contribute 
to the observed anti-inflammatory effect (Green et al., 2011; Macrae et al., 
139 
 
2013; Xue et al., 2012). As such, the finding that OA and LOA enhance AMPK 
activation would suggest that, the kinase may contribute, in part, towards 
beneficial effect of LOA and OA by preventing PA-induced inflammatory effect. 
However, it remains unclear how important AMPK is for the overall 
improvement in insulin-signalling especially in light of the finding that α1-AMPK 
silencing appeared to have no impact on the OA and LOA insulin-sensitising 
response in L6 myotubes. 
Another potential mechanism by which MUFAs and PUFAs may exert their 
beneficial effects is via activation of cellular fatty acid sensors such as Ubxd8, 
which respond to graded increases in unsaturated fatty acids and support 
greater triglyceride synthesis (Lee et al., 2010). It is plausible that by increasing 
partitioning of fatty acids into neutral lipid that this produces beneficial changes 
in metabolic status (by reducing the carbon load on mitochondria) and cellular 
sensitivity to insulin.  
In summary, the enhanced insulin signalling associated with supply of fatty 
acids such as OA and LOA is likely to reflect their ability to repress action of 
phosphatases such as PP2A (via modulation of upstream kinases like Src and 
that of enzymes mediating carboxymethylation of PP2Ac), but potentially are 
also contingent on benefits accrued, for example, by activation of PPARs that 
facilitate more efficient metabolic handling of fatty acids especially those that 
are likely to impose a heavy burden on the metabolic/oxidative machinery. My 
observations would support the view that diets enriched with OA and/or LOA 
may confer important insulin-sensitising and metabolic benefits. Indeed, a 
recent study assessing dietary fatty acid composition and insulin sensitivity in 
young adults found that replacing dietary PA with OA benefits clinically relevant 
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measures of metabolic wellbeing, including insulin sensitivity (Kien et al., 
2013a). Although the precise molecular events that underpin this benefit remain 
unclear, the authors did report that unlike those on the OA diet, those on the 
PA-enriched diet had more of their fatty acid routed towards production of 
acylcarnitines and ceramide consistent with the idea that PA promotes greater 
metabolic dysfunction, whereas OA is protective in this regard. 
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Chapter 4 
Fatty acid modulation of neutral 
amino acid transporter SNAT2 in 
L6 myotubes and HeLa cells 
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4.1 Introduction 
SNAT 2 is the most widely expressed member of the “System A” SLC38 family 
of amino acid transporters, which mediate the cellular uptake of short chain 
neutral amino acids and are characterised by their ability to mediate uptake of 
N-methylated amino acid substrates, such as Me-AIB (Mackenzie and Erickson, 
2004).  Amino acid uptake via SLC38 transporters is coupled to the inward 
movement of sodium ion down its electrochemical gradient, which promotes an 
outwardly-directed concentration gradient for System A substrates that can be 
utilised to drive the exchange uptake of a range of essential amino acids (e.g. 
leucine) through transporters (such as System L) that function in parallel with 
SLC38 in the plasma membrane (Baird et al., 2009; Hundal and Taylor, 2009).  
This amino acid exchange arrangement is considered pivotal for sensing of 
amino acids upstream of mTORC1 (the mammalian target of rapamycin 
complex 1) and since SNAT2 itself is subject to extensive regulation by growth 
factors, hormones (e.g. IGF-1 and insulin), amino acid availability as well as 
osmotic stress (see reviews (Hundal and Taylor, 2009; Mackenzie and 
Erickson, 2004)), its activity not only influences mTOR signaling (Pinilla et al., 
2011) but controls diverse amino acid-dependent processes that impact on cell, 
tissue and whole body function (Hundal and Taylor, 2009). 
A key conserved cellular trait is the ability of SNAT2 to be upregulated in 
response to extracellular amino acid limitation, a process known as adaptive 
regulation (Hyde et al., 2003; Kilberg et al., 2005).  Sustained periods of 
extracellular amino acid deprivation result in upregulation of SNAT2 
expression/function by a mechanism partly sensitive to inhibitors of RNA and 
protein synthesis (Gazzola et al., 1981; Hyde et al., 2001). The transcriptional 
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upregulation of SNAT2 in response to amino acid withdrawal relies upon a 
tripartite amino acid response element in the first intron of the SLC38A2 gene 
(Palii et al., 2006).  Precisely how an increase in SNAT2 transcription is 
triggered by amino acid deficiency remains unclear, although genetic 
interventions and use of pharmacological inhibitors have implicated the 
GCN2/ATF4 pathway (Kilberg et al., 2005) and members of the MAP kinase 
family (ERK1/2 and JNK) although, as yet, the nutrient signalling loci that lie 
upstream of MAPKs remain unidentified (Franchi-Gazzola et al., 1999; Lopez-
Fontanals et al., 2003).  Whilst increased SNAT2 transcription contributes to the 
overall increase in SNAT2 abundance, previous work from the Hundal lab has 
shown that the SNAT2 adaptive response also includes a non-genomic 
component involving enhanced stabilization of the SNAT2 protein (Hyde et al., 
2007).  It is thought that under amino acid deficient conditions SNAT2 adopts a 
structurally more stable configuration, whereas SNAT2 occupancy by any one 
single amino acid substrate is sensed as reflecting a state of amino acid 
sufficiency and one that signals a reduction in SNAT2 transcription and 
associated destabilization/loss of SNAT2 protein (Hyde et al., 2007).  
Consequently, SNAT2 is thought to function as an amino acid sensor or 
“transceptor” with the capacity to signal to nutrient responsive pathways that 
impact upon gene expression and protein turnover.   
Although numerous studies have explored the processes by which SNAT2 is 
upregulated in response to amino acid deprivation, our knowledge of the 
mechanisms that induce SNAT2 degradation by contrast remain poorly 
investigated. One potential process that may serve as an important determinant 
of SNAT2 turnover is the ubiquitin proteasome system (UPS) given that 
144 
 
Nedd4.2, a ubiquitin E3-ligase, has previously been implicated in the 
polyubiquitination and degradation of SNAT2 (Hatanaka et al., 2006). No 
information currently exists of how SNAT2 processing via the UPS may be 
stimulated but given that fatty acid-derived lipids such as ceramide promote a 
reduction in cell surface SNAT2 with a concomitant loss in membrane transport 
activity (Hyde et al., 2005), it is plausible that SNAT2 processing via the UPS 
may be subject to regulation by fatty acid availability.  Indeed, evidence showing 
that fatty acids (e.g. oleic and linoleic acid) can stimulate proteolytic activity in 
muscle (Dahlmann et al., 1985) and promote proteasomal degradation of 
membrane (e.g. CD36 (Smith et al., 2008), tyrosinase (Ando et al., 2004)) and 
cytosolic proteins (e.g. fatty acid synthase (Wojcik et al., 2014)) provide strong 
support for this hypothesis.  
In this chapter, I investigated the effect of linoleic acid; (LOA, a PUFA (C18:2, 
-6)), oleic acid (OA, a MUFA (C18:1, ω-9)) and palmitate (PA, a SFA (C16)) 
upon the SNAT2 adaptation response to osmotic stess and/or amino acid 
withdrawal. I demonstrate that, whilst amino acid deprivation induces a robust 
increase in cellular SNAT2 expression and function, this adaptive increase in 
SNAT2 can be significantly suppressed by pretreatment of cells with LOA, OA 
and PA, with the PUFA and the SFA having a more potent effect than the 
MUFA. This fatty acid-induced suppression in SNAT2 adaptation cannot be 
attributed to reduced transcription of the SLC38A2 gene but rather is a 
consequence of enhanced loss of SNAT2 protein abundance at the surface. 
However, PA and LOA appear to act through different molecular mechanisms. 
The effect exerted by LOA occurs via the UPS given that the fatty acid-induced 
loss in SNAT2 can be attenuated by MG132, a potent cell permeable 
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proteasomal inhibitor. In contrast, the repressive effect of PA on SNAT2 
protein/activity is likely to involve its derived lipid, ceramide, and possible 
SNAT2 degradaton by a non-UPS route. 
The aims of the studies reported in this chapter were as follows: 
 To investigate the effects of OA, LOA and PA upon the SNAT2 
adaptation response to hypertonicity and/or amino acid withdrawal in 
skeletal muscle cells and HeLa cells. 
 To investigate how LOA induces a loss in SNAT2 protein abundance in 
skeletal muscle cells and HeLa cells. 
 To assess whether the repressive effect of PA upon SNAT2 activity is 
mediated by its derived lipid ceramide in skeletal muscle cells. 
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4.2 Results 
4.2.1 Amino acid deprivation induces SNAT2 adaptation response in L6 
myotubes 
To assess System A adaptation to extracellular amino acid limitation in skeletal 
muscle cells, L6 myotubes were incubated with amino acid containing media for 
24 h and amino acid deprived for the last 4 h of this incubation. As mentioned 
earlier, SNAT2 adaptation response consists of both an increase in SNAT2 
transcription and enhanced SNAT2 protein stabilization. Fig 4.1A and 4.1B 
show that a 4 h amino acid deprivation period induces a ~2-fold increase in 
SNAT2 mRNA abundance and significantly enhances SNAT2 protein content in 
L6 myotubes. It is noteworthy that under amino acid restricted conditions, 
antibodies to SNAT2 detect two distinct but broad protein bands of ~60 kDa and 
~40 kDa respectively, in L6 myotubes. Previous work from the Hundal lab has 
reported that the 60 kDa band most likely represents the “heavy” mature cell 
surface glycosylated transporter, whereas the diffuse “lighter” band most likely 
reflects a partially processed but immature intracellular pool of SNAT2 protein 
(Hyde et al., 2001). Consistent with the increase in SNAT2 protein, amino acid 
deprivation resulted in a ~6-fold increase in SNAT2 transport activity measured 
using Me-AIB, a paradigm non-metabolisable System A/SNAT2 substrate (Fig 
4.1C).  
4.2.2 Medium/long chain fatty acids repress the System A adaptation response  
To assess whether System A adaptation to extracellular amino acid withdrawal 
would be sensitive to fatty acid availability I initially monitored the effect of 
different   saturated, monunsaturated  and   polyunsaturated  fatty   acids   upon   
147 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Amino acid deprivation induces SNAT2 adaptation response in 
L6 myotubes. 
(A-C) L6 myotubes were incubated with EBSS media containing amino acids 
(+) for 24 h and amino acid deprived (-) for the last 4 h of this incubation. (A) 
The expression of SNAT2 was tested by quantitative PCR analysis of RNA 
isolated from L6 myotubes. (B) Total membranes were isolated and 
immunoblotted using antibodies against SNAT2 and Na/K-ATPase. (C) System 
A/SNAT2 activity was assayed by measuring the uptake of MeAIB. Data in the 
bar graphs is presented as mean + SEM (n=3).   
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Figure 4.2 Long-chain fatty acids repress the adaptive increase in System 
A transport activity.  
L6 myotubes were incubated with EBSS media containing amino acids (+) and 
2% (w/v) BSA ± 300 μM caprylic acid (CA, C8), decanoic acid (DA, C10), lauric 
acid (LA, C12), palmitate (PA, C16), heptadecanoic acid (HAD, C17), 
palmitoleate (PO, C16:1 ω-7), oleic acid (OA, C18:1 ω-9), linoleic acid (LOA, 
C18:2 ω-6), docosahexanoic acid (DHA, C22:6 ω-3) for 24 h and amino acid 
deprived (-) for the last 4 h of this incubation as indicated prior to measuring 
MeAIB transport. The bar graph values are presented as mean ± SEM of three 
separate experiments each conducted in triplicate with asterisks indicating a 
significant change (P<0.05) from the solid black bar value.   
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System A transport activity assayed by analysis of Me-AIB uptake. Fig 4.2 
shows that fatty acids with a carbon chain equal or longer than 12 carbons 
induce a decrease in System A adaptation response despite differences in their 
degree of saturation. 
4.2.3 Linoleic acid represses the System A adaptation response  
Given that in Chapter 3 I had assessed the effect of linoleic acid (LOA; a 
polyunsaturated (C18:2) -6 fatty acid) and oleic acid (OA; a monounsaturated 
(C18:1) ω9 fatty acid) upon insulin signalling in cultured skeletal muscle cells, I 
focussed on investigating the effect of these unsaturated fatty acids upon amino 
acid transport and transporter turnover. Fig 4.3A and 4.3B show that a 4 h 
amino acid deprivation period induces more than a 6-fold increase in System A 
transport in L6 myotubes compared to cells held in amino acid-containing 
media. Strikingly, this adaptive increase in System A transport was reduced 
when myotubes were preincubated with LOA or OA in time and dose-dependent 
manner – the suppressive effect of the fatty acid being maximal when myotubes 
were treated with LOA or OA for 24 h at a dose of 300 μM, with the PUFA 
having a more potent effect than the MUFA. The observed suppressive effect of 
LOA on System A was not restricted to L6 myotubes. Fig 4.3C shows that HeLa 
cells (an immortalised human adenocarcinoma cell line) also display a 
significant (9-fold) increase in System A adaptation upon being subjected to 
amino acid withdrawal, but that this was strongly repressed when cells were 
pretreated with LOA.  
To assess whether LOA and OA could also affect other amino acid transporters, 
L6 myotubes and HeLa cells were treated with the fatty acids as indicated for 24  
150 
 
 
  
151 
 
 
 
 
 
Figure 4.3 The effect of LOA and OA on SystemA/SNAT2-mediated MeAIB 
uptake in L6 myotubes and HeLa cells.  
(A) L6 myotubes were incubated with EBSS media containing amino acids (+) 
and 2% (w/v) BSA + 300 μM linoleic acid (LOA) or oleic acid (OA) for times 
indicated and amino acid deprived (-) for the last 4 h of this incubation as 
indicated prior to measuring MeAIB transport. (B) L6 myotubes were incubated 
as in (A) + increasing concentration of LOA or OA as indicated for 24 h and 
amino acid deprived (-) for the last 4 h of this incubation prior to measuring 
MeAIB transport. (C) HeLa cells were incubated as in (A) + 300 μM linoleic acid 
(LOA) for 24 h and amino acid deprived (-) for the last 4 h of this incubation 
prior to measuring MeAIB transport. The bar graph values are presented as 
mean + SEM of three separate experiments with asterisks indicating a 
significant change (P<0.05) between the indicated bars. 
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Figure 4.4 LOA and OA do not affect leucine uptake in L6 myotubes and 
HeLa cells.  
(A, B) L6 myotubes (A) and HeLa cells (B) were incubated with EBSS media 
containing amino acids and 2% (w/v) BSA + 300 μM linoleic acid (LOA) or oleic 
acid (OA) as indicated for 24 h prior to measuring leucine uptake. The bar graph 
values are presented as mean + SEM of three separate experiments with NS 
indicating no significant change between the indicated bars. 
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h at a dose of 300 μM and leucine uptake assayed. Leucine transport is 
mediated by the System L family of transporters, a major nutrient transport 
system that is responsible for Na+-independent transport of neutral amino acids 
(Hundal and Taylor, 2009). Fig 4.4A and 4.4B show that LOA or OA do not 
affect leucine uptake in L6 myotubes or HeLa cells indicating that provision of 
these unsaturated fatty acids may selectively target the SNAT2 transporter.  
4.2.4 LOA impairs the adaptive increase in SNAT2 protein abundance 
Previous studies from the Hundal lab have indicated that the adaptive response 
is principally attributed to increases in cellular SNAT2 abundance (Hyde et al., 
2001). In line with this proposition, Fig 4.5A shows that there is a robust 
increase in protein abundance of both the mature and immature form of SNAT2 
in total membranes prepared from L6 myotubes and HeLa cells following a 4h 
amino acid deprivation period. In vitro deglycosylation of total membranes with 
PNGaseF results in loss of the “heavier” immunoreactive band and detection of 
a more defined 40 kDa band that most likely represents the unprocessed core 
SNAT2 protein (Fig 4.5A left panel). My findings reveal that HeLa cells also 
display the adaptive increase in the mature 60 kDa SNAT2 protein, but, unlike 
L6 myotubes, exhibit very little expression of the “lighter” form of SNAT2. 
However, in vitro deglycosylation of the mature SNAT2 from HeLa cells also 
generates a more defined lighter 40 kDa SNAT2 band suggesting that HeLa 
cells readily process new synthesised SNAT2 and retain very little of the 
immature SNAT2 protein within intracellular membranes such as the ER (Fig 
4.5A right panel). The adaptive increase in SNAT2 triggered by amino acid 
deprivation was  substantially muted  when L6  myotubes  and  HeLa cells were 
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Figure 4.5 LOA reduces SNAT2 protein abundance in response to amino 
acid deprivation in L6 myotubes, HeLa cells and MEFi cells.  
(A-D) L6 myotubes, HeLa cells and MEFi cells were incubated with EBSS 
media containing amino acids (+) and 2% (w/v) BSA + 300 μM linoleic acid 
(LOA) for 24 h and amino acid deprived (-) for the last 4 h of this incubation as 
indicated prior to total membranes isolation. In some experiments, membranes 
were deglycosylated using PNGaseF as indicated. Isolated total membranes 
from A-C were subsequently immunoblotted using antibodies against SNAT2 
and Na/K-ATPase. The immunoblots are representative of three (A-C) and two 
(D) separate experiments. (B, C) Values in the bar graph are mean ± SEM 
(n=3) with asterisks signifying a significant change (P<0.05) compared to the 
amino acid deprived alone value.   
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pre-incubated with OA or LOA as indicated (Fig 4.5B and 4.5C), consistent with 
the diminished functional System A transport capacity that is observed in cells 
treated with the fatty acid (Fig 4.3). The repressive effect of LOA was still 
greater than that induced by OA and was not just restricted to L6 myotubes and 
HeLa cells but also observed in MEFi cells, an immortalised mouse embryonic 
fibroblast cell line (Fig 4.5D). 
4.2.5 LOA does not suppress the transcriptional upregulation of SNAT2 gene 
expression  
One possible explanation that may account for the reduction in SNAT2 
adaptation induced by these unsaturated fatty acids is a failure to induce an 
upregulation in SLC38A2 gene expression. However, quantitative PCR analysis 
of RNA isolated from L6 myotubes and HeLa cells revealed that OA and LOA 
do not significantly affect the increase in SNAT2 mRNA elicited in response to 
amino acid withdrawal (Fig 4.6A and 4.6B).  The adaptive increase in SNAT2 
gene expression is, in part, dependent upon ATF4 (Kilberg et al., 2005); a 
transcription factor whose expression, like that of the SNAT2 gene, is 
upregulated in response to amino acid deficiency.  Fig 4.6C and 4.6D show that 
ATF4 expression is increased upon cellular amino acid depletion and that it 
remains unaffected by pre-incubation of cells with LOA or OA. This latter 
observation is fully in keeping with the increased transcription of the SNAT2 
gene, an ATF4 target. Fig 4.6B and 4.6D show that HeLa cells do not exhibit a 
pronounced increase in SNAT2 and ATF4 gene expression in response to 
amino acid withdrawal as observed in L6 myotubes. Therefore, I wanted to 
assess  whether  enhanced  SNAT2  trascription  was,  by  comparison  to  L6   
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Figure 4.6 LOA does not affect the transcriptional upregulation of SNAT2 
in L6 myotubes and HeLa cells.  
(A-D) L6 myotubes (A, C) and HeLa cells (B, D) were incubated with EBSS 
media containing amino acids (+) and 2% (w/v) BSA + 300 µM linoleic acid 
(LOA) or oleic acid (OA) for 24 h and amino acid deprived (-) for the last 4 h of 
this incubation as indicated. The expression of SNAT2 (A, B) and ATF4 (C, D) 
was tested by quantitative PCR analysis of RNA isolated from L6 myotubes (A, 
C) and HeLa cells (B, D). Data in the bar graphs is presented as mean + SEM 
(n=3) with NS indicating no significant change between the indicated bars.  
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Figure 4.7 Increased SNAT2 transcription makes a major contribution to 
the System A adaptation response in HeLa cells. 
(A, B) HeLa cells were incubated with EBSS media containing amino acids (+) 
for 24 h and amino acid deprived (-) for the last 4 h of this incubation. In some 
experiments cells were treated with Actinomycin D (5 μM) for the last 5 h of fatty 
acid incubation. (A) Total membranes were isolated and immunoblotted using 
antibodies against SNAT2 and Na/K-ATPase. The immunoblots are 
representative of three separate experiments. (B) System A/SNAT2 activity was 
assayed by measuring the uptake of MeAIB. Data in the bar graphs is 
presented as mean + SEM (n=3) with asterisks indicating a significant change 
(P<0.05) between the bars indicated. 
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myotubes, a minor contributer to the SNAT2 adaptation response in this cell 
line. To address this issue, HeLa cells were incubated with amino acid 
containing media for 24 h and amino acid deprived for the last 4 h of this 
incubation in absence or presence of actinomycin D, a well established 
transcription inhibitor. Fig 4.7A and 4.7B show that the inhibitory effect of 
actinomycin D significantly reduced SNAT2 protein level and transport activity, 
suggesting that, despite the lower increase in SNAT2 and ATF4 mRNA, the 
adaptive response to amino acid withdrawal in HeLa cells is crucially dependent 
upon the modest increase in SNAT2 gene expression, which is likely to be 
efficiently translated.  
4.2.6 LOA suppresses the adaptation response to hyperosmotic stress 
System A expression/activity is also known to be transcriptionally upregulated in 
response to cellular hyperosmotic stress although the signaling mechanisms 
that drive this increase in SNAT2 gene expression are considered distinct from 
those that are responsive to amino acid withdrawal (Lopez-Fontanals et al., 
2003).   
Given that LOA exerted a potent suppressive effect on SNAT2/System A 
adaptation in response to amino acid starvation, I assessed if this fatty acid 
could also perturb the upregulation of SNAT2 expression/function normally 
induced by hyperosmotic stress. Fig 4.8A shows that L6 myotubes exposed to 
sucrose-induced hypertonic stress exhibit a 6-fold increase in SNAT2 mRNA 
expression and that this induction was unaffected in myotubes pretreated with 
LOA. However, subsequent analysis of System A function reveals that whilst 
System A-mediated Me-AIB uptake was elevated by ~4-fold in osmotically  
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Figure 4.8 LOA suppresses the increase in SNAT2 expression/function 
induced in response to hyperosmotic stress in L6 myotubes.  
(A-C) L6 myotubes were incubated with α-MEM and 2% (w/v) BSA + 300 μM 
linoleic acid (LOA) for 24 h and with 100 mM sucrose for the last 4 h of this 
incubation as indicated. (A) The expression of SNAT2 was tested by 
quantitative PCR analysis of RNA isolated from L6 myotubes. (B) System 
A/SNAT2 activity was assayed by measuring the uptake of MeAIB. (C) Total 
membranes were isolated and immunoblotted using antibodies against SNAT2 
and Na/K-ATPase. Data in the bar graphs is presented as mean + SEM (n=3) 
with asterisks indicating a significant change (P<0.05) between the indicated 
pairs of bars. 
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shocked cells, it was significantly blunted in LOA-treated myotubes (Fig 4.8B). 
The observed loss in transport capacity tallies with loss of the mature (cell 
surface) and immature SNAT2 protein as judged by immunoblotting total 
membranes prepared from L6 myotubes with SNAT2 antibodies (Fig 4.8C). 
4.2.7 Regulation of SNAT2 protein abundance by LOA 
The data presented in Figure 4.5 support the idea that SNAT2 protein 
abundance may be specifically modulated in response to LOA availability in 
both L6 myotubes and HeLa cells. Since SNAT2 stability has previously been 
shown to be regulated by the ubiquitin proteasome system (UPS) (Hatanaka et 
al., 2006) I subsequently explored whether LOA may promote SNAT2 
degradation via this proteolytic pathway.  Consistent with the idea that SNAT2 
ubiquitination/degradation would be reduced in amino acid deprived cells (i.e. 
those exhibiting an adaptive increase in SNAT2), HeLa cells transiently 
cotransfected with plasmids containing a CMV-driven SNAT2 construct 
(containing a C-terminal V5-His6 epitope tag) and Flag-ubiquitin exhibit reduced 
SNAT2 ubiquitination compared to cells maintained in amino acid containing 
media under conditions when the UPS is inhibited with MG132 (Fig 4.9A).  To 
assess the impact of LOA on cellular ubiquitination under amino acid deprived 
conditions whole cell lysates from HeLa cells incubated with the fatty acid for 24 
h were immunoblotted with anti-ubiquitin antibodies.  Fig 4.9B shows that the 
presence of MG132 is required for detection of accumulated ubiquitinated 
proteins and that HeLa cells incubated with LOA exhibit a significant increase in 
protein ubiquitination when the signal intensity is quantified along the vertical 
length of the gel lane using Image J software (Fig 4.9B upper panel).  
Intriguingly, whilst the expression of transiently expressed SNAT2-V5 in HeLa 
164 
 
cells under amino acid deprived conditions is not detected, the abundance of 
the V5-tagged transporter is considerably elevated upon inhibiting the UPS with 
MG132  (Fig 4.9C compare lanes 2 and 4).  Importantly and in line with data 
already presented LOA induces a marked loss in SNAT2-V5 protein (compare 
lanes 2 and 3) that was not observed when MG132 was present (compare 
lanes 4 and 5). 
The LOA-induced increase in protein ubiquitination is not restricted to HeLa 
cells. Fig 4.10A shows that, in the presence of MG132, L6 myotubes also 
exhibit the classic ubiquitin smear widely accepted as a typical biochemical 
signature for protein ubiquitination. The intensity of this ubiquitin smear was 
significantly enhanced in myotubes treated with LOA and, as expected, was 
further elevated with prolonged exposure to MG132 as this would contribute to 
increased accumulation of ubiquitinated proteins (Fig 4.10A). Interestingly, the 
increase in UPS and consequent protein breakdown promoted by LOA is likely 
to be accompanied by a decrease in protein synthesis, as indicated by reduced 
phosphorylation/activation of P70S6K1 and its downstream target S6, which 
serve as crucial regulators of mRNA translation (Fig 4.10B). Since LOA also 
attenuates increases in SNAT2 protein that occur in response to hypertonic 
stress it was not all together surprising to discover that the fatty acid also 
enhances protein ubiquitination in myotubes subjected to a 4 h hyperosmotic 
challenge with sucrose (Fig 4.10C). To further substantiate the idea that LOA 
can induce proteasomal degradation of cellular proteins, such as SNAT2, I 
monitored the effect of LOA on lysine 48 (K48) or 63 (K63)-specific 
ubiquitination using linkage-specific antibodies.  K48-ubiquitin chains primarily 
target  proteins  for  proteasomal  degradation  (Thrower et al., 2000), whereas   
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Figure 4.9 Proteasomal inhibition by MG132 prevents LOA-induced loss of 
SNAT2 protein.  
(A) HeLa cells were transiently co-transfected with SNAT2-V5 and ubiquitin-
Flag plasmids by the PEI method. 48 h post-transfection cells were incubated 
with EBSS media containing amino acids (+) for 8 h and amino acid deprived (-) 
for the last 4 h of this incubation in media containing or lacking MG132 (10 μM). 
SNAT2 was immunoprecipitated from whole cell lysates using an anti-V5 
antibody and then immunoblotted using antibody against Flag to detect 
ubiquitin-Flag. (B) HeLa cells were incubated with EBSS media containing 
amino acids (+) and 2% (w/v) BSA + 300 µM linoleic acid (LOA) for 24 h and 
amino acid deprived (-) for the last 4 h of this incubation in media containing or 
lacking MG132 (10 μM) as indicated. (C) HeLa cells were transiently transfected 
with SNAT2-V5 using lipofectamine. 24h post-transfection cells were incubated 
with EBSS media containing amino acids (+) and 2% (w/v) BSA + 300 µM 
linoleic acid (LOA) for 24 h but amino acid deprived (-) during the last 4 h of this 
incubation in media containing or lacking MG132 (10 μM). Bar graph data is 
presented as mean + SEM (n=3) with asterisks indicating a significant change 
(P<0.05) between the indicated bars. 
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Figure 4.10 LOA induces the UPS in L6 myotubes.  
(A, B) L6 myotubes were incubated with EBSS media containing amino acids 
and 2% (w/v) BSA + 300 µM linoleic acid (LOA) for 24 h. In some experiments 
cell were treated with MG132 (10 μM) for the penultimate hours of this 
incubation as indicated. (C-D) L6 myotubes were incubated with α-MEM (B) or 
EBSS (C) media containing amino acids and 2% (w/v) BSA + 300 µM linoleic 
acid (LOA) for 24 h and treated with 100 mM sucrose  (B) or amino acid 
deprived (C) for the last 4 h of this incubation in media containing or lacking 
MG132 (10 μM). Cell lysates from A-D were immunoblotted using antibodies 
against phospho/total proteins, ubiquitin or antibodies specific for detecting K48- 
and K63-linked ubiquitin as indicated. Immunoblots are representative of three 
distinct experiments. Data in the bar graphs is presented as mean + SEM (n=3) 
with asterisks indicating a significant change (P<0.05) between the filled and 
unfilled bars (A), compared to control (B) or between the indicated bars (C, D).   
169 
 
formation of K63-ubiquitin chains direct proteins to alternative fates such as 
trafficking to the lysosome, participation in intracellular signalling and DNA 
repair in a manner unaffected by proteasomal inhibitors (Ikeda and Dikic, 2008). 
Fig 4.10D shows  that  whilst  LOA  induces  a  significant  gain  in cellular K48-
protein ubiquitination I was unable to detect any notable changes in the K63-
protein ubiquitination pattern irrespective of whether cells had been incubated 
with MG132 or not. 
4.2.8 Effects of LOA and proteasomal inhibition on SNAT2 protein and System 
A transport  
Having established that LOA can promote a net increase in cellular protein 
ubiquitination (Fig 4.10) and that MG132 can halt loss of SNAT2 protein by LOA 
(Fig 4.9C), I subsequently monitored the effect of LOA and MG132 on SNAT2 
stability and function in L6 myotubes subjected to amino acid deprivation and 
hypertonic stress. Fig 4.11A and 4.11B show that a 4 h period of extracellular 
amino acid depletion or hypertonic stress induces a 4-5 fold increase in the 
expression of the mature “heavy” cell surface SNAT2 protein, which is 
associated with a significant (3-5 fold) increase in Me-AIB uptake under both 
circumstances (Fig 4.11C and 4.11D).  However, pretreatment of L6 myotubes 
with LOA for 24 h prior to amino acid depletion or hypertonic stress during the 
penultimate 4 h of the LOA incubation period significantly restrains the increase 
in the abundance of both the “light” and “heavy” SNAT2 forms (Fig 4.11A and 
4.11B) as well as the associated stimulus-induced increase in System A 
transport activity (Fig 4.11C and 4.11D).  Intriguingly, cell treatment with MG132 
not only halts the LOA-induced loss of the lighter SNAT2 form but induces its 
accumulation,  whereas the inhibitor was unable to protect against loss of the   
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Figure 4.11 LOA targets the immature SNAT2 form for proteasomal 
degradation in L6 myotubes subjected to amino acid withdrawal and 
hyperosmotic shock.  
(A-D) L6 myotubes were incubated with EBSS media containing amino acids 
(A, C) or α-MEM (B, D) and 2% (w/v) BSA + 300 μM linoleic acid (LOA) for 24 h 
and amino acid deprived (A, C) or stimulated with 100 mM sucrose (B, D) for 
the last 4 h of this incubation. (A, B) Total membranes were isolated and 
subsequently immunoblotted using antibodies against SNAT2 and Na/K-
ATPase. (C, D) System A/SNAT2 activity was assayed by measuring the 
uptake of MeAIB. Data in the bar graphs is presented as mean + SEM (n=3) 
with asterisks indicating a significant change (P<0.05) compared to the amino 
acid deprived (C) or the sucrose stimulated (D) alone value. 
 
  
172 
 
mature (cell surface) SNAT2 protein.  The finding that Me-AIB uptake was not 
enhanced in cells that were amino acid depleted or those subject to hypertonic 
stress when having been pre-incubated with LOA and MG132 is fully consistent 
with loss of the cell surface SNAT2 protein.  
4.2.9 Modulation of Nedd4.2 expression by LOA 
 One potential modifier of SNAT2 protein stability is Nedd4.2, an E3-ubiquitin 
ligase that has previously been implicated in the turnover of SNAT2 via the UPS 
(Hatanaka et al., 2006).  Analysis of Nedd4.2 mRNA expression in both L6 
myotubes and HeLa cells revealed that whilst amino acid availability per se had 
no effect on Nedd4.2 gene expression in presence of LOA, cells treated with 
LOA under amino acid deprived conditions exhibit a significant increase in both 
Nedd4.2 mRNA and protein abundance (Fig 4.12A-D). To further investigate if 
this LOA-induced increase in Nedd4.2 contributes to the 
destabilization/functional loss of SNAT2, expression of Nedd4.2 was stably 
silenced using shRNA in HeLa cells.  Fig 4.13A shows that compared to control 
cells transfected with the empty lentiviral vector, Nedd4.2 protein was 
undetectable in cells expressing shRNA targeting Nedd4.2 mRNA.  However, 
despite the effective silencing of Nedd4.2 expression, little impact was observed 
upon the adaptive increase in SNAT2 that occurs following amino acid 
withdrawal or upon the ability of LOA to curb the increase in both SNAT2 
protein (Fig 4.13B) and System A transport activity (Fig 4.13C). 
Work from the Hundal lab has previously indicated that the cytoplasmic N-
terminal domain of SNAT2 plays an important role with respect to stability of the 
transporter (Hyde et al., 2007).  Whilst the ubiquitination sites on SNAT2 have  
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Figure 4.12 LOA enhances Nedd4.2 mRNA and protein level in amino acid-
deprived L6 myotubes and HeLa cells.  
(A-D) L6 myotubes (A, C) and HeLa cells (B, D) were incubated with EBSS 
media containing amino acids (+) and 2% (w/v) BSA + 300 µM linoleic acid 
(LOA) for 24 h and amino acid deprived (-) for the last 4 h of this incubation as 
indicated. (A, B) The expression of Nedd4.2 was assessed by quantitative PCR 
analysis of RNA isolated from L6 myotubes (A) and HeLa cells (B). (C, D) Cell 
lysates were immunoblotted using antibodies against Nedd4.2 and GAPDH. 
Data in the bar graphs is presented as mean + SEM (n=3) with asterisks 
indicating a significant change (p<0.05) between the indicated bars (A, B) or 
compared to the control (C, D). 
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Figure 4.13 The suppressive effect of LOA upon SNAT2 adaptation does 
not involve Nedd4.2 in HeLa cells.  
(A-C) HeLa cells stably expressing empty vector or shRNA targeting Nedd4.2 
were incubated with EBSS media containing amino acids (+) and 2% (w/v) BSA 
+ 300 µM linoleic acid (LOA) for 24 h and amino acid deprived (-) for the last 4 h 
of this incubation as indicated. (A, B) Cell lysates (A) and isolated total 
membranes (B) were immunoblotted using antibodies against the proteins 
indicated. (C) System A/SNAT2 activity was assayed by measuring the uptake 
of MeAIB. (D) HeLa cells were transiently transfected with SNAT2-V5 or 7A-
SNAT2-V5 mutant using lipofectamine. 24 h post-transfection cells were 
incubated with EBSS media containing amino acids (+) and 2% (w/v) BSA + 
300 µM linoleic acid (LOA) for 24 h and amino acid deprived (-) for the last 4 h 
of this incubation. Cell lysates were immunoblotted using antibodies against V5 
and GAPDH. Immunoblots are representative of three (A, B) and two (D) 
distinct experiments. Data in the bar graphs is presented as mean + SEM (n=3) 
with asterisks indicating a significant change (P<0.05) between the indicated 
bars (B, C).  
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not yet been mapped, of the 12 cytosolic exposed lysine residues that may 
potentially be ubiquitinated, seven are located within the N-terminal tail. Thus, 
one or more of these lysine residues may influence SNAT2 stability.  To test this 
possibility all 7 lysine residues in the N-terminal tail were mutated to an alanine 
(7A mutant) and the mutated 7A-SNAT2-V5 construct expressed from a CMV-
non amino acid responsive promoter.  The reason for using this strategy was to 
avoid increases in SNAT2 transcription driven by amino acid deprivation and 
allow focus on SNAT2 protein stability alone.  Figure 4.13D shows that whilst 
HeLa cells expressing wild-type SNAT2-V5 only exhibit stabilization of SNAT2 
protein in amino acid deprived cells, the 7A-SNAT2-V5 appears to be equally 
stable under all conditions tested.   
4.2.10 Effects of palmitate upon the System A adaptation response in L6 
myotubes 
Interestingly, whilst palmitate (PA) and LOA are known to have opposing effects 
upon insulin signalling, both induced a similar repressive effect on SNAT2 
transport activity (Fig 4.2). To assess whether PA and LOA promote this 
repression by the same mechanism I further investigated the effect of PA 
provision upon SNAT2 transport activity, protein abundance and mRNA level in 
L6 myotubes and HeLa cells. Previous work from the Hundal lab has already 
demonstrated that PA represses basal System A transport activity in L6 
myotubes  (Fig 4.14A). Fig 4.14B and 4.14C show that the fatty acid reduces 
also the adaptive increase in System A transport in a time- and dose-dependent 
manner in this skeletal muscle cell line. Interestingly, unlike LOA, the 
suppressive effect of PA upon System A adaptation was not observed in HeLa   
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Figure 4.14 Effects of PA on SystemA/SNAT2-mediated Me-AIB uptake in 
L6 myotubes and HeLa cells.  
(A) L6 myotubes were incubated with EBSS media containing amino acids (+) 
and 2% (w/v) BSA + 750 μM palmitate (PA) for 16 h prior to measuring MeAIB 
transport. (B) L6 myotubes were incubated with EBSS media containing amino 
acids (+) and 2% (w/v) BSA + 300 μM palmitate (PA) for times indicated and 
amino acid deprived (-) for the last 4 h of this incubation prior to measuring 
MeAIB transport. (C) L6 myotubes were incubated as in (A) + increasing 
concentration of PA as indicated for 24 h and amino acid deprived (-) for the last 
4 h of this incubation prior to measuring MeAIB transport. (D) HeLa cells were 
incubated as in (A) + 300 μM palmitate (PA) for 24 h and amino acid deprived 
for the last 4 h of this incubation prior to measuring MeAIB transport. The bar 
graph values are presented as mean + SEM of three separate experiments with 
asterisks indicating a significant change (P<0.05) compared to the amino acid 
deprived alone value and NS no significant change between the indicated bars. 
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cells indicating that the fatty acid may have a cell-specific effect on the 
modulation of the SNAT2 adaptive response (Fig 4.14D). 
4.2.11 PA impairs abundance of the mature glycosylated SNAT2 without 
affecting that of the immature form in L6 myotubes 
To assess whether the observed reduction in System A transport induced by PA 
could be attributed to changes in SNAT2 protein abundance, L6 myotubes and 
HeLa cells were incubated with 300 μM PA in medium containing amino acids 
and amino acid deprived for the last 4 h of this incubation before total 
membranes were isolated. Fig 4.15A shows that the protein abundance of both 
the glycosylated mature form and immature intracellular form of SNAT2 was 
significantly increased by amino acid withdrawal in L6 myotubes. The adaptive 
increase in the mature “heavy” SNAT2 form was reduced substantially when L6 
myotubes were incubated with PA (Fig 4.15.A), in line with the reduction in 
System A transport activity induced by the saturated fatty acid (Fig 4.14B and 
4.14C). PA treatment results also in a slight reduction of mature SNAT2 protein 
abundance in cells held in amino acid containing media (Fig 4.15A, compare 
lanes 1 and 3), consistent with PA-induced reduction of basal System A 
transport acitivty (Fig 4.14A). However, unlike LOA (Fig 4.5B), PA provision 
does not affect the abundance of the immature intracellular form of the 
transporter, which is still enhanced to a level comparable to amino acid 
deprived cells not exposed to the fatty acid (Fig 4.15A). Moreovoer, PA does 
not affect the adaptive increase in SNAT2 protein abundance in HeLa cells (Fig 
4.15B), consistent with the finding that it also has no effect on System A 
transport activity in this cell line (Fig 4.14D).  
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Figure 4.15 Effects of PA upon SNAT2 protein abundance in L6 myotubes 
but not in HeLa cells.  
(A, B) L6 myotubes and HeLa cells were incubated with EBSS media 
containing amino acids (+) and 2% (w/v) BSA + 300 μM palmitate (PA) for 24 h 
and amino acid deprived (-) for the last 4 h of this incubation as indicated prior 
to isolation of total membranes. Total membranes were subsequently 
immunoblotted using antibodies against SNAT2 and Na/K-ATPase. The 
immunoblots are representative of three separate experiments. The asterisks 
signify a significant change (P<0.05) between the indicated bars.   
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4.2.12 Effects of PA upon SNAT2 gene transcription in L6 myotubes 
As mentioned earlier, fatty acids may potentially reduce the SNAT2 adaptive 
response via impaired upregulation of the SLC38A2 gene. Surprisingly, 
however, Fig 4.16A shows that SNAT2 mRNA abundance was increased in L6 
myotubes pre-incubated with PA regardless of whether cells were subjected to 
amino acid deprivation or not. This observation is consistent with the finding that 
ATF4 mRNA abundance is also enhanced by PA in L6 myotubes held in amino 
acid containing media (Fig 4.16C). In contrast, and in line with the findings that 
PA has no effect upon SNAT2 protein abundance and transport activity in 
response to amino acid withdrawal in HeLa cells, also the adaptive increase in 
mRNA abundance of SNAT2 and ATF4 of cells pre-incubated with the saturated 
fatty acid are comparable to that of amino acid deprived cells not exposed to PA 
(Fig 4.16B and 4.16D). 
It is well documented that PA can induce pro-inflammatory signalling and ER 
stress in insulin target tissues (Green et al., 2011; Macrae et al., 2013; Salvado 
et al., 2013). ATF4 is one of several transcription factors activated by ER-stress 
and PA has been shown to increase ATF4 mRNA abundance in hepatocytes 
(Wei et al., 2009; Wei et al., 2006), which is in line with my findings in skeletal 
muscle cells (Fig 4.16C). Since OA has been shown to prevent PA-induced ER 
stress (Salvado et al., 2013), I wanted to test whether co-provision of the MUFA 
could counteract the increase in SNAT2 and ATF4 mRNA level triggered by PA 
in L6 myotubes. Fig 4.17A and 4.17B show that, while OA per se does not 
affect SNAT2 and ATF4 mRNA expression, PA induces a ~2-fold increase. 
However,   when  PA  is  co-applied  with   OA,  the   MUFA   antagonises   the   
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Figure 4.16 PA does not repress the transcriptional upregulation of SNAT2 
in L6 myotubes and HeLa cells.  
(A-D) L6 myotubes (A, C) and HeLa cells (B, D) were incubated with EBSS 
media containing amino acids (+) and 2% (w/v) BSA + 300 µM palmitate (PA) 
for 24 h and amino acid deprived (-) for the last 4 h of this incubation as 
indicated. The expression of SNAT2 (A, B) and ATF4 (C, D) was tested by 
quantitative PCR analysis of RNA isolated from L6 myotubes (A, C) and HeLa 
cells (B, D). Data in the bar graphs is presented as mean + SEM (n=3) with 
asterisks indicating a significant difference (p<0.05) and NS a no significant 
change between the indicated bars.  
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Figure 4.17 OA prevents the activatory effect of PA on SNAT2 
transcription in L6 myotubes.  
(A, B) L6 myotubes were incubated with EBSS media containing amino acids 
and 2% BSA + 300 µM palmitate (PA), oleic acid (OA) or both for 24 h as 
indicated. The expression of SNAT2 (A) and ATF4 (B) was tested by 
quantitative PCR analysis of RNA isolated from L6 myotubes. Data in the bar 
graphs is presented as mean + SEM (n=3) with asterisk indicating a significant 
difference (p<0.05) between the indicated bars. 
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stimulatory effect of PA on ATF4 and consequently upon SNAT2 gene 
expression. 
4.2.12 PA may repress the SNAT2 adaptive response via ceramide 
Although PA reduced the adaptive increase in SNAT2 transport activity and the 
abundance of the mature “heavy” SNAT2 protein, it most likely does so through 
a mechanism that differs from that utilised by LOA. Data in the literature show 
that PA and LOA exert opposite effects on the ubiquitin-proteasome pathway 
(Ando et al., 2004; Pauloin et al., 2010). To assess whether this is the case in 
my experimental model, L6 myotubes were incubated with 300 μM LOA or PA 
for 24 h and amino acid deprived for the last 4 h of this period in presence of 
MG132. As shown earlier, the intensity of the ubiquitin smear observed in 
presence of MG132 was enhanced in myotubes treated with LOA, while PA 
provision does not promote accumulation of ubiquitinated proteins, suggesting 
that its suppressive effect on System A transport is unlikely to involve SNAT2-
degradation via the UPS (Fig 4.18). The inhibitory effect that PA exerts upon 
SNAT2 function might be partially mediated by its derivative ceramide, which 
has been previously shown to promote a reduction in SNAT2 activity by 
increasing internalisation of surface SNAT2 transporters, without significant loss 
in total cell SNAT2 content in L6 myotubes (Hyde et al., 2005). This possible 
mechanism would be in line with the finding that PA reduces the abundance of 
the mature SNAT2 glycosylated form without affecting the intracellular pool of 
the transporter. However, unlike in cells that were treated with ceramide, I 
observed a reduction in total cellular SNAT2 protein abundance in amino acid 
depleted cells incubated with PA compared to those not exposed to the fatty 
acid   (Fig 4.15A  compare  lanes  2  and  4).  This   would  suggest   that,   not   
187 
 
 
 
 
Figure 4.18 PA does not promote UPS activation.  
L6 myotubes were incubated with EBSS media containing amino acids and 2% 
(w/v) BSA + 300 µM linoleic acid (LOA) or palmitate (PA) for 24 h and treated 
with MG132 (10 μM) for the penultimate 4 h of this incubation as indicated. The 
immunoblots and relative quantifications are representative of two separate 
experiments.  
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withstanding the ability of ceramide to promote internalisation of SNAT2 from 
the cell surface, PA may target and direct the “surface” and internalised SNAT2 
to non-proteasomal degradation, like, for example, lysosomal proteolysis. 
Moreover, it is important to consider that PA-induced ceramide production may 
be more pronounced in insulin target tissues, where these lipids have a major 
role as signaling factors influencing metabolic functions. If so, this would 
potentially explain why PA has an effect in L6 myotubes and not in HeLa cells. 
To test this hypothesis protein levels of LCB1, a subunit of the rate-limiting 
enzyme responsible for the de novo synthesis of ceramide from PA, serine 
palmitoyltransferase (SPT), were analysed in both cell lines. Fig 4.19A shows 
that LCB1 content was significantly higher in L6 myotubes than HeLa cells, 
suggesting that ceramide production was likely to be more pronounced in the 
skeletal muscle cell line. Ceramide involvement in mediating the PA 
suppressive effect was then tested by using myriocin, a well documented 
inhibitor of SPT and ceramide production. Fig 4.19B shows that the adaptive 
increase in the abundance of the “heavier” glycosylated SNAT2 was 
significantly reduced in L6 myotubes treated with PA for 24 h. However, when 
cells were co-incubated with PA and myriocin, the suppressive effect of the 
saturated fatty acid was significantly attenuated, indicating that ceramide 
synthesis was likely to be an important factor in the PA-induced reduction in cell 
surface SNAT2 expression and function (Fig 4.19B). As shown before, PA does 
not repress SNAT2 protein abundance in HeLa cells and this was not affected 
by co-provision of myrocin (Fig 4.19C). 
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Figure 4.19 PA-induced loss of the mature “heavy” glycosylated SNAT2 
protein involves ceramide production.  
(A) L6 myotubes and HeLa cells were incubated with EBSS media containing 
amino acids (+) for 24 h and amino acid deprived (-) for the last 4 h of this 
incubation. (B, C) L6 myotubes (B) and HeLa cells (C) were incubated with 
EBSS media containing amino acids (+) and 2% (w/v) BSA + 300 µM palmitate 
(PA) for 24 h and amino acid deprived (-) for the last 4 h. In some experiments 
cells were treated with myriocin (10 μM) for 4 h prior to and for the duration of 
the fatty acid incubation (i.e. total time of 28 h). Cell lysates (A) and isolated 
total membranes (B, C) were immunoblotted using antibodies against SNAT2 
and NA/K-ATPase. Immunoblots are representative of three separate 
experiments. Data in the bar graphs is presented as mean + SEM (n=3) with the 
asterisk indicating a significant difference between the indicated bars. 
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4.3 Discussion 
4.3.1 LOA promotes SNAT2 degradation via proteasomal ubiquitin system 
The work presented in this Chapter demonstrates that sustained cell incubation 
with LOA perturbs the adaptive upregulation of System A/SNAT2 that is 
normally instituted when cells are subjected to amino acid deprivation or a 
hypertonic-inducing stress stimulus.  The upregulation of SNAT2 in response to 
such stimuli is not just a consequence of increased transcription of the 
SLC38A2 gene (Palii et al., 2006) but also involves greater stabilization of the 
SNAT2 protein itself.  However, my observations indicate that whilst the 
increase in SNAT2 gene expression triggered by extracellular amino acid 
deficiency or hypertonicity is unaffected, the resultant increase in SNAT2 
protein and transport activity fail to materialise in cells preincubated with LOA 
because the transporter is targeted for degradation by the UPS.  The ability of 
fatty acids to modulate SNAT2 abundance via this proteolytic route has not, to 
my knowledge, been previously documented and provides an additional facet to 
the biology of one of the most extensively regulated mammalian amino acid 
transporters known.  However, it is important to stress that whilst the adaptive 
increase in SNAT2 abundance is diminished by LOA, the fatty acid also 
increases the total content of ubiquitinated proteins in cells (Fig 4.10A-C) 
suggesting that SNAT2 is likely to be one of many proteins targeted to the UPS 
in response to increased fatty acid availability.  The ability of LOA to promote 
increased cellular protein ubiquitination and hence protein breakdown is likely to 
be matched by an ability to suppress protein synthesis given that the fatty acid 
also markedly reduced phosphorylation of P70S6K – a key upstream regulator 
of mRNA translation (Fig 4.10A and B).  Thus a net consequence of LOA 
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oversupply to cells being subjected to amino-acid deprivation is accelerated 
loss in cellular protein, which may serve as a potential mechanism that helps 
maintain the intracellular amino acid pool during nutrient limited conditions.  
Precisely how unsaturated fatty acids, including LOA, stimulate the UPS 
remains unclear although in rat skeletal muscle they are known to stimulate the 
proteolytic activity of 20S proteasomes (Dahlmann et al., 1985).  Accelerated 
skeletal muscle protein degradation is also a feature in mice fed a high fat diet 
in which enhanced in vivo muscle proteolysis has been linked to increased 
expression of two E3 ubiquitin ligases, atrogin-1/muscle atrophy F-box (MAFbx) 
and muscle RING finger-1 (MuRF-1) (Zhou et al., 2007), that are closely 
associated with muscle protein degradation (Sandri et al., 2004).  Although 
there is no evidence in the literature linking MAFbx or MuRF-1 to regulation of 
SNAT2 turnover, I postulated that Nedd4.2 may be a prime candidate in the 
fatty acid induced degradation of SNAT2 given that this E3 ligase has been 
implicated in the ubiquitination of the transporter in 3T3-L1 adipocytes 
(Hatanaka et al., 2006).  However, my data indicates that whilst LOA induces 
upregulation of Nedd4.2 in amino acid deprived cells in a manner that would be 
consistent with the observed reduction in SNAT2 triggered by LOA, cellular 
depletion of Nedd4.2 (using shRNA) was unable to prevent the loss in SNAT2 
protein caused by the fatty acid.  This latter observation, along with the finding 
that I do not observe any net increase in SNAT2 abundance in cells lacking 
Nedd4.2 vis a vis control cells (i.e. those infected with the empty lentiviral 
vector), would imply that Nedd4.2 is dispensable with respect to regulation of 
SNAT2 turnover via the UPS, at least in the cells used in my study.  
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Ectopic expression of EGFP-labelled SNAT2 (aka ATA2) in 3T3-L1 adipocytes 
has been used as a strategy for investigating SNAT2 ubiquitination and turnover 
and it is noteworthy that proteasomal inhibition within these cells using MG132 
induced marked perinuclear accumulation of the transporter (Hatanaka et al., 
2006).  Intriguingly, in these cells MG132 also increased adipocyte Me-AIB 
uptake, which, coupled with the observation that Nedd4.2 partially colocalised 
with SNAT2 at the cell surface, led the authors of this study to conclude that 
surface SNAT2 would normally be internalised and degraded by the UPS 
(Hatanaka et al., 2006).  Whilst there is some evidence that such a mechanism 
may account for the regulation and turnover of certain plasma membrane 
proteins (Malik et al., 2001; Smith et al., 2008; Zhao et al., 2014), most are 
internalised and undergo trafficking to early endosomes and sorting to 
multivesicular bodies prior to lysosomal fusion and proteolysis (Luzio et al., 
2009; Piper and Katzmann, 2007). My studies assessing the effect of LOA on 
the SNAT2 adaptive response lead me to propose that SNAT2 may have two 
potential proteolytic fates depending on its cellular localization. It is my view that 
LOA targets the immature intracellular SNAT2 protein for degradation by the 
UPS, whereas the mature surface form is likely to be degraded by a non-UPS 
route (Fig 4.20).  This proposition is based on the finding that MG132 not only 
curtails loss of immature SNAT2 ear-marked for degradation by LOA, but 
promotes its intracellular accumulation – much like that seen in adipocytes 
expressing EGFP-labelled SNAT2 (Hatanaka et al., 2006). However, since 
MG132 will have no direct inhibitory effect upon LOA-induced protein 
ubiquitination, I believe that the normal processing, maturation and delivery of 
SNAT2 to the cell surface (which represents an integral part of the System A 
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adaptive response) is likely to be arrested by its ubiquitination.  Consistent with 
this view, MG132 fails to promote any buildup of the mature (cell surface) 
SNAT2 form in muscle cells and, as a consequence, System A transport activity 
cannot be raised to the level induced by amino acid deprivation or hypertonic 
stress as occurs in cells not treated with LOA and MG132 (Fig 4.11C and 
4.11D). In addition, it is noteworthy that whilst Me-AIB uptake in cells 
maintained in an amino acid sufficient environment is normally low, LOA per se 
has no impact on basal amino acid uptake or upon the abundance of the 
mature/heavy SNAT2 protein although the fatty acid is still capable of causing a 
modest reduction in the abundance of the immature SNAT2 protein (compare 
lanes 1 and 3 in Fig 4.11A and 4.11B). 
Previous work from the Hundal lab has indicated that the cytoplasmic domains 
of SNAT2 are the most likely candidate regions for associating with the 
proteolytic machinery and therefore most likely to confer amino acid-regulated 
stability effects (Hyde et al., 2007).  Consistent with this idea, it has been shown 
that grafting the N-terminal tail of SNAT2 onto SNAT5 (a related family member 
that does not exhibit adaptation to amino acid withdrawal) renders the stability 
of the SNAT5 protein sensitive to amino acid availability (Hyde et al., 2007).  
Closer inspection of the cytoplasmic SNAT2 N-terminal tail reveals the 
presence of 7 lysine residues that may potentially serve as ubiquitin conjugation 
sites.  The finding that transfection of HeLa cells with a SNAT2-V5 construct in 
which all 7 lysine residues were mutated to alanine results in expression of a 
SNAT2 protein that is constitutively more stable than wild-type SNAT2 and one 
that is protected against LOA-induced proteolysis would tend to support this 
proposition.  A key unresolved issue concerns the identity of the E3-ligase that 
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promotes ubiquitination of one or more of these lysine residues and the 
mechanism by which LOA enhances this SNAT2-ubiquitin tagging process. 
Whilst increased expression of E3 ligases in response to unsaturated fatty acids 
may serve to drive ubiquitination/degradation of cellular proteins, the signalling 
events responsible for sensing and initiating this response remain poorly 
understood.  However, two potential pathways that may contribute to fatty acid 
induced activation of the UPS include signalling initiated by TLR4, a member of 
the Toll-like family of receptors, and peroxisome proliferator-activated receptor α 
(PPARα), which functions as a major regulator of lipid metabolism in tissues 
such as liver and muscle (Burri et al., 2010).  TLR4 activation can be typically 
initiated by binding of lipopolysaccharide (LPS) but also by fatty acids 
(Schaeffler et al., 2009; Shi et al., 2006) and, as such, activation of the receptor 
by LPS has been linked to upregulation of both MAFbx and MuRF-1 and 
increased muscle atrophy by the UPS (Doyle et al., 2011).  Whether TLR4 
signalling  accounts for LOA-induced SNAT2 ubiquitination is currently 
unknown, but in separate experiments performed in the Hundal lab it has been 
found that whilst treatment of L6 myotubes with LPS induces TLR4 signalling 
there are no significant changes in System A mediated Me-AIB uptake (data not 
shown).  Although this latter finding tends to negate involvement of the TLR4 
signalling axis as a specific regulator of SNAT2 turnover it does not discount the 
possibility that it may stimulate loss of other cellular proteins by the UPS.  Much 
like TLR4, PPARα also binds a variety of fatty acid ligands, preferentially 
unsaturated fatty acids including LOA, and recent work has highlighted that 
activation of PPARα increases content of ubiquitinated proteins in rat skeletal 
muscle and stimulates proteolytic flux through the UPS with a consequential 
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increase in muscle atrophy (Ringseis et al., 2013).  As with TLR4 activation, the 
increase in protein ubiquitination associated with ligand-induced activation of 
PPARα involves higher muscle expression of MAFbx and MuRF-1.  Whilst the 
impact of PPARα activation upon SNAT2 turnover has not been directly 
investigated, it is noteworthy that increases in SNAT2 abundance in response to 
chronic insulin stimulation can be fully repressed by PPARα activation in human 
trophoblasts (Jones et al., 2010).  Whether this PPARα-linked repression is due 
to enhanced proteasomal degradation of SNAT2 or the result of impaired insulin 
signalling events that participate in the upregulation of SNAT2 expression is 
currently unknown, but testing these possibilities represent important 
investigative goals of future work.  
4.3.2 PA-induced repression of SNAT2 transport activity is mediated by 
ceramide 
It is well documented that PA, the most common circulating saturated fatty acid, 
induces insulin resistance (Powell et al., 2004), ER stress (Wei et al., 2006) and 
pro-inflammatory signalling (Joshi-Barve et al., 2007; Macrae et al., 2013) in 
insulin target tissues, while unsaturated fatty acids do not exert these 
detrimental effects but rather can mitigate the effects of saturated fatty acids 
(Coll et al., 2008; Dimopoulos et al., 2006; Kwon et al., 2014; Lee et al., 2006; 
Macrae et al., 2013; Yuzefovych et al., 2010). However, little is known of how 
fatty acids impact on amino acid transport. Data presented in this Chapter show 
that PA (a SFA) and LOA (a PUFA) have a similar inhibitory effect upon the 
SNAT2 adaptation response, even though they do so through different 
molecular mechanisms. Both LOA and PA impair the adaptive upregulation of 
SNAT2 transport activity induced by amino acid deprivation. This suppressive 
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effect manifests itself at doses of PA as low as 100 μM and is most apparent 
after a chronic incubation of cells with the fatty acid. One possible mechanism 
by which PA may repress SNAT2 adaptation is by decreasing SLC38A2 gene 
expression in response to amino acid withdrawal. Interestingly, however, I found 
that PA enhanced SNAT2 mRNA abundance regardless of whether L6 cells 
were amino acid deprived or not (Fig 4.16A). SNAT2 expression is promoted by 
stresses, such as amino acid deprivation or osmotic shock, and this effect is 
partially dependent upon ATF4, a transcription factor that plays an important 
role in the cellular stress response (Hundal and Taylor, 2009). PA is known to 
induce oxidative stress and ER stress in insulin target tissues (Green et al., 
2011; Macrae et al., 2013; Salvado et al., 2013) and has been shown to 
increase ATF4 gene expression in hepatocytes (Wei et al., 2009; Wei et al., 
2006). Since SNAT2 is an ATF4 gene target it is plausible that it might 
upregulate SNAT2 gene expression in response to stress. The finding that 
ATF4 mRNA was increased by PA treatment in the presence of amino acids is 
in line with this idea (Fig 4.16C). Moreover, co-provision of the MUFA oleic acid, 
which is known to antagonise PA-induced ER stress (Salvado et al., 2013), 
counteracts the stimulatory effect of PA on ATF4 gene expression and that on 
its gene target SNAT2 (Fig 4.17A and 4.17B), confirming the idea that PA 
upregulates amino acid transporter expression by promoting a cellular stress 
response. SNAT2, but not ATF4, mRNA levels were further enhanced when 
PA-treated cells were subject to amino acid deprivation. This might be due to 
the fact that the GCN2/ATF4 is not the only pathway regulating SNAT2 
transcription in response to amino acid withdrawal. Previous work from the 
Hundal lab has in fact shown that JNK (a MAPK family member) is involved in 
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mediating the adaptive response in L6 myotubes (Hyde et al., 2007). c-Jun, a 
JNK substrate, has also been shown to bind the SNAT2 promoter (Palii et al., 
2006). Since PA can induce pro-inflammatory signalling by activation of the 
MAPK pathways (Green et al., 2011), it is possible that the saturated fatty acid 
enhances SNAT2 gene expression by both activating ATF4 and JNK following 
amino acid depletion.  
Althought treatment of L6 myotubes with PA increased the mRNA abundance of 
SNAT2 both in basal and amino acid deprived conditions, it was accompanied 
by a corresponding increase in protein expression only in cells held in amino 
acid containing media. The reduction in the adaptive increase of System A 
activity triggered by PA can in fact be attributed to a loss in the protein 
abundance of the mature/glycosylated form of SNAT2 during amino acid 
starvation. However, unlike LOA, which decreases content of both the “heavy” 
and “light” form of SNAT2, PA represses only the abundance of the mature form 
of the transporter while not affecting that of the intracellular form (Fig 4.15A). 
These results suggest that the repressive effect of PA on SNAT2 membrane 
transport activity is unlikely to be mediated by the same mechanism as that 
utilised by LOA, which targets the intracellular pool of SNAT2 for degradation. 
The notion that saturated and unsaturated fatty acids may mechanistically affect 
SNAT2 function by different mechanisms is further supported by data in the 
literature showing that PA and LOA exert opposite effects on the ubiquitin-
proteasome pathway. LOA has been shown to increase ubiquitination and 
consequent degradation of the protein tyrosinase, while PA retards its 
proteolysis (Ando et al., 2004). The increased degradation of tyrosinase as well 
as SNAT2 is the result of a general enhancement in proteasomal activity 
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promoted by LOA, as evidenced by the significant accumulation of ubiquitinated 
proteins in L6 myotubes (Fig 4.10A) and cultured mouse melanoma cells (Ando 
et al., 2004) when co-incubated with the PUFA and MG132. On the contrary, in 
both cell lines PA treatment fail to promote an increase in ubiquitinated proteins 
in the presence of the proteasome inhibitor (Fig 4.18) (Ando et al., 2004).  
In the absence of any effects on the UPS, the inhibitory effect of PA on SNAT2 
activity appears to be, in part, attributable to enhanced synthesis of its lipid 
derivative, ceramide. Previous work from the Hundal Lab has in fact shown that 
ceramide inhibits System A transport activity by enhancing internalisation of the 
transporter, thereby reducing the abundance of functional SNAT2 carriers at the 
cell surface (Hyde et al., 2005). One might assume that such internalisation is 
associated with the deglycosylation of the transporter, given that PA treatment 
preferentially results in accumulation of the “lighter” deglycosylated form of 
SNAT2.  Although it is not possible to totally exclude ceramide involvement in 
LOA-induced repression of SNAT2 protein abundance, it is noterworthy that 
ceramide production from PUFAs is very restricted (Blachnio-Zabielska et al., 
2010). Moreover, unlike LOA, which has no impact on protein abundance of the 
mature/glycosylated form of SNAT2 in amino acid sufficient conditions, 
ceramide has been shown to suppress both basal and insulin-stimulated 
System A activity as a result of depleting  the plasma membrane abundance of 
SNAT2 (Hyde et al., 2005). This is in line with my finding, which shows that 
whilst PA upregulates SNAT2 expression, the fatty acid causes a modest 
reduction in the abundance of the mature “surface” SNAT2 protein (Fig 4.15A, 
compare lanes 1 and 3) and consequently in System A transport activity (Fig 
4.14A). Ceramide involvement in mediating loss of plasma membrane SNAT2 in 
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response to PA was confirmed by the finding that myriocin, a well documented 
inhibitor of de novo fatty acid-derived synthesis of ceramide can partially 
prevent this loss in surface SNAT2 (Fig 4.19B, compare lanes 4 and 6). The 
inability of myriocin to completely restore protein levels of the 
mature/glycosylated form of SNAT2 following amino acid withdrawal may be 
explained by two possibilities. First, myriocin may not fully suppress SPT and 
consequently some de novo synthesis of ceramide still prevails. Moreover, 
amino acid depletion has been shown to increase ceramide production at least 
partly from sphingomyelin, a process catalysed by acid sphingomyelinase 
(SMase) activity, which is completely independent from SPT (Taniguchi et al., 
2012). Second, it is plausible that, unlike ceramide, PA may induce degradation 
of the mature surface form of SNAT2. Whereas ceramide, generated from PA, 
may cause internalisation of SNAT2, the fatty acid may also target the 
mature/glycosylated form of SNAT2 for degradation by lysosome, since PA 
does not stimulate the ubiquitin-proteasome system. This proposition is 
supported by the finding that excess provision of SFAs in high-fat diets to mice 
(Guo et al., 2013) or exposure of pancreatic β cells to PA (Chen et al., 2013; 
Martino et al., 2012) enhances autophagic/lysosomal activity. Moreover, 
proteolysis induced by amino acid deprivation in skeletal muscle cells is mainly 
mediated by the lysosomal system (Bechet et al., 2005; Capel et al., 2009; 
Mordier et al., 2000). The ability of PA to modulate protein degradation via the 
lysosomal-proteolytic system is not unprecedented. In fact, the SFA has 
previously been shown to induce ER-stress and lipotoxicity in pancreatic β-cells 
by targeting carboxypeptidase E, the enzyme involved in the conversion of pro-
insulin to insulin, for lysosomal degradation (Jeffrey et al., 2008). Thus, it is 
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possible that while ceramide promotes the internalisation of mature/ 
glycosylated form of SNAT2, PA might induce its K-63 linkage specific 
ubiquitination, which targets the mature “surface” form of the transporter for 
endocytosis and lysosomal degradation in cells subject to amino acid 
withdrawal (Fig 4.20).  
In conclusion, the data presented in this Chapter show for the first time that 
LOA (a PUFA) and PA (a SFA) modulate System A transport activity by 
affecting SNAT2 protein stability. Both fatty acids exert a similar repressive 
effect upon the SNAT2 adaptive response, although they do so through distinct 
molecular mechanisms: 
 LOA attenuates the adaptive upregulation of SNAT2 that is normally 
instigated in response to cellular amino acid depletion or hypertonic 
stress. This fatty acid-induced reduction is not due to suppression of 
SNAT2 gene transcription that is initiated by the amino acid withdrawal or 
hypertonic stimulus, but to enhanced destabilization and degradation of 
intracellular SNAT2 by the UPS.  As a consequence, delivery of newly 
synthesised/processed SNAT2 to the cell surface is substantially 
diminished resulting in a concomitant loss in System A transport activity 
which will have implications for cellular adaptation to reduced 
extracellular amino acid availability and hypertonicity. 
 PA reduces both basal and amino acid deprivation-induced SNAT2 
transport activity. PA does not induce this decrease by suppressing 
ATF4 gene transcription or that of its target gene SNAT2, but rather via 
membrane depletion of the mature SNAT2 protein. Ceramide, a lipid 
derivative    of   PA,    appears   to    mediate   this   effect    by   inducing  
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internalisation of mature/glycosylated form of SNAT2, while PA 
potentially targets the “surface” mature form of SNAT2 for lysosomal 
degradation in cells subjected to amino acid depletion. 
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Chapter 5 
Conclusions and Future Work 
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5.1 Key observations from Chapter 3 
 Oleic acid (OA, MUFA) and linoleic acid (LOA, A PUFA) enhance insulin-
induced phosphorylation/activation of Akt and ERK1/2 and that of their 
downstream targets; this improved insulin action is not due to augmented 
IRS1/PI3K activation, but rather involves suppressed activation of protein 
phosphatase 2A (PP2A). 
 OA and LOA mitigate the insulin-desensitising effects of  palmitate (PA, a 
SFA) via counter-modulation of PP2A.  
 An increase in fatty acid oxidation is not a requirement  for promoting the 
protective effects of OA and LOA against PA-induced impairment of 
insulin signalling. 
 The insulin-sensitising effects of OA and LOA do not involve modulation 
of AMPK nor do they rely upon the signalling-related functions of 
caveolin-enriched microdomains. 
There is considerable scope for follow up work to try and further understand 
how MUFAs and PUFAs may potentially initiate and promote their effects upon 
insulin signalling.  Three prospective avenues of research include (i) analysis of 
the role played by GPR40, a fatty acid receptor, (ii) changes in lipid 
handling/storage and (iii) effects upon mitochondrial biology.  Possible 
experimental work in each of these areas is outlined below:      
i. Does GPR40 mediate LOA and OA-induced inhibition of PP2A? 
The data presented in Chapter 3 indicate that OA and LOA can oppose the 
insulin-desensitising effects of PA by countering the stimulatory effects that the 
SFA has upon PP2A. Tyrosine phosphorylation of the catalytic PP2A subunit on 
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Y307 is associated with its inhibition.  Phosphorylation of this site is catalysed 
by the tyrosine kinase, Src, and given that this was enhanced in my studies with 
OA and LOA, my work would suggest that these fatty acids have the capacity to 
induce Src activation. However, the molecular mechanism by which OA and 
LOA induce Src activation remains unknown, but it is possible that it may 
involve activation of GPR40, a fatty acid receptor. GPR40 activates the Gαq/11 
pathway, leading to release of Ca2+ from the ER (Burant, 2013), which has been 
associated with Src activation (El-Yassimi et al., 2008). Since unsaturated fatty 
acids, such as OA and LOA, have been shown to bind GPR40 (Briscoe et al., 
2003) it would be of value to investigate its involvement in their beneficial 
effects by silencing expression of this receptor in L6 skeletal muscle cells and 
determine whether this negates the improvement in insulin sensitivity by UFAs.  
Several studies have identified GPR40 as a key protein in the modulation of 
fatty acid-induced insulin secretion (Edfalk et al., 2008; Steneberg et al., 2005), 
thus in the past few years the receptor has become the focus of considerable 
interest as a novel therapeutic target for type 2 diabetes (Burant, 2013; Liu et 
al., 2014). Treatment of  insulin resistant diabetic rodents with two of the most 
effective and potent GPR40 agonists identified so far, TAK-875 and AM 837, 
has been shown to increase glucose-stimulated insulin secretion and lower 
post-prandial blood glucose level (Lin et al., 2011; Tsujihata et al., 2011)., It 
would, therefore, be of interest to assess whether treating L6 myotubes with 
these agonists can mimic the insulin sensitising effect promoted by LOA and 
OA upon insulin signalling and, if so, whether this involves inhibition of protein 
phosphatase PP2A. 
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ii. TAG storage  
Data presented in Chapter 3 indicate that fatty acid oxidation is not a 
requirement  for promoting the beneficial effects of OA and LOA, given that 
etomoxir, an inhibitor of CPT-1 and therefore of fatty acid oxidation, did not 
diminish the ability of UFAs to enhance Akt activation and mitigate the 
detrimental effects of PA. This observation implies that OA and LOA may 
overcome the insulin desensitising effects of PA by channeling the fatty acid 
into neutral lipids (i.e. triglyceride), rather than increasing its oxidation. As 
discussed in section 1.6.3, increased  partitioning and incorporation of SFAs 
towards TAG synthesis may lessen synthesis of other lipids, such as DAG and 
ceramides, implicated in insulin resistance (Cheon and Cho, 2014; Listenberger 
et al., 2003). Moreover, sequestering PA into TAG would be expected to reduce 
the carbon load placed on mitochondria thereby alleviating metabolic stress and 
promoting beneficial gains in insulin sensitivity. To explore whether increased 
TAG accumulation is a feature cells can be stained with oil red O, an oil soluble 
dye that accumulates within intramyocellular lipid droplets, as an initial 
approach to determine the amount of neutral lipid present in cells treated with 
PA alone or when coapplied with OA and LOA. TAG accumulation can also be 
quantitated using a radiometric assay in which the effects of UFAs upon 
incorporation of 14C-palmitate into TAG can be determined. If UFAs do stimulate 
PA incorporation into neutral lipids then testing the involvement of Ubxd8 as a 
regulator of this process would be instructive. As discussed in Chapter 3, Ubxd8 
acts as a key sensor of and mediator by which UFAs promote TAG synthesis 
(Lee et al., 2010). By binding Ubxd8, UFAs block Ubxd8-mediated degradation 
of Insig-1, a negative regulator of sterol regulatory element-binding protein 1 
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(SREBP-1) and consequently of fatty acid synthesis (Lee et al., 2010). 
Therefore, it would be interesting to determine the protein abundance of Insig-1 
in L6 myotubes treated with PA alone or in combination with UFAs. One would 
postulate that Insig-1 would be degraded in cells incubated with the SFA but 
that OA and LOA would prevent this degradation. If so, it would be of value to 
explore whether silencing Ubxd8 expression in muscle cells would also stabilise 
Insig-1 expression and if this is able to improve TAG production/accumulation 
even in PA treated cells. This might mimic the protective effect associated with 
OA and LOA provision. 
As mentioned above, binding of UFAs to Ubxd8 results in a decreased fatty acid 
synthesis via inhibition of SREBP-1. It is important to stress that down 
regulation of SREBP-1 and its target genes could itself have implications for the 
ability of UFAs to antagonise the repressive effect that PA exerts upon insulin 
signalling. This proposition is based on the finding that insulin resistance in 
humans and mice with primary hyperlipidemia (HPL) was correlated with 
increased level of SREBP-1 (Chu et al., 2013). This promoted elongation of PA 
to stearic acid, a process catalysed by very long-chain fatty acid elongase 6 
(ELOVL6), a SREBP-1 target gene (Chu et al., 2013). Downregulation of 
SREBP-1 and ELOVL6 by small interfering RNA reduced serum stearic acid 
levels and ameliorated insulin resistance in HPL mice (Chu et al., 2013). In 
addition, knockdown of ELOVL6 has been shown to mitigate PA-induced ER 
stress and apoptosis in INS-1 β-cells (Green and Olson, 2011) while mice 
deficient in  ELOVL6 on a high-fat diet display improved insulin sensitivity and 
are protected from hyperinsulinemia and hyperglycemia (Matsuzaka et al., 
2007). Interestingly, several studies report that PUFA provision dramatically 
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suppresses ELOVL6 expression and improves insulin sensitivity in rodent 
hepatocytes and human colon epithelial cells (Howell et al., 2009; Narayanan et 
al., 2001; Sekiya et al., 2003). However, little is known about regulation of 
ELOVL6 by UFAs and how it may potentially help curb fatty acid-induced insulin 
resistance in skeletal muscle cells. Thus, it would be useful to establish whether 
PA upregulates expression of ELOVL6 and whether this increase can be 
antagonised when cells are coincubated with OA or LOA. If so, this study could 
be extended to assess whether treating L6 myotubes with ELOVL6 inhibitors, 
such as Compound A and B (Shimamura et al., 2010), could mimic the 
beneficial effects that OA and LOA have upon ameliorating PA-induced 
reduction in insulin signalling. 
iii.  Fatty acid regulation of mitochondrial function and morphology 
In Chapter 3 I demonstrated the ability of OA and LOA to mitigate the  insulin 
desensitising effects of PA via counter modulation of PP2A. However, it is 
highly likely that the mitigating effect of UFAs involves additional cellular 
mechanisms. There is mounting evidence to suggest that mitochondrial 
dysfunction and impaired oxidative capacity may play a significant role in SFA-
induced insulin resistance in skeletal muscle (Bonnard et al., 2008; Hirabara et 
al., 2010; Koves et al., 2008; Muoio and Neufer, 2012; Turner and Heilbronn, 
2008). Sustained incubation of muscle cells with PA is known, for example, to  
impair fatty acid oxidation, increase ROS production and decrease expression 
of proteins implicated in mitochondrial biogenesis, such as PGC1α and Tfam in 
muscle cells (Martins et al., 2012; Yuzefovych et al., 2010). Therefore, it is 
plausibile that the long-term benefits of UFAs on cellular function may depend 
upon preserving mitochondrial capacity and biogenesis. This could be assessed 
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via analysis of gene and protein expression of markers of mitochondrial 
biogenesis and function, such as PGC1α and COX 4.1, in muscle cells treated 
with LOA and OA alone or when coapplied with PA. Xue et al. demonstrated 
that the expression of SIRT1, a protein involved in the deacetylation and 
consequent activation of PGC1α, was increased by PUFAs in macrophages 
(Lagouge et al., 2006; Xue et al., 2012). Therefore, it would be of value to 
assess whether PGC1α is maintained in an acetylated/inactive state in cells 
treated with PA and whether cotreatment with OA and LOA promotes its 
deacetylation and activation. This could be assessed by immunoprecipitating 
PGC1α from L6 myotubes incubated with PA alone or with OA/LOA and 
immunoblotting with anti-acetyl lysine antibodies. If fatty acids do regulate 
PGC1α acetylation, the involvement of SIRT1 in mediating such modulation 
could be further confirmed through use of SIRT1 inhibitors such as X-527 and 
tenovin-1, or cells in which SIRT1 expression has been silenced using shRNA. 
One would predict that SIRT1 ablation would negate the beneficial effects 
associated with OA and LOA provision. Moreover, agonists of SIRT1 could be 
used to assess whether they mimic the insulin-sensitising effect of UFAs and 
antagonise PA-induced insulin resistance. 
PA-induced mitochondrial dysfunction has been also linked to dysregulation of 
mitochondrial dynamics (Jheng et al., 2012). Mitochondria are dynamic 
organelles that constantly fuse and divide, events respectively called “fusion” 
and “fission”. Dynamin-related protein 1 (DRP1) regulates the fission process 
and has been shown to mediate PA-induced mitochodrial fragmentation and 
insulin resistance in skeletal muscle (Jheng et al., 2012; Watanabe et al., 2014). 
Therefore, it would be of interest to investigate whether the increase in DRP1 
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protein expression induced by PA can be prevented by cotreatment with OA 
and LOA. Moreover, it would be of value to assess whether the use of Mdivi-1, 
which inhibits DRP1 activity, mimics the beneficial effects promoted by UFAs 
upon insulin signalling in skeletal muscle cells. Studies performed in β-cells 
show that AMPK activation leads to phosphorylation of an inhibitory residue of 
DRP1, S637, preventing alterations in ER and mitochondrial morphology 
induced by PA (Wikstrom et al., 2013). Data presented in Chapter 3 indicate 
that although OA and LOA induce AMPK activation, this enhancement was 
dispensable for their insulin sensitising effect. However, whether AMPK is 
involved in mediating the ability of UFAs to antagonise the insulin-desensitising 
effect and, if so, whether this involves AMPK-mediated DRP1 inhibition remains 
unclear. This could be tested by assessing whether UFAs fail to attenuate the 
loss in Akt phosphorylation triggered by PA in AMPK-silenced L6 myotubes. If it 
is then the importance of DRP1 inhibition can be assessed using a specific 
phospho-antibody targeting the DRP1S637 residue in lysates from L6 myotubes 
treated with PA or UFAs. If UFAs do act as proposed above then one might 
predict that they may improve DRP1S637 phosphorylation when muscle cells are 
treated either alone with UFAs or when coapplied with PA. 
 
5.2 Key observations from Chapter 4 
 LOA represses adaptive System A/SNAT2 transport activity by targeting 
the immature “light” form of SNAT2 for degradation via the UPS. 
 LOA-induced proteasomal loss of SNAT2 via the UPS does not involve 
the E3 ubiquitin ligase Nedd4.2. 
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 PA partially represses System A transport activity via ceramide 
synthesis. 
There is considerable scope for further investigation of how UFAs and SFAs 
modulate the proteolytic machinery and more specifically SNAT2 stability. 
These include investigating (i) the identity and nature of the proteins that are 
sensitive to LOA-induced proteosomal degradation, (ii) the E3 ligase(s) 
responsible for LOA-induced SNAT2 ubiquitination, (iii) understanding more 
fully the mechanism by which PA regulates SNAT2 degradation and (iv) 
establishing the role played by the N-terminal SNAT2 tail in regulating its 
stability. These issues can be further explored by performing the types of 
experiments described below: 
 
i. LOA-induced activation of UPS 
The whole cell ubiquitin blots presented in Fig 4.9 and 4.10 indicate that SNAT2 
is only one of many proteins ubiquitinated in response to LOA. As yet, the 
identity of these proteins and what cellular processes may be modulated as a 
consequence of their loss remains currently unknown. Therefore, a SILAC 
(stable isotope labeling with amino acids in cell culture) proteomic approach 
could be used to identify proteins sensitive to LOA-induced proteosomal 
degradation. This could be done, for example, by maintaining two identical 
myotube populations in custom media containing either 'light/natural' or 'heavy' 
forms of arginine (i.e. 12C and 13C labelled L-arginine, respectively). Cells will 
incorporate heavy arginine into newly synthesised proteins in the same manner 
as the normal “light” isotope. Unlabelled and labelled cells will be treated 
respectively with or without LOA for 24 h, and MG132 added to the media for 
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the last 4 h. Cells from both populations will then be pooled, proteins extracted 
and digested with trypsin. Ubiquitination occurs on the ɛ-amino group of lysine 
residues of target proteins; trypsin cleaves off all but the two C-terminal glycine 
residues of ubiquitin, which remain linked to the ɛ-amino group of the modified 
lysine residue. Peptides obtained from protein digests will be enriched by 
immunoprecipitation using a lysine-ɛ-GG antibody and peptide fragments 
subsequently analysed by Liquid Chromatography–Mass Spectrometry (LC-
MS). Sequence-identical peptides will be differentiated on the basis of mass 
difference and the ratio of peak intensities in the mass spectrum for such 
peptide pairs calculated to reflect the abundance ratio for the two peptides 
within the immunoprecipitate. This approach will identify which peptides become 
enriched in a LOA-dependent manner. The ms/ms spectra will then be 
searched against local databases using search engines (e.g. Mascot) to identify 
ubiquitinated proteins. This will allow classification/mapping of identified 
proteins to specific cell functions/pathways and follow-up studies on key 
candidate proteins for which commercial antibodies are available will help 
monitor/validate the effect LOA has upon their expression and/or function. This 
approach could provide new insights into the cellular processes regulated by 
fatty acid-induced modulation of the UPS. 
ii. Which E3 ligase mediates LOA-induced SNAT2 ubiquitination? 
Hatanaka et al. demonstrated that the E3 ubiquitin ligase Nedd4.2 regulates 
SNAT2 ubiquitination in 3T3-L1 adipocytes (Hatanaka et al., 2006). However, 
my data indicates that loss of SNAT2 protein induced by LOA is unlikely to 
involve this E3 ligase, since the ability of the fatty acid to promote SNAT2 
degradation was not diminished in cells in which Nedd4.2 had been stably 
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depleted. Therefore, determining the identity of the E3-ligase that promotes 
LOA-induced SNAT2 degradation remains an unresolved issue. This issue 
could also be addressed using the SILAC proteomic approach described above, 
which would assess quantitative differences, at the protein level, between 
unlabelled and labelled cells treated or not with LOA for 24 h. This approach 
could help identify, among other proteins, which E3 ligases are up regulated by 
fatty acid treatment and, moreover, may also identify E2 and E1 ligases whose 
involvement and regulation by LOA cannot be excluded. qRT-PCR and western 
blot analysis could then be used to validate the differentially expressed E3 
ligases quantified by SILAC. Their involvement in mediating the LOA-induced 
loss in SNAT2 protein could subsequently be assessed by silencing their 
expression in L6 myotubes and HeLa cells and asessesing whether this 
approach antagonises UPS-mediated SNAT2 degradation triggered by the fatty 
acid. The E3 ligases MAFbx and MuRF-1 remain potential candidates for 
mediating LOA-induced SNAT2 protein loss following amino acid deprivation. At 
present there is no evidence linking these E3 ligases to SNAT2 proteasomal 
degradation, but given that both have been implicated in proteolysis of muscle 
specific proteins (Bodine and Baehr, 2014; Zhou et al., 2007), their involvement 
in regulation of SNAT2 warrants further investigation. Therefore, it would be 
interesting to determine whether the SILAC-proteomic analysis discussed 
earlier identifies them as proteins upregulated by LOA treatment and, if so, 
whether suppressing their cellular expression mitigates the LOA-induced loss of 
SNAT2. If MAFbx and MuRF-1 is upregulated by LOA and can be linked to 
LOA-induced SNAT2 degradation then two possible molecular mechanisms 
may account for their upregulation. First, AMPK, which is activated in response 
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to stress-inducing conditions such as amino acid deprivation (Ghislat et al., 
2012; Xiao et al., 2011) or hypertonic shock (Barnes et al., 2002; Sid et al., 
2010), has been shown to increase MAFbx and MuRF-1 expression in C2C12 
cells (Krawiec et al., 2007). My work, and that of others, has shown that 
unsaturated fatty acids enhance AMPK phosphorylation/activation (Salvado et 
al., 2013; Watt et al., 2006). Thus, it is plausible that LOA might induce these 
two E3 ligases as a consequence of stress-induced activation of AMPK. To test 
this hypothesis, the effect of LOA treatment upon the SNAT2 adaptive response 
triggered by amino acid deprivation or hypertonicity could be investigated in L6 
myotubes in which AMPK has been stably silenced using shRNA. Another 
possible mechanism by which LOA could promote UPS activation is through 
activation of PPAR receptors such as PPARα. As indicated in Chapter 3 and 4, 
PPARα is a major transcriptional regulator of lipid metabolism in skeletal muscle 
(Burri et al., 2010) and can be activated by binding fatty acid ligands, such as 
LOA (Forman et al., 1997). Ringseis et al. have shown that treating rats with 
PPARα agonists results in upregulation of MAFbx and MurF-1 genes, even 
though their promoters are not directly regulated by the receptor (Ringseis et 
al., 2013). The involvement of PPARα in mediating LOA-induced up regulation 
of UPS could be explored by testing whether the fatty acid-induced loss of 
SNAT2 can be repressed by the use of PPARα antagonists, such as GW 6471 
and MK 886, or PPARα gene silencing.  
iii. Does PA induce lysosomal degradation of the mature “surface” form 
of SNAT2? 
Data presented in Chapter 4 indicate that subjecting cells to PA treatment under 
conditions when they are being amino acid deprived results not only in a cellular 
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redistribution of the transporter, an event linked to PA-derived ceramide 
synthesis, but also a reduction in its total cellular content. Given that, unlike 
LOA, PA does not induce the UPS, it is plausible that it targets the mature form 
of SNAT2 for internalisation and degradation by the lysosome. Several 
membrane proteins are sorted and delivered to the lysosome in response to 
various stimuli in both yeast and mammalian cells (Ghaddar et al., 2014; Piper 
and Luzio, 2007). To test whether this is also the fate of the mature “surface” 
form of SNAT2, it would be of value to assess whether PA treatment increases 
accumulation of K63-ubiquitinated proteins in presence of a lysosomal inhibitor, 
such as leupeptin or chloroquine. While formation of K48-ubiquitin chains 
primarily directs proteins to the proteasome (Thrower et al., 2000), K63-ubiquitin 
chains target proteins mainly for lysosomal degradation (Ikeda and Dikic, 2008). 
If PA stimulates the lysosomal proteolytic system, it would then be of interest to 
investigate its effect upon the ubiquitination of the “surface” form of SNAT2. 
One possible strategy would involve using cell-impermeable reagents to 
biotinylate plasma membrane proteins. Biotin-labelled cell surface proteins will 
be then isolated by incubation with streptavidin agarose resins. The mature 
form of SNAT2 will be immunoprecipitated and probed for K-63 linkage specific 
ubiquitin. This strategy could be used in amino acid deprived cells treated with 
or without PA in presence of an endocytosis inhibitor, such as cytochalasin B 
(CB), so as to block internalisation of ubiquitin tagged SNAT2. One would 
expect that in presence of CB, PA treatment results in the accumulation of K-63 
ubiquitinated mature “surface” form of SNAT2. PA-mediated internalisation and 
degradation of SNAT2 by the lysosome could be further validated by 
immunofluorescence analysis. It would be interesting to assess whether SNAT2 
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accumulates and colocalises with lysosomal markers in amino acid depleted L6 
myotubes treated with PA and a lysosomal protease inhibitor, such as E64D. 
Moreover, SNAT2 protein loss at the plasma membrane induced by PA could 
be confirmed by performing immunofluorescence on non-permeabilised L6 
myotubes using an antibody directed against an external (exo-facial) loop of the 
transporter.  
iv. The N-terminal domain of SNAT2 is targeted by ubiquitin  
Of the 12 lysine residues that may potentially be ubiquitinated on SNAT2, 7 are 
located within the SNAT2 N-terminal tail, making it highly likely that this 
transporter domain plays an important role in modulating transporter stability. 
This hypothesis was confirmed by the finding that in HeLa cells transiently 
expressing a SNAT2-V5 mutant, in which the 7 lysine residues had been 
mutated to alanine, the SNAT2 protein was more stable and resistant to LOA-
induced proteasomal loss. However, it is still unknown which lysine residue(s) 
are selectively targeted for ubiquitination. Moreover, it is plausible that different 
lysines may be targeted by different type of ubiquitin chains, such as K48 and 
K63, thereby directing the protein to distinct proteolytic fates. To address this 
issue, it will be interesting to compare protein stability of different SNAT2-V5 
mutants, in which the different lysine residues are systemically mutated to 
alanine with a view to identifying which mutated lysine residue(s) confer the 
greatest stability. Moreover, it would be of value to repeat this set of 
experiments in cells treated with either LOA or PA, in order to investigate which 
of the lysine residues are ubiquitinated under treatment with these fatty acids. It 
218 
 
will be possible to determine such residues as their mutation will prevent the 
loss in SNAT2 protein promoted by LOA or PA.  
Identifying which lysines are ubiquitinated and which target the transporter for 
proteasomal or lysosomal degradation could help us understand why the 
mature and immature forms of SNAT2 protein have two different fates. It is 
plausible that, once at the plasma membrane, the mature “surface” form of 
SNAT2 would be subject to stimulus-induced conformational changes that may 
result in exposure of particular lysine residues that are targeted for K63-specific 
ubiquitination whereas these might not be accessible on the intracellularly 
localised protein. Recent studies have shown that, upon amino acid binding, 
yeast amino acid permeases shift to a conformation that favours their 
ubiquitination and consequent endocytosis. These structural changes involve 
the N-terminal tail and an intracellular loop of the permeases (Ghaddar et al., 
2014). Whether this mechanism also holds for a mammalian amino acid 
transporter, such as SNAT2, is unknown but the concept is potentially testable 
by comparing protein stability of wild type (wt) SNAT2-V5 and the 7A-SNAT2-
V5 mutant in HeLa cells or L6 myotubes subject to amino acid deprivation and 
then fed with a single SNAT2 amino acid substrate. One would expect that, 
upon amino acid binding, the wt SNAT2-V5 would be internalised and degraded 
by the lysosome whereas the 7A-SNAT2-V5 would be stable. This experiment 
can be repeated with the single lysine/alanine-SNAT2-V5 mutants to establish 
which lysine residue might be potentially targeted for K63 ubiquitination.  
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5.3 Concluding statement  
Most international dietary guidelines suggest replacement of SFAs with MUFAs 
and PUFAs. Diets rich in UFAs have been shown to convey health benefits, 
including ameliorating the risk of metabolic syndrome and cardiovascular 
disease associated with SFA provision (Jones et al., 2014; Parillo et al., 1992; 
Summers et al., 2002). The work presented in this thesis provides novel insight 
into the beneficial effects that linoleic (a PUFA (LOA)) and oleic acid (a MUFA 
(OA)) confer against the adverse effects of the SFA palmitate (PA) in skeletal 
muscle. My studies show that these UFAs enhance insulin sensitivity and 
antagonise the detrimental effects of PA through counter modulation of PP2A in 
skeletal muscle. These findings are in line with previous work demonstrating 
that inhibition of PP2A restores insulin signalling in insulin-resistant ZDF rats 
(Galbo et al., 2011). In light of this evidence, PP2A activity can be considered 
as a valuable target for the treatment of type 2 diabetes and other metabolic 
disorders. Thus, the studies presented herein support the view that changing 
the dietary fatty acid composition in favour of UFAs may enhance insulin 
sensitivity in both normal and insulin-resistant skeletal muscle. 
Interestingly, while increased PUFA intake is generally thought to bring about 
beneficial effects on health my results also demonstrate that LOA may 
compromise the function of molecules involved in nutrient uptake, such as the 
SNAT2 amino acid transporter. This effect is most evident under conditions of 
amino acid restriction and, moreover, is not limited to LOA but also observed in 
response to certain MUFAs and SFAs.  Consequently, this fatty acid-induced 
effect may form part of a generic stress response that is triggered by nutrient 
limitation.  During fasting, the body is metabolically challenged to maintain 
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energy homeostasis. After muscle and liver glycogen reservoirs have been 
depleted, triacylglycerol stores are broken down resulting in the release and 
subsequent rise in circulating free fatty acids. Indeed, recent studies have 
shown that the concentration of plasma free fatty acids increases from 0.19 (± 
0.02) mmol/l to 0.76 (± 0.06) mmol/l in human subjects after 10 h of fasting 
(Wijngaarden et al., 2014). This increased lipolytic activity furnishes tissues 
such as muscle with fatty acids for use as metabolic fuel during fasting.  
However, prolonged periods of fasting will ultimately promote increased cellular 
proteolytic activity in which protein breakdown liberates amino acids, such as 
alanine, for use in hepatic gluconeogenesis and energy metabolism. There is 
evidence that certain fatty acids enhance the activity of the proteasomal or 
lysosomal proteolytic system (Dahlmann et al., 1985; Woodworth-Hobbs et al., 
2014). Indeed, my studies indicate that LOA enhances protein breakdown 
through UPS induction and, furthermore, potentially decreases protein synthesis 
via modulation of kinases implicated in mRNA translation – such events would 
usually occur in the fasting state to maintain the free amino acid pool size. 
Therefore, it is plausible that free fatty acids, including LOA, released as a result 
of increased lipolysis may serve as a signal for improving the release of 
gluconeogenic precursors, such as alanine, via enhanced proteolysis by the 
UPS. 
 
The SNAT2 adaptive phenomenon is a highly conserved cellular response that 
is initiated upon cells experiencing extracellular nutrient depletion. However, 
one might question the value of such response in the context of cellular 
adaptation to nutrient limitation given that provision of a single SNAT2 substrate 
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(in a backdrop when all other amino acids are still absent) is able to repress the 
SNAT2 adaptive response (Gazzola et al., 1981).  Clearly, provision of a single 
amino acid will not be able to maintain the intracellular amino acid pool nor will it 
be sufficient for supporting protein synthesis.  Consequently, the SNAT2 
adaptation response might be considered as a conserved evolutionary 
mechanism that perhaps is now dispensable. The proteolytic process is highly 
selective in targeting non essential proteins for ubiquitination and avoids 
degrading proteins vital to the functioning of the cell. It is not surprising then, 
that SNAT2 falls within the proteins sensitive to LOA-induced proteasomal 
degradation. However, it is important to stress that, unlike an in vitro 
experimental setup, the physiological plasma amino acid pool during the fasting 
state is never completely depleted; therefore even a modest adaptive increase 
in SNAT2 abundance at the cell surface may enhance amino acid uptake. It is 
worth considering that glutamine and alanine, two of the main precursors of 
gluconeogenesis in small intestine and liver respectively (Garber et al., 1976), 
are also substrates of SNAT2. Therefore, LOA-induced inhibition of the 
transporter would reduce muscle tissue from extracting these amino acids from 
the circulation, which, instead, would be directed to gluconeogenic tissues, like 
the liver. 
 
The ability of LOA to positively modulate glucose production in hepatocytes is 
not unprecedented (Suh et al., 2008). Indeed, it has been amply documented, 
both in vivo and in vitro, that free fatty acids improve gluconeogenesis (Chen et 
al., 1999; Gonzalez-Manchon et al., 1989; Morand et al., 1993; Williamson et 
al., 1966). Such enhancement has been linked to enhanced fatty acid oxidation. 
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During the fasting state fatty acids become the dominant fuel and their oxidation 
is increased in liver, resulting in enhanced level of acetyl-CoA generation. 
Acetyl-CoA allosterically activates pyruvate carboxylase, the enzyme catalysing 
the first committed step in gluconeogenesis (Lam et al., 2003).  Thus, the 
studies presented herein suggest that during fasting state free fatty acids could 
stimulate glucose production not only by activating gluconeogenic enzymes, but 
also via increased provision of gluconeogenic precursors derived from 
breakdown of proteins in tissues such as muscle. 
 
In conclusion, the work presented in this thesis has provided new insights into 
how fatty acids induce modulation of insulin signalling and nutrient uptake. The 
results indicate that provision of UFAs enhances insulin sensitivity and 
antagonise the deterimental effects of PA in skeletal muscle. However, my 
observations also suggest that, regardless of whether the fatty acid is saturated 
or unsaturated, free fatty acids released from lipid stores during the fasted state 
are likely to modulate the cellular ubiquitination machinery in order to enhance 
proteolysis, which, in turn, would be expected to promote release of amino 
acids that potentially could serve as substrates for hepatic gluconeogenesis.  
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Appendix 1. Antibodies 
Antibody Dilution Size 
(kDa) 
Company 
4G10 phospho tyrosine 1:5000  Millipore 
Acetyl-CoA Carboxylase 
phospho S79 
1:1000 280 Cell Signaling 
Β-Actin 1:2000 42 Sigma 
Akt/PKB phospho S473 1:1000 60 Cell Signaling 
Akt/PKB phospho T308 1:1000 60 Cell Signaling 
Akt/PKB 1:1000 60 Cell Signaling 
AMPK phospho T172 1:1000 62 Cell Signaling 
AMPK α1 1:1000 62 Cell Signaling 
Caveolin 1  20 DSTT 
Caveolin 3  17 DSTT 
CREB S133 1:1000 36 Cell Signaling 
GAPDH 1:10000 37 Sigma 
GSK3 phospho S9/21 1:1000 47 Santa Cruz 
GSK3 1:1000 47 Santa Cruz 
ERK1/2 phospho 
T202/Y204 
1:1000 42/44 Cell Signaling 
ERK1/2 1:1000 42/44 Cell Signaling 
Flag 1:3000  Sigma 
IRβ 1:1000 97 Upstate Biotechnology 
IRS1 1:1000 130 Upstate Biotechnology 
JNK T183/Y185 1:1000 46/54 Cell Signaling 
Nedd4.2  120 DSTT 
P70S6K phospho T389 1:1000 70 Cell Signaling 
P70S6K 1:1000 70 Cell Signaling 
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p38 T180/Y182 1:1000 43 Cell Signaling 
PI3K p85 1:1000 85 Upstate Biotechnology 
PP2Ac demethylated 1:1000 37 Upstate Biotechnology 
PP2A pospho Y307 1:2000 37 Abcam 
PP2A (for IP)  37 DSTT 
PTEN 1:1000 47 Santa Cruz 
S6 S240/244 1:1000 32 Cell Signaling 
Slc382 (SNAT2) 1:1000 40/60 MBL 
Src Y416 1:1000 60 Cell Signaling 
α-subunit Na+/K+ ATPase 1:500 100 DSHB 
Ubiquitin 1:1000  Dako 
Ubiquitin linkage specific 
K48  
1:1000  Abcam 
Ubiquitin linkage specifi 
K63 
1:1000  Abcam 
V5 1:5000  Life Technologies 
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Appendix 2. Buffers 
Common 
buffers 
Phosphate-buffered 
saline (PBS) 
150mM NaCl 
3mM KCl 
10mM Na2HPO4 
2mM KH2PO4 
Hepes-buffered saline 
(HBS) 
20mM Hepes 
140mM NaCl 
16mM KCl 
5mM MgSO4 
1.3mM CaCl2 
pH 7.4 
Buffer I 
20mM Hepes 
250mM Sucrose 
2mM EGTA 
3mM Na Azide 
pH 7.4 
(+ protease cocktails) 
Lysis buffer 
50mM TRIS pH 7.4 
0,27 M Sucrose 
1mM Na-Orthovanadate pH 10 
(inhibits tyrosine phosphatases) 
1mM EDTA (chelates Mg2+ ions 
to inactivate protein kinases) 
1mM EGTA 
10mM Na-β-glycerophosphate 
50mM NaF (inhibits 
serine/threonine phosphatases) 
5mM Na-pyrophosphate 
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1% Triton X-100 
0.1% 2-Mercaptoethanol 
(+ protease cocktail) 
Protease cocktail 
10μM E-64 (inhibits cysteine 
peptidases) 
10μM Leupeptin (inhibits 
cysteine/serine/threonine 
peptidases) 
1μM Pepstatin A (inhibits 
asprtyl proteases) 
1 mM PMSF (inhibits serine 
proteases) 
2μg/ml Aprotinin (inhibits 
trypsin and related proteolytic 
enzymes) 
SDS-PAGE and 
immunoblotting 
buffers 
Running Buffer 
25mM Tris base 
200mM Glycine 
pH 8.3 
1%(w/v) SDS 
Transfer buffer 
20mM Tris base 
150mM Glycine 
20%(v/v) Methanol 
Tris-buffered saline with 
Tween 
10mM Tris HCl 
150mM NaCl 
pH 7.6 
0.2% (v/v) Tween 
Laemmli buffer 
62.5mM Tris/HCl 
pH 6.8 
10% (v/v) glycerol 
0.01% (w/v) Bromophneol blue 
2% (w/v) SDS 
Enhanced 
chemiluminescence (ECL) 
100mM TRIS pH 8.5 
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Solution 1 
 
ECL Solution 2 
2.5mM luminal 
396μM p-Coumaric acid 
 
100mM TRIS ph8.5 
5.63mM H2O2  
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Appendix 3. shRNA sequences 
Sense and antisense strands are underlined, hairpin loop is indicated by italics. 
 
Hairpin shRNA Sequences 
Cav-1 
sh483 
Oligo 1: 
CCGGAAGCGATTGGCAAGATATTCACTCGAGTGAATATCTTG
CCAATCGCTTTTTTTG 
Oligo 2:  
AATTCAAAAAAAGCGATTGGCAAGATATTCACTCGAGTGAATA
TCTTGCCAATCGCTT 
Cav-3 
sh35 
Oligo 1:  
CCGGGGATCATCAAGGACATTCACTCTCGAGAGTGAATGTCC
TTGATGATCCTTTTTG 
Oligo 2: 
AATTCAAAAAGGATCATCAAGGACATTCACTCTCGAGAGTGAA
TGTCCTTGATGATCC   
Ampk α1 
Oligo 1: 
CCGGATGAGTCTACAGCTATACCAACTCGAGTTGGTATAGCT
GTAGACTCATTTTTTG 
Oligo 2: 
AATTCAAAAAATGAGTCTACAGCTATACCAACTCGAGTTGGTA
TAGCTGTAGACTCAT  
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Scramble 
Oligo 1: 
CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACT
TAACCTTAGGTTTTTG 
 
Oligo2: 
AATTCAAAAAACCTAAGGAATTGTCGCCCTCGCTCGAGCGAGG
GCGACTTAACCTTAGG 
 
Nedd4.2 
Oligo 1   
CCGGAACAATCGAACCACAACTTGGCTCGAGCCAAGTTGTG
GTTCGATTGTTTTTTTG 
Oligo 2   
AATTCAAAAAAACAATCGAACCACAACTTGGCTCGAGCCAAGT
TGTGGTTCGATTGTT 
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Appendix 4. Primer sequences 
Target Sense primer 
(5’-3’) 
      Anti-sense primer 
       (5’-3’) 
PP2Ac-rat CAGCTGGTGATGGAGGGATA TAGTCTGGGGTACGACGAG
T 
PME1-rat CTGCTCTTGGCAGGTGTTGA GTCGGATCAGGAAAGTGGC
A  
Actin-rat CCGACAGGATGCAGAAGAAG ATCCACATCTGCTGGAAGG
TC 
SNAT2-rat GCAGCCGGAGAAGGATGATG
AAC 
GAAGAGGGCGGCAAGCAAA
TACA 
SNAT2-
human 
GTGTTAATGGCTGTGACCCT
GAC 
GAGACTATGACGCCACCAA
CTGA 
ATF4-rat ACCCAAACCTTATGACCCAC
CTG 
GCTGCTGTCTTGTTTTGCTC
CATC 
ATF4-human GGTCAGTCCCTCCAACAACA
GC 
CCAACAGGGCATCCAAGTC
G 
Nedd4.2-rat TCTGCCACGGACAACTACAC  CACAGGCCTGAGTTGGGAT
T 
Nedd4.2-
human 
CTTAGTCATCCAGTGGAGATT
TGTG 
AGCAACTCCAGCTCATTTTC
ATC 
GAPDH-all TGGAAAGCTGTGGCGTGAT GCTTCACCACCTTCTTGAT 
pLKO.1 AATGGACTATCATATGCTTAC
CGT 
CCAAAGTGGATCTCTGCTGT
C 
SNAT2-rat 
(insert vector 
V5-His6) 
CCGCTCGAGGGCCAGTGC GGCTCTAGAATGTCCGCCT
GCAGAGGC 
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